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Abstract
There has been great interest in a definable prodromal period of Parkinson’s
disease (PD), which is thought to be characterised by non-motor manifestations.
In preparatory work, an extensive review of early non-motor features and risk
factors was undertaken to develop a preliminary algorithm to identify subjects
at increased risk of PD. A website was configured and keyboard-tapping test
developed to aid in risk-stratifying subjects for future PD.
This thesis first documents the validation of the keyboard-tapping test in PD
patients and healthy controls, before its use alongside objective smell testing and
a questionnaire formulated to assess early non-motor features and risk factors, all
of which were delivered via the internet. The thesis describes the recruitment at
baseline of over 1,300 healthy older people and annual follow-up assessments with
the questionnaire, smell test and tapping test, which comprise the preliminary
screening algorithm. Each year those estimated to be at higher risk were compared
to lower risk subjects in terms of intermediate markers (smell loss, sleep distur-
bance and finger tapping speed) and differences between extremes of risk have
been observed, consistent with the notion that higher risk subjects possess early
features of PD. Selected higher and lower risk subjects were further investigated
to determine whether there were differences in the frequency of genes associated
with PD (GBA and LRRK2 ), and a proportion of subjects have been scanned
using transcranial sonography and 123I-FP-CIT SPECT to determine whether
there were imaging differences between extremes of risk. The thesis concludes by
demonstrating that higher risk subjects were more likely to be diagnosed with
PD during follow-up over 3 years and proposes further lines of enquiry that can
be followed, building on the work undertaken to-date.
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Chapter 1
Introduction
Parkinson’s disease (PD) is the most common degenerative movement disorder.
It has a lifetime prevalence of 0.2%, which increases significantly with age.1,2 It
is diagnosed clinically, upon an appropriate history and observing bradykinesia,
which must be present along with either rigidity or tremor.3 Bradykinesia describes
the sequence effect of reducing rate and/or amplitude with repetitive movements
such as finger tapping. The classic PD tremor occurs at rest, rigidity occurs
through the full range of movement, and the motor features persist asymmetrically
in almost all cases.
Motor features of PD may emerge relatively late in the disease process when at
least 50-60% of dopaminergic neurons have been lost in the substantia nigra (Figure
1.1).4 However, there is substantial heterogeneity in the clinical manifestations,
even soon after diagnosis.5 Symptomatic treatment is efficacious, but there are
currently no drugs that demonstrably slow the disease course and there is no cure.
Progressive cell loss leads to increasing physical disability, and often cognitive
impairment, with treatment failing to provide adequate control in the advanced
stages. It is believed, albeit not proven, that disease may be too far advanced
at the point of clinical diagnosis to be affected by potentially neuroprotective
treatments (assuming that these were available).6 In recent years, there has been
great interest in the prodromes of PD, which may precede overt motor features.7,8
Associations between a number of clinical entities and a subsequent diagnosis of
PD have been established through observational study. Infrequent bowel opening
or constipation, loss of smell sense, anxiety and depression, sleep disorders, not
smoking and not drinking coffee, have all been consistently associated with PD.
Most of these, in isolation, are also found commonly in the older adult population,
but in combination could perhaps ‘predict’ individuals at risk of PD. However,
the temporality and magnitude of effect of association with PD differs for each of
these early features.
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Fig. 1.1: A schematic depicting normal (black solid line) and PD-related (red
solid line) nigral cell loss over time, including the point at which diagnosis
typically occurs (hashed black line) and the potential for modifying the trajectory
of degeneration, if identified earlier (hashed red line).
The pathological hallmark of PD is intra-neuronal inclusions (Lewy bodies) or
linear deposits (Lewy neurites), which stain positive for alpha-synuclein.3 Braak
and colleagues proposed the now widely accepted pathological staging system for
PD, which suggested that Lewy pathology occurs in discrete areas of the brain
before progressing to involve the basal ganglia.9 The progression of PD can be
approximately clinically and pathologically correlated to the six stages described
by Braak and colleagues, although there are many exceptions.
Stage 1 marks the onset of the disease process and involves the anterior
olfactory nucleus, the olfactory bulbs and the dorsal motor nuclear complex of
cranial nerves IX and X (DMV).9 Olfactory and autonomic dysfunction have
frequently been reported as early non-motor features of PD. Separately, alpha-
synuclein deposits have also been found in gastrointestinal neuronal tissue in
patients with established PD and in subjects that underwent bowel biopsy pre-
morbidly and were subsequently diagnosed with PD.10,11,12
Braak stage 2 involves the locus coeruleus and subcoeruleus complex, the
magnocellular area of the reticular formation and posterior raphe nucleus.9 Disease
involvement in these areas could account for recognised sleep and mood disorders,
including anxiety and depression, which have been reported to antedate motor
disease. Stage 3 involves structures including the substantia nigra and amygdala,
which may correspond with the onset of the classical motor features of PD. Stages
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1.1 Identification of individuals ‘at-risk’ of PD
4 to 6 are defined by progressive involvement of cortical structures, perhaps
accounting for the later features such as memory impairment, visual hallucinations
and other visual disturbances, change in personality, and overt dementia.
Identifying individuals at the earliest stages of disease may enable clinical
trials of emerging and repurposed drugs with the aim of preventing/delaying
progression to clinically overt PD at a time when neuronal loss is not too far
advanced (Figure 1.1). However, modifying risk in those that do not yet have
a diagnosis represents a challenge. The terms ‘early disease’ or ‘at-risk’ may be
used synonymously due to uncertainty about the point at which the pathological
process starts, and there remains a lack of sufficiently validated biomarkers that
may distinguish the two. Clarification is important since it will determine whether
prevention is attempted on a primary or secondary basis, and the factors that
initiate the pathological process may not necessarily be the same as those that
subsequently drive progression.
1.1 Identification of individuals ‘at-risk’ of PD
1.1.1 Genetic risk factors
Understanding of the role that genes play in the pathogenesis of PD is growing.
Approximately 11% of patients with PD have a first degree relative with PD,
which is significantly higher than the frequency in age-matched control populations
(approximately 5%).13 Mutations in a number of genes have been identified as
causal for PD including those in alpha-synuclein (SNCA), leucine-rich repeat
kinase 2 (LRRK2 ), parkin (PARK2 ), oncogene DJ1 (DJ1 ) and PTEN-induced
putative kinase 1 (PINK1 ). Most result in early-onset disease and follow Mendelian
inheritance patterns. PARK2, DJ1 and PINK1 are inherited in a recessive fashion,
and SNCA and LRRK2 are dominant.14,15 Study into the role of these genes
implicates lysosomal and mitochondrial dysfunction, as well as inflammation
in pathogenesis.16,17 Of the confirmed monogenic forms of PD, most result in
abnormalities of one or more of these processes, but are rare and do not account for
elevated risk at a population level (Figure 1.2).14 A key factor is alpha-synuclein,
both in sporadic disease and monogenic forms due to mutations in SNCA (and
potentially other genes). As well as forming the basis of Lewy pathology in an
aggregated form, mounting evidence suggests that oligomeric forms of alpha-
synuclein may be neurotoxic.3,18,19 The full picture of how these complex processes
combine to result in neurodegeneration remains incomplete, but in addition to the
above mechanisms, current theories include the possibility of prion-like cell-to-cell
propagation.20
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LRRK2
Mutations in the LRRK2 gene are the commonest known genetic cause for PD and
the G2019S mutation occurs in 4% of hereditary and 1% of sporadic PD.21 LRRK2 -
related PD demonstrates age-dependent penetrance (28% have PD at 59 years,
51% at 69 years and 74% at 79 years), meaning that only a proportion of carriers
will develop PD during life.21 The function of LRRK2 (and its protein product
Dardarin) is yet to be fully determined. It exists predominantly in the cytosol,
but approximately 10% associates with the mitochondrial membrane, leading to
the notion that pathogenicity may arise through mitochondrial dysfunction.22,23
LRRK2 mutations result in heterogeneous pathology. The type of pathology is
somewhat dependent on the actual mutation that has occurred, and includes
alpha synuclein-containing Lewy bodies or neurites, neuronal degeneration and
tauopathy.24
The LRRK2 consortium reported that incidence varies according to ethnicity
(highest in north African Arabs and Ashkenazi Jews), and that the phenotype
found in LRRK2 -positive PD can be clinically indistinguishable from sporadic
PD.21 LRRK2 mutation carriers have been shown to have subclinical dopaminergic
abnormalities, measured with functional imaging.25 Parkinsonian carriers of the
G2019S mutation have olfactory impairment comparable to that of PD in some,
but not all series.26,27
The relatively high frequency of LRRK2 mutations makes it attractive to
consider for pre-symptomatic case detection and recruitment to neuroprotective
clinical trials. The high frequency of G2019S mutations in the UK is fortunate
because LRRK2 is a large gene, making it difficult and costly to screen for all
known mutations. Genetic testing for LRRK2 in the clinical setting is an area of
controversy. In the absence of effective therapy, the main benefit currently is in
improving diagnostic accuracy in those manifesting symptoms.28
GBA
Gaucher’s disease (GD) is the most common lysosomal storage disorder and
results from a deficiency in the enzyme glucocerebrosidase. It follows Mendelian
recessive inheritance patterns and is most commonly found in Ashkenazi Jews.
Phenotypically, GD is divided into three types according to degree of neurological
involvement. Type 1 is a mild form, whilst types 3 and 2 (especially) are more
severe and are typically associated with neurological sequelae in early life. All
result from mutations in the GBA gene, which is located on the long arm of
chromosome 1.
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An association between type 1 (typically non-neuronopathic) GD and early-
onset parkinsonism was noted in reports of GD patients who began to manifest
clinical features of PD.29 In light of these observations, studies were initiated
to identify whether an excess frequency of GBA mutations could be found in
PD patients.30 Heterozygous mutations in the GBA gene were associated with
an increased odds of PD (odds ratio (OR) 5.43; 95% confidence interval (CI)
3.89 to 7.57) in a large multi-centre study.31 The same study showed that GBA
mutations were particularly common in Ashkenazi Jews with PD, occurring in 15%
of patients and 3% of controls. Whereas in unselected PD patients, 3.5% carry
disease-associated GBA mutations compared to <1% of controls.31,32 Patients
with GBA mutations tend to have earlier onset of parkinsonism and higher rates
of cognitive impairment, but generally respond well to levodopa.32,33
The study of manifesting and non-manifesting carriers of LRRK2 and GBA
mutations is important for understanding the prodromal phase of PD and for
studies of drugs targeting specific pathways in the disease. Cohorts of these
subjects have been (or are being) assembled to fulfil these aims.34 The other
causes of monogenic PD listed previously, are probably too rare to base predictive
studies on, but continue to give important insight into disease mechanisms and
therapeutic targets.
Lower risk genetic variants
Mutations in single genes do not account for all the heritable risk apparent in
complex diseases, and genome-wide association studies (GWAS), in which large
numbers of unrelated cases are compared to unrelated controls, have yielded
informative results.35 There are at least 28 independent risk genetic variants
associated with PD that increase or decrease risk in a small but potentially additive
way.36 Many of these can be linked to putative disease mechanisms or are supported
by the findings of candidate gene studies in PD and other neurodegenerative
diseases, which increases confidence that the identified associations are real. The
effect size estimates for individual gene variants are too small to power predictive
studies, but recently polygenic risk profiles have been constructed by pooling
the combined effect of multiple variants to estimate risk of PD, or indeed age of
disease onset.37
The heritable component of PD is estimated to be greater still, at around 30%,
and identified risk loci and monogenic forms account for only about 5-10%.14,38
Over time, with increasing numbers of studied cases and controls, along with deep
re-sequencing and precision phenotyping, a greater proportion of the heritability
of PD will be uncovered. The influence that genetic variation has on PD is not
limited to risk of getting disease alone, and specific variants are likely to contribute
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additionally to age of disease onset, progression and phenotype, with a number
of indicative studies reported thus far.32,39,40 Furthermore, these and additional
genetic factors may dictate therapeutic choices in the future both in the clinical
setting and in recruitment to clinical trials. The genetic architecture of PD is
continually expanding and increasingly complex. It has implications for multiple
aspects of the disease, but other factors are also important in determining risk.
Fig. 1.2: Risk factors and early features of PD associated with increased (or
decreased) risk of subsequent diagnosis. In the diagram, estimated magnitude of
effect is plotted against estimated frequency.
Legend: SN+ is hyperechogenicity in the region of the substantia nigra using
transcranial sonography. Risk factors are shown in orange, early non-motor
features in green, genetic risk factors in red and imaging risk factors in blue.
1.1.2 Environmental risk factors
There is a large body of evidence demonstrating small but significantly elevated risk
of PD associated with a number of environmental risk factors (Figure 1.2). Cohorts
have been assembled to study the role of environmental factors in PD, as well as
their interaction with genetic factors, including the Parkinson’s Environment and
Gene (PEG) study, the Agricultural Health Study, the PAQUID study, and the
Geoparkinson Study.41,42,43,44 Environmental factors and associations with PD
have been studied in larger community-based cohorts not exclusively focussed on
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PD such as the Honolulu Asia Aging Study (HAAS) and the Cancer Prevention
Study II Nutrition Cohort.45,46
Some of the strongest evidence exists for pesticide exposure and proxies for
this including farming occupation, rural living and well water drinking.47 Specific
pesticides implicated include rotenone and paraquat (structurally related to 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which has also been linked
to parkinsonism in illicit drug users48), and both of these chemicals are used to
create animal models of PD. Other potential toxins include heavy metals such
as manganese, with exposure arising through occupations such as welding and
in recreational ephedrone users.49 It seems unlikely that environmental toxins
play more than a minor role in PD risk overall, with most observational studies
suggesting odds ratios in the region of 1.2-2.0.
Observational study data implicate head injury as a minor but significant risk
factor for PD.50 There is increasing evidence that individuals who suffer recurrent
head injury, particularly sportspersons such as boxers, jockeys, American football
and rugby players, are at risk of developing a range of degenerative neurological
conditions including parkinsonism, dementia and motor neurone disease, although
pathological examination of these subjects tends to reveal alternative pathology
to that typically associated with PD.51
In stark contrast to other common chronic diseases, there exist a number
of intriguing but consistent negative associations with PD and lifestyle factors
such as smoking, caffeine and alcohol. The inverse relationship between cigarette
smoking and PD was first recognised over 50 years ago, with multiple studies
since confirming this association.52 A meta-analysis of the inverse relationship
between smoking and caffeine consumption and PD, analysed results from 44
case-control studies and 4 cohort studies of smoking and PD, and 8 case-control
and 5 cohort studies of coffee and PD. It concluded that the pooled relative risk
(RR) for ‘ever’ versus ‘never’ smokers was 0.59 (95% CI 0.54 to 0.63) and that the
risk of PD decreased as number of pack years increased. Furthermore it found
that, compared with non-coffee drinkers, the pooled RR for PD in coffee drinkers
was 0.69 (95% CI 0.59 to 0.80) and that each additional cup of coffee per day was
associated with a 10% risk reduction.53 Since this meta-analysis was undertaken
a large number of additional observational studies have been published.
Whether these exposures offer true neuroprotective properties or whether
negative association, at least with lifestyle factors, arises due to a common feature
(e.g. avoidance as part of an early PD personality change) is yet to be determined.
A true neuroprotective effect is supported by clinical studies reporting improvement
of motor function in a clinical trial of caffeine to treat excessive daytime somnolence
(EDS) in PD, improvement of dyskinesia with nicotine, lack of smoking-related
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decline in olfaction in PD subjects, and PD animal models that show protective
effects of nicotine on nigrostriatal damage.54,55,56,57 Spurious negative associations
may arise as a result of a common problem with observational studies, which is
reverse causality or confounding by prevalent disease. This may be plausible even
in prospective studies that exclude cases of incident PD in the first few years of
follow-up, because the prodromes of PD are likely to be very long, during which
time the disease may be active, but the classical features not yet evident.
There are a number of drugs for which negative associations with PD have been
reported in observational studies, including calcium channel blockers, non-steroidal
anti-inflammatories and statins, and clinical trials to explore repurposing of some
of these agents are underway.58,59,60 Another consistent negative association exists
between levels of serum urate and PD, with a number of studies demonstrating a
protective effect of elevated serum urate against PD.61,62,63 Given the consistency
of this relationship, therapeutic alteration of urate levels is also a strong target
for clinical trials.
The emergence and further characterisation of risk factors for PD (both genetic
and environmental) will continue, but viewing these in independent silos is likely
to hinder progress. Increasing research activity in understanding the overlap
between genes and the environment will enhance further understanding of the
causal basis of disease. As for many diseases, the total picture of risk remains
incomplete due to apparent and substantial randomness of onset, the obscuration
of risk factors either because of rarity, ubiquity or poor measurement, or the fact
that disease tends to strike those at moderate risk, simply because those at highest
risk are far fewer.
1.1.3 Early clinical features
Recognition of the importance of non-motor features of PD has been increasing
for several years.64,65 Some non-motor symptoms are experienced early and there
is substantial evidence which suggests that they can predate diagnosis by several
years (Figure 1.2).7 A number of studies have demonstrated the association of
PD with earlier diagnoses such as depression, anxiety, constipation and erectile
dysfunction (ED).66 The best characterised early non-motor features of PD however
are idiopathic anosmia and rapid eye movement (REM) sleep behaviour disorder
(RBD).
Olfactory loss (anosmia)
Anosmia is relatively common in the ageing population but a proportion of subjects
with unexplained smell loss, may go on to develop neurodegenerative disease.67
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Olfactory disturbance is a common finding in patients with PD, occurring in up to
80% of cases, which is similar to the frequency of tremor.68 There is also evidence
that hyposmia (which describes impaired smell as opposed to absent smell) may
precede the onset of motor features of PD, as follows:
1. A study recruited subjects that were first-degree relatives of patients with
sporadic PD and performed smell identification tests and dopamine trans-
porter (DaT) imaging in some. Of the 40 hyposmic subjects at baseline,
4 had abnormal DaT binding at 2 years follow-up and clinically had PD.
The remaining 36 had accelerated decline in DaT binding, compared to
normosmic subjects.69
2. Transcranial sonography (TCS) was performed on 26 patients with idiopathic
anosmia. Of these, 10 that had abnormal TCS went on to have DaT imaging,
which showed abnormalities in dopamine uptake in 5 subjects.70
3. In the HAAS, over 2000 subjects were tested with the Brief Smell Identifica-
tion Test (B-SIT) at baseline and followed up for 8 years. This prospective,
population-based study demonstrated a relative odds of 5.2 (95% CI 1.5 to
25.6) for developing PD over 4 years if the lowest smell quartile was com-
pared to the reference group (the highest two quartiles). The relationship
weakened at over 4 years.71
These examples highlight the potential value in identifying cases with idiopathic
anosmia to study the prodromal phase of PD and the potential for olfactory testing
as a clinical marker for ‘at-risk’ individuals.
Sleep disorders
RBD is characterised by vigorous, and sometimes injurious, enactment of vivid,
action-packed dreams, caused by loss of normal REM sleep atonia, which is
diagnosed using polysomnography (PSG). An investigation of 29 patients with
RBD found that 11 of these (38%) had developed PD at 4 years follow-up.72
Another group studied subjects with RBD (perhaps occurring at Braak stage 2)
for the presence of anosmia (Braak stage 1), and clinical and imaging evidence
of striatal neuronal loss (Braak stage 3). Compared with normative data, the 30
RBD patients had significantly higher olfactory thresholds and five had clinical
features consistent with PD, four of which were supported by imaging.73 Other
observational studies support the high rate of ‘conversion’ to parkinsonism in
subjects with idiopathic RBD.74,75 Subtle motor changes have also been demon-
strated many years prior to a diagnosis of parkinsonism in patients with confirmed
RBD.76
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Despite high rates of conversion to a parkinsonian syndrome, RBD is clinically
and pathologically heterogenous in that it can predate PD, dementia with Lewy
bodies (DLB) and multiple system atrophy (MSA).74,75 RBD is rare in the
general population and the largest observational study has only studied just over
300 subjects despite international collaborative efforts.77 Twenty-five percent of
idiopathic RBD subjects will convert to neurodegenerative disease at 3 years (40%
at 5 years) and this timeline is feasible when considering clinical trials.77 The
emergence of anosmia or subtle motor signs in those with RBD appears to further
refine estimates of those that are likely to convert.78,79
Excessive daytime somnolence (EDS) may also antedate PD and is a common
non-motor feature in established PD.80 Investigation of over 3000 subjects from
the HAAS reported an adjusted OR of 2.8 (95% CI 1.1 to 6.4) for developing
PD if there was a history of EDS at baseline.81 However EDS can occur in older
people for a myriad of reasons and case-finding of pre-diagnostic PD on EDS alone
is unlikely to be fruitful.
Anxiety and depression
Anxiety and depression have been observed to precede the diagnosis of PD in
several observational studies. One US case-control study collected data using
a self-administered questionnaire and observed that a history of depression was
associated with subsequent PD with an OR of 2.74 (95% CI 1.07 to 7.57).82
Further evidence was provided from another case-control study that examined
medical records of PD patients to identify previous mental health problems.83
The frequency of depression and anxiety was higher in cases than controls, with
ORs of 1.9 (95% CI 1.1 to 3.2) and 2.2 (95% CI 1.4 to 3.4) respectively, and
an OR of 2.4 (95% CI 1.2 to 4.8) for coexistent depression and anxiety. The
association with depression was lost at 5 years prior to onset of motor PD, but
a relationship with anxiety was noted at 20 years prior to disease onset.83 A
systematic review of depression and mental illness preceding PD concluded that
in 5 out of 6 case-control studies, premorbid depression was significantly more
common in PD patients than controls, but the association between anxiety and
PD appeared less profound.84
Autonomic dysfunction
The Honolulu Heart Programme (HHP) collected baseline data on 6,790 male
subjects (average age 60 years old) regarding bowel habit and laxative use. At
an average of 12 years follow-up, the excess risk of PD was 2.7 (95% CI 1.3 to
5.5) in those who reported <1 bowel motion compared to those who reported 1
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bowel motion per day.85 The risk increased further if ‘constipated’ individuals were
compared to those who reported 2 bowel motions per day (excess risk 4.5, 95%
CI 1.2 to 16.9). Further support for this association comes from a pathological
study of the brain stem in patients from the HHP. Those with <1 bowel motion
per day had a 4-fold relative odds of incidental brain stem Lewy bodies (ILB)
compared to those that had >1 bowel motion per day.86 It has been proposed
that ILB might be the pathological precursor of PD.4,87 Retrospective studies also
support infrequency of bowel opening prior to motor disease manifestation.88,89
Impaired erectile function is a common non-motor manifestation of PD. Anal-
ysis of 32,616 men enrolled in the Health Professionals Follow-up Study (HPFS)
was undertaken to identify whether ED antedated PD. This study reported a RR
of 3.8 (95% CI 2.4 to 6.0) of developing PD in subjects reporting ED up to 16
years earlier compared to those that reported good erectile function.90
Whilst bladder complaints are well recognised in PD, there is no substantial
observational study evidence to indicate that disturbances in bladder control
precede PD. A cohort study examined surgical specimens of 100 patients with
immuno-staining for alpha-synuclein in abdominopelvic organs. Organs of the
urinary tract were found to be more likely to contain alpha-synuclein than organs
of the digestive tract. A small number of study subjects were followed up. Whilst
there were no cases of PD or dementia at 16 months follow-up, one subject had
RBD and anosmia, and an abnormal motor score on the Unified Parkinon’s
Disease Rating scale (UPDRS). Two other patients had accelerated decline in
motor performance on the UPDRS between their 16-month and 30-month follow-up
assessments.91
Relevance of early non-motor features
Recognition of early non-motor features is potentially valuable for early identifica-
tion of PD. The research literature initially described the early phase of PD as
being the ‘pre-motor’ phase, but more recently this has fallen out of favour with the
appreciation that subtle motor features can be present before diagnosis.66,76,92,93
The clinical diagnosis of PD requires multiple motor features to be established
and whilst subtle motor signs may be present, a clinical diagnosis of PD cannot
be made until these become more definite.3 Given that subtle or single motor
abnormalities occur prior to diagnosis and alongside early non-motor features,
this period is better referred to as the pre-diagnostic phase.66 The Movement
Disorders Society (MDS) Task Force has proposed the following terminology:94
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1. Preclinical PD - presence of neurodegenerative synucleinopathy without
clinical symptoms (this stage will be defined by disease biomarkers when
available).
2. Prodromal PD - presence of early symptoms and signs before PD diagnosis
is possible.
3. Clinical PD - diagnosis of PD has been made based on the presence of
classical motor signs.
The emergence of large longitudinal primary care datasets has and will allow
detailed exploration of the full range of early motor and non-motor symptoms
that predate PD, whilst being free from the biases implicit in many traditional
observational studies. Alongside this, advances in wearable technology and the
availability of remote testing could aid objective measurement of emerging motor
dysfunction in those ‘at risk’ of PD.
1.2 Imaging markers of pre-diagnostic PD
Radio-tracer imaging with single photon emission computer tomography (SPECT)
or positron emission tomography (PET), or transcranial sonography (TCS) have
repeatedly demonstrated the ability to differentiate patients with PD from healthy
individuals, with adequate sensitivity and specificity.95 SPECT and PET imaging
are accepted as diagnostic imaging modalities for PD, with results of diagnos-
tic accuracy for TCS tending to vary between centres.96,97 SPECT imaging of
pre-synaptic dopamine transporters (DaT) using 123I-ioflupane, is used in rou-
tine clinical practice for the investigation of tremor and secondary parkinsonian
disorders, particularly in specialist centres. In established PD, diagnostic per-
formance of DaT-SPECT is high, with strong inter-rater agreement, and good
long-term safety data.98,99,100 However, some patients with clinically suspected
PD, have normal appearances on DaT-SPECT imaging and have been described
as SWEDDs (scans without evidence of dopaminergic deficit). In some of these
patients, imaging subsequently becomes abnormal, consistent with the suspected
neurodegenerative process, but in others it remains normal, and most of these
subjects probably have alternative underlying diagnoses.101
A variety of imaging modalities may also have the potential to identify sub-
clinical PD prior to diagnosis.102 In the pre-diagnostic phase, SPECT and TCS
were shown to be abnormal in small studies of patients with anosmia and RBD
that were subsequently diagnosed with PD, suggesting that these were good
radiological markers of likely progression in selected subjects with early non-motor
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features.69,70,73 Progressive change in SPECT imaging prior to diagnosis has now
been further reported in a larger study of patients with RBD.103 Most recently, in
the Parkinson’s At Risk Study (PARS), subjects with idiopathic anosmia (and
other prodromal markers) have been shown to have greater risk of DaT deficit
using 123I β-CIT SPECT.104
In contrast to SPECT, TCS demonstrating hyperechogenicity of the substantia
nigra (SN) appears to be a static rather than changing marker.105 Nonetheless,
the finding of SN hyperechogenicity in otherwise healthy subjects over the age
of 50 years, is believed to be a strong risk factor for PD, albeit with a low
positive predictive value when used in isolation.106 Improved standardisation
and quantitative analysis for TCS and SPECT may increase their utility in the
pre-diagnostic phase of disease, with SPECT more likely to demonstrate sensitivity
to change. Further consideration of TCS and SPECT is given in chapter 7.
High-field and novel sequences of magnetic resonance imaging (MRI) may also
provide opportunities to address the challenge of imaging disease progression in the
pre-diagnostic phase. Recent studies in established PD have shown correlations
of MRI micro-structural imaging abnormalities with post-mortem findings and
quantitative differences between patients and healthy subjects in terms of iron
deposition, loss of neuromelanin and alterations in nigrosome 1.107,108,109,110,111
Two other imaging modalities used in the assessment of parkinsonian syndromes
are 123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy and optical
coherence tomography (OCT). MIBG scintigraphy has been largely studied in
Japan, with multiple reports showing a reduction in heart to mediastinum ratio of
MIBG uptake in PD patients, compared with healthy controls or other degenerative
causes of parkinsonism.112 Cardiac sympathetic nerve involvement is a feature of
ILB pathology.113,114 Altered MIBG uptake has been reported in patients with a
range of early non-motor features of PD, including autonomic dysfunction, mood
disorders and sleep disorders, meaning that it may be a good prodromal imaging
marker for PD, but further studies are required.115 OCT is a widely available
imaging modality and studies have shown thinning of the retinal nerve fibre layer
in patients with PD, as well as correlation with disease duration and severity.116
Meta-analysis of thirteen case-control studies was undertaken and showed clear
differences between patients and controls, however, as far as it known, it has not
been applied in subjects with early non-motor features of PD.117 A summary of
imaging modalities and considerations for their use is shown in Table 1.1.
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1.3 Studies of pre- and peri-diagnostic PD
Several studies (Table 1.2) have been initiated to:
1. Identify those in the pre-diagnostic and prodromal phases of PD.
2. Identify clinical and biological markers to track progression of pathology
before diagnosis.
3. Create platforms to identify subjects for inclusion in neuroprotective drug
trials.
Some studies have recruited individuals with a single strong risk factor such
as carrier status for LRRK2 or GBA mutations, or idiopathic RBD or anosmia,
in order that subjects may be followed prospectively, whereas other approaches
employ large population-based cohorts or retrospective case-control methods to
examine associations with PD and previous medical history. From the former
much is learned about the emergence of PD in specific risk groups, which in
turn may prove to be appropriate cohorts for recruitment to clinical trials. They
are likely to more homogeneous in terms of their disease mechanisms, pathology
and clinical features, as well as being the simplest in which to determine time
to conversion. However, they are perhaps not representative of the spectrum
of PD as a whole. The latter studies are difficult and costly to conduct, with
in-depth assessments and appropriate sample sizes, but allow the investigation
of risk/protective factors and early symptoms and signs that precede emergence
of established PD. This may in turn enable strategic combination of factors to
try and delineate individuals at high risk, whilst also capturing the full spectrum
of PD. Although the magnitude of risk associated with individual risk factors
and early non-motor features has been reported, the best combination of risk
factors for predicting PD remains unknown. Several studies are now seeking to
combine risk factors for PD in order improve predictive power with which those
at increased risk of PD can be identified, with and without imaging markers.
The Prospective validation of Risk factors for the development of Parkinson
Syndromes (PRIPS) study was a large study that sought to determine the mag-
nitude of risk of PD that SN hyperechogenicity conveyed.106 It showed that SN
hyperechogenicity in healthy individuals over the age of 50 years was a risk factor
for PD which carried a RR of 17.3 (95% CI 3.7 to 81.3) for development of parkin-
sonism at 3 years of follow-up. The aforementioned PARS study used objective
smell testing to identify subjects with idiopathic anosmia at stage 1, followed by
DaT-SPECT at stage 2 to identify subclinical presynaptic denervation.104 The
study has reported early results which demonstrated reductions in nigrostriatal
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DaT binding in subjects with hyposmia compared to those with normal smell, as
well as associations between a number of prodromal features of PD within the
study cohort. The Tübinger evaluation of Risk factors for the Early detection of
NeuroDegeneration (TREND) study examines subjects over 50 years of age with
a limited combination of risk factors (age plus anosmia or depression or RBD),
using serial studies of movement, laboratory tests and imaging, with follow up to
incident PD. Baseline data from this cohort have recently been reported showing
associations between prodromal markers and other early associated features of
PD.118
Two large multi-centre studies, one coordinated from the US (the Parkinson’s
Progression Markers Initiative, PPMI) and one based in the UK (the Tracking
Parkinson’s or PRoBaND study), recruit patients immediately after the clinical
diagnosis of PD and undertake detailed clinical, imaging and biomarker studies
longitudinally. Whilst not strictly looking at pre-diagnostic PD, the PPMI and
PRoBaND studies will help define the role of clinical markers (motor and non-
motor) in the early measurement of PD and the identification of novel imaging
and laboratory biomarkers, as well as giving insight into what might be apparent
through reverse extrapolation to the pre-diagnostic phase. The PPMI study also
includes a prodromal arm (P-PPMI) which recruits subjects with RBD or anosmia,
and a genetic arm for those with LRRK2, GBA or SNCA mutations, all of whom
are assessed and followed in the same way as PD subjects, allowing for a seamless
examination of the pre-diagnostic and early disease stages of PD. Similarly, the
PRoBaND recruits first-degree relatives of patients for further assessment. Finally,
as part of a large study aimed at understanding the biological basis of early
PD in patients with established PD, the Oxford Parkinson’s Disease Centre
(OPDC) includes smaller high-risk groups of first-degree relatives or idiopathic
RBD. Clinical assessments, laboratory and imaging biomarker studies are being
undertaken and early results are emerging.119
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1.3 Studies of pre- and peri-diagnostic PD
A
cr
on
ym
S
tu
d
y
n
am
e
P
ar
ti
ci
p
an
ts
C
ou
nt
ry
N
u
m
b
er
T
es
ts
/
O
u
tc
om
e
re
cr
u
it
ed
ex
p
os
u
re
s
H
A
A
S
H
on
ol
ul
u
A
si
a
A
gi
ng
St
ud
y
M
id
dl
e-
ol
de
r
ag
e
U
S
8,
00
6
Sm
el
l(
B
-S
IT
),
E
D
S,
C
lin
ic
al
di
ag
no
si
s
of
P
D
,
m
en
of
Ja
pa
ne
se
co
ns
ti
pa
ti
on
,r
ea
ct
io
n
ti
m
e
pa
th
ol
og
ic
al
di
ag
no
si
s
of
de
sc
en
t
Le
w
y
bo
dy
di
so
rd
er
P
R
IP
S
P
ro
sp
ec
ti
ve
va
lid
at
io
n
of
Su
bj
ec
ts
ov
er
50
G
er
m
an
y/
A
us
tr
ia
1,
84
7
T
C
S,
sm
el
l(
SS
),
U
P
D
R
S
C
lin
ic
al
di
ag
no
si
s
of
P
D
R
is
k
fa
ct
or
s
fo
r
th
e
ye
ar
s
ol
d
de
ve
lo
pm
en
t
of
P
ar
ki
ns
on
Sy
nd
ro
m
es
T
R
E
N
D
T
üb
in
ge
r
ev
al
ua
ti
on
of
R
is
k
Su
bj
ec
ts
ov
er
50
G
er
m
an
y
>
1,
20
0
T
C
S,
sm
el
l(
SS
),
U
P
D
R
S
C
lin
ic
al
di
ag
no
si
s
of
P
D
fa
ct
or
s
fo
r
th
e
E
ar
ly
de
te
ct
io
n
ye
ar
s
w
it
h
an
os
m
ia
,
qu
an
ti
ta
ti
ve
m
ot
or
,b
lo
od
of
N
eu
ro
-D
eg
en
er
at
io
n
se
lf-
re
po
rt
R
B
D
bi
om
ar
ke
rs
,p
sy
ch
om
et
ry
or
de
pr
es
si
on
PA
R
S
P
ar
ki
ns
on
’s
A
t-
R
is
k
Su
bj
ec
ts
ov
er
50
U
S
4,
99
9
U
P
SI
T
U
P
SI
T
,D
aT
-S
P
E
C
T
,
C
lin
ic
al
di
ag
no
si
s
of
P
D
/
Sy
nd
ro
m
e
st
ud
y
ye
ar
s
w
it
h
hy
po
sm
ia
sm
el
lt
es
t
U
P
D
R
S,
co
gn
it
io
n
D
aT
de
fic
it
on
SP
E
C
T
&
D
aT
de
fic
it
at
ba
se
lin
e
bl
oo
d
bi
om
ar
ke
rs
P
-P
P
M
I
P
ro
dr
om
al
P
ar
ki
ns
on
’s
Su
bj
ec
ts
w
it
h
In
te
rn
at
io
na
l
A
no
sm
ia
/
C
SF
&
bl
oo
d
C
lin
ic
al
di
ag
no
si
s
of
P
D
P
ro
gr
es
si
on
M
ar
ke
rs
pr
od
ro
m
al
fe
at
ur
es
R
B
D
=
65
bi
om
ar
ke
rs
,U
P
D
R
S,
In
it
ia
ti
ve
or
ge
ne
m
ut
at
io
ns
G
en
et
ic
co
gn
it
io
n,
sl
ee
p
an
d
=
15
0
au
to
no
m
ic
s,
U
P
SI
T
O
P
D
C
O
xf
or
d
P
ar
ki
ns
on
’s
Su
bj
ec
ts
w
it
h
fir
st
-
U
K
19
0
U
P
D
R
S,
no
n-
m
ot
or
C
lin
ic
al
di
ag
no
si
s
of
P
D
D
is
ea
se
C
en
tr
e
st
ud
y
de
gr
ee
re
la
ti
ve
as
se
ss
m
en
ts
,U
P
SI
T
,
w
it
h
P
D
or
su
bj
ec
ts
bl
oo
d
an
d
C
SF
w
it
h
R
B
D
bi
om
ar
ke
rs
Ta
bl
e
1.
2:
St
ud
ie
s
of
th
e
pr
e-
di
ag
no
st
ic
ph
as
e
of
P
ar
ki
ns
on
’s
di
se
as
e
Le
ge
nd
:
P
D
=
P
ar
ki
ns
on
’s
di
se
as
e;
R
B
D
=
R
E
M
sl
ee
p
be
ha
vi
ou
r
di
so
rd
er
;U
P
SI
T
=
U
ni
ve
rs
it
y
of
P
en
ns
yl
va
ni
a
sm
el
li
de
nt
ifi
ca
ti
on
te
st
;B
-S
IT
=
br
ie
f
sm
el
l
id
en
ti
fic
at
io
n
te
st
;S
S
=
Sn
iffi
n’
st
ic
ks
;D
aT
=
do
pa
m
in
e
tr
an
sp
or
te
r;
SP
E
C
T
=
si
ng
le
ph
ot
on
em
is
si
on
co
m
pu
te
d
to
m
og
ra
ph
y;
U
P
D
R
S
=
un
ifi
ed
P
ar
ki
ns
on
’s
di
se
as
e
ra
ti
ng
sc
al
e;
T
C
S
=
tr
an
sc
ra
ni
al
so
no
gr
ap
hy
;C
SF
=
ce
re
br
os
pi
na
lfl
ui
d;
E
D
S
=
ex
ce
ss
iv
e
da
yt
im
e
so
m
no
le
nc
e.
41
Introduction
1.4 Challenges and opportunities
The above studies aim to overcome the challenge of identifying ‘at-risk’ individuals
that may develop PD with a view to initiating treatment to avoid or delay
symptoms. It is also important to explore biomarkers that might be sensitive to
progression and reflect the underlying disease process, at a time when clinical
features are variable or not yet established (Figure 1.3). These studies aim to
document the time immediately before, during and after the emergence of clinically
recognisable PD, and aim to delineate the clinical and biomarker features of this
phase that will be crucial to commencing clinical trials. However, the screening
potential offered by approaches that rely on limited combinations of risk factors
and early non-motor features, or have a restricted focus to gene carriers only,
may limit the potential gain for the wider patient community. An approach that
combines large numbers of risk factors for PD and that has the potential to screen
a large, community-based population, in order to capture the full spectrum of PD,
whilst remaining cost-effective, would be ideal.
Fig. 1.3: A schematic showing determinants of risk, the pre-diagnostic phase
(pre-clinical and prodromal phases) and clinical phase of PD, with the parallel
application of risk and disease progression markers to measure disease activity
across phases.
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Chapter 2
Preliminary Work
2.1 Early non-motor features, risk and protective
factors for PD - systematic review & meta-
analysis
Observational studies have reported a variety of risk factors for PD and early
non-motor features occurring before a diagnosis of PD (see chapter 1). There have
been a small number of systematic reviews and meta-analyses seeking to pool risk
estimates from these studies, including those considering associations with smoking,
coffee consumption, pesticide exposure, use of non-steroidal anti-inflammatory
drugs (NSAIDs), and subsequent PD.53,59,120,121 No study has comprehensively
assessed the range of early non-motor features and risk factors that predate a
diagnosis of PD. A systematic review of published literaturei was initiated to
determine the range of early non-motor features and risk factors that predate
diagnosis of PD, restricted to those amenable to community screening.122
2.1.1 Methods
Search strategy
The PRISMA 2009 guidelines for systematic review and meta-analysis and the
Cochrane Collaboration definition of both terms were followed.123,124 A MEDLINE
database search was undertaken using Pubmed from 1966 until March 2011 for
studies reporting factors that could be used to screen for risk of future PD.
The MeSH terms search used was: "Constipation" OR "Sleep Disorders" OR
"Olfaction Disorders" OR "Smoking" OR "Colour Vision" OR "Coffee" OR
"Erectile Dysfunction" OR "Depression" OR "Anxiety" OR "Mood Disorders"
iThis was undertaken prior to commencing the work described in subsequent chapters but
is crucial to the project and is therefore replicated in full here.
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OR "Hydroxymethylglutaryl-CoA Reductase Inhibitors" OR "Anti-Inflammatory
Agents, Non-Steroidal" OR "Solvents" OR "Pesticides" OR "Body Mass Index"
OR "Family" OR "Risk" OR "Risk Factors" AND "Parkinson Disease". Analysis
was restricted to articles written in English. Reference lists of suitable retrieved
articles were hand searched for any missed references, as were the reference lists of
existing relevant meta-analyses identified in the original search. The final search
was carried out on 31st March 2011.
Inclusion criteria
Published studies were included if they fulfilled the following criteria: a) assessed
at least one risk factor or early non-motor symptom preceding a subsequent
diagnosis of PD; b) reported original data on relative risks (RR) or odds ratios
(OR) from cohorts representative of the general population or case-control studies
with cases defined as patients diagnosed with PD; c) reported data that could be
easily obtained in a community or primary care environment, i.e. those factors
that could be determined through questionnaires or widely-available blood tests.
Exclusion criteria
Review articles, editorials and commentaries, hypothesis papers, letters that
reported no new data, meta-analyses and abstracts were all excluded. Studies
were also excluded if they: a) reported on treatment and management of PD, b)
considered associations with established PD (i.e. not preceding PD), c) reported
factors not easily ascertainable in the community setting (e.g. complicated
questionnaires on food frequencies, life events, physical activity, environmental,
solvent or toxin exposures and occupations), d) studied young-onset PD only,
e) did not use a control group or provide adequate details of the control group
(including prevalence studies), f) used blood relatives as the control group, g) were
twin studies, h) genetic studies or laboratory studies not used widely, i) reported
on the same risk factor in a common study population (where more than one
paper reported on the same population, the larger or, where equal size, the most
recent report was chosen), j) reported on a disease other than PD, k) reported
measures other than OR/RR or an equivalent (such as proportional mortality
rate and standardised hospitalisation rate) or from which an OR could not be
calculated. If there was disagreement between investigators (AJN, JB, AS), the
articles were discussed in further detail until an agreement was reached.
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2.1 Early non-motor features, risk and protective factors for PD -
systematic review & meta-analysis
Data extraction
Study characteristics, risk estimate of the main study finding and secondary
findings, were extracted for all eligible studies using a standardised template.
Only factors for which a significant association was reported in at least one study
were included. Risk factors were included according to binary measurements
e.g. ‘yes’ versus ‘no’ for having a first degree relative with PD and ‘ever’ versus
‘never’ for alcohol. Data that reported exposures as quartiles or quintiles where
the lowest exposure quartile was equal to zero were converted to binary terms.
Associations reported with medical conditions, drugs or toxins known to cause
symptomatic parkinsonism such as antipsychotics or carbon monoxide poisoning
were excluded. Studies that reported associations with dementia occurring before
onset of PD were not included, as these cases would not fulfil current criteria
for PD and might include cases of Dementia with Lewy Bodies (DLB).125 For
cases, figures were used for PD instead of parkinsonism. In studies that reported
data for both young-onset and typical-age-of-onset PD, the young-onset data were
excluded where possible. If case-control studies made comparison with more than
one control group, the control group most representative of the healthy general
population was used. If studies did not report OR, RR or an equivalent measure,
the raw data were reviewed to determine if ORs could be calculated. In studies
that reported both crude ORs and adjusted ORs, the adjusted figures were used.
After application of the above methods, no additional studies required exclusion
for quality reasons. Length of time that any given factor preceded onset of PD
was not included in the analysis due to inconsistent reporting of these data.
Statistical Analysis
Where a factor of interest was reported by two or more studies in a consistent
manner, these were combined in a meta-analysis; first separately for case-control
and cohort studies (given that cohort studies are less subject to bias), and secondly
for all studies together (considering ORs from case-control studies to be estimates
of RRs) to generate a pooled effect size and 95% confidence interval (CI) for
each factor. Heterogeneity between studies was assessed using the I2 statistic
and, where statistically significant heterogeneity was found (p<0.05), the random
effects model was used to combine results.126,127 Publication bias was assessed
using Egger’s test and where statistically significant bias was found the ‘trim and
fill’ method was used to adjust for it.128,129 Where data were not given in a way
that could be used in the meta-analysis or where only one significant study was
identified for a given risk factor, the findings of these studies were listed as part
of the review. All analyses were performed using Stata.
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2.1.2 Results
The literature search yielded 3,856 English-language articles, of which 202 were
eligible for inclusion in the systematic review and 173 in the meta-analysis (Figure
2.1). The reasons for exclusion of other studies are provided. Full details of
studies included in the meta-analysis are listed in Appendix A (Tables 1 and 2).
Twenty-nine articles that could not be included in the meta-analysis, primarily
due to inconsistencies in method of measurement of the studied risk factor or
because only one study had reported a significant result on a given factor, are
described and shown in Appendix A (Table 3).
Summary results for positive and negative associations with PD found in
the meta-analysis and those where no association was found are shown (Figures
2.2, 2.3 and 2.4). Significant positive associations were found for family history
of PD (including any relative and first degree relatives only), family history of
tremor, preceding constipation, prior mood disorder, exposure to pesticides (or
herbicides or insecticides), previous head injury, rural living, beta-blocker use,
farming/agricultural occupation and well water drinking. Significant negative
associations were found for smoking, coffee drinking, prior hypertension, use of
NSAIDs, calcium channel-blocker (CCB) use and alcohol consumption. No signifi-
cant association was found for oral contraceptive pill use, preceding oophorectomy,
hormone replacement therapy, preceding diabetes mellitus, cancer or gastric ulcer,
acetaminophen/paracetamol or aspirin, tea drinking and prior general anaesthetic.
There was a trend towards a protective effect associated with the use of statins
that fell just short of statistical significance.
In the systematic review additional associations that were reported but could
not be categorised consistently included negative associations with raised serum
urate, and conflicting results with total serum cholesterol, obesity, physical activity,
any antihypertensive medication (without further sub-classification), education
and various occupations. Single studies also reported negative associations with
both parents having smoked and use of smokeless tobacco, and positive associations
with family history of any neurological disease, hyposmia, erectile dysfunction and
excessive daytime sleepiness (EDS), complaints of stiffness, imbalance or tremor,
having a first degree relative with melanoma, having brown, blond and red hair
relative to black hair, a variety of infectious diseases, immediate-type hypersen-
sitivity, anaemia, duration of fertile life and cumulative length of pregnancies,
having three or more children and having no children (see Appendix A, Table 3).
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systematic review & meta-analysis
Fig. 2.1: Studies included and excluded from the systematic review and
meta-analyses.
Legend: OR = odds ratio; PD = Parkinson disease; RR = relative risk.
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Fig. 2.2: Meta-analyses of significant positive associations with future PD.
Legend: CI = confidence interval; RR = relative risk; OR = odds ratio.
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2.1 Early non-motor features, risk and protective factors for PD -
systematic review & meta-analysis
Fig. 2.3: Meta-analyses of significant negative associations with future PD.
Legend: CCB’s = calcium channel blockers; CI = confidence interval; NSAID’s =
non-steroidal anti-inflammatory drugs; RR = relative risk; OR = odds ratio.
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Fig. 2.4: Meta-analyses of non-significant associations with future PD.
Legend: CI = confidence interval; HRT = hormone replacement therapy; RR =
relative risk; OR = odds ratio.
50
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systematic review & meta-analysis
Assessment of publication bias
According to Egger’s test there was evidence of publication bias for the factors ever
smoking (p=0.017), coffee (p=0.002), pesticides (p<0.001), oestrogen (p=0.016),
statins (p=0.038), any family history of PD (p=0.011), family history of tremor
(p=0.009) and well water drinking (p=0.005). Using the ‘trim and fill’ method to
account for bias had no effect on the summary estimate for ever smoking, coffee,
oestrogen or statins but did diminish the summary estimates for pesticides (RR
from 1.78 to 1.53 (95% CI 1.29 to 1.80)), any family history of PD (from 4.45 to
3.25 (95% CI 2.43 to 4.35)), family history of tremor (from 2.74 to 2.51 (95% CI
1.96 to 3.22)) and well water drinking (from 1.21 to 1.20 (95%CI 1.04 to 1.39))
but the conclusion that these were statistically significant risk factors for PD was
not altered.
2.1.3 Discussion
The systematic review identified over 40 individual risk factors of potential value
for clinical screening. Identified factors include genetic and environmental risk
factors, co-morbidities and medication exposures, as well as early non-motor
features which may represent the earliest stages of PD. Whilst some of these have
possible pathogenic importance and others may represent the earliest stages of
PD, they serve as markers which may help identify subjects who are at high risk of
a future diagnosis of PD. They also provide important information for the earlier
diagnosis of PD, which is often delayed by several years.130 Of the 30 factors that
had data amenable to meta-analysis, 19 significantly altered risk of future PD and
11 did not reach statistical significance. This information may be used to form
the basis for primary care or community-based screening as well as improve our
understanding of contribution of risk to subsequent PD for each of these factors.
Family history
Having a family member with PD was the strongest risk factor for later diagnosis
of PD. A number of monogenic causes of PD have been identified and multiple
susceptibility loci described (see chapter 1).14,15,36 Whilst there is still a large
genetic component of risk, as yet unexplained, familial aggregation may also occur
through the effect of a shared environment e.g. concordance for not smoking and
avoidance of coffee, which may influence the risk of PD, either independently or
in conjunction with genetic susceptibility.
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Lifestyle and environmental factors
A history of smoking reduced the risk of PD by about 36%, with coffee and alcohol
(but not tea) consumption also reducing risk. For smoking the effect was strongest
in current smokers and weakest in past smokers (56% for current smokers and
22% for past smokers), but the association remained significant in all. The nature
of this association is still poorly understood, and cannot be explained simply
by selection bias and confounding.131,132,133,134,135 The risk reduction from ‘ever’
versus ‘never’ coffee use and ‘ever’ versus ‘never’ alcohol use was approximately
33% and 10% respectively. A confounding effect of smoking, coffee and alcohol
use in combination has been noted but other investigators suggest independence
of these factors.136,137
Pesticide exposure has been frequently implicated in PD causation.48,138 Despite
differences in populations studied and study design, an overall positive association
with ‘ever’ exposure to pesticides was identified. Some suggest there may be
a greater risk associated with length of exposure to pesticides, but this was
not evaluated in this analysis. The finding that farming was also associated
with subsequent PD may be in part due to increased likelihood of exposure to
pesticides and other chemicals. Inconsistencies in adjustment between studies
made it impossible to determine the importance of this interaction. Rural living
and well water exposure were also significant positive associations. Additional
surrogates for pesticide or chemical exposures were not included such as gardening,
plantation work and solvent exposures requiring more detailed exposure and
lifestyle questionnaires. Other occupations that significantly increased the risk
of PD included being a physician, clerk, carpenter, cleaner or having a legal
occupation. Production workers, drivers, technicians, transport/communication
workers, mechanical/factory workers, metal workers, sales occupations, service
occupations and engineers were reported to have a significantly reduced risk of
subsequent PD. Construction/extraction work had a significant positive effect in
one study and a significant negative effect in another.
Head injury may carry increased risk of PD, particularly in those with re-
peated head injury.50,51 In this meta-analysis head injury with or without loss
of consciousness had a significant but modest effect on the risk of subsequent
diagnosis of PD.
Early symptoms
This review re-affirms the proposed early non-motor symptoms, which may predate
the diagnosis of PD by several years. Constipation and mood disorders appeared to
approximately double an individual’s risk of subsequent PD in the meta-analysis.
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Both constipation and mood disorders have been suggested to correlate with
brainstem involvement that together with olfactory bulb involvement, occurs
early in PD and later spreads to the substantia nigra and to the cortex.9 This
notion would also support a role for hyposmia, erectile dysfunction and EDS
as early features of PD, all of which have been reported to be associated with
significantly increased risk in well-conducted cohort studies.71,81,90 For RBD there
was no suitable observational study to allow the calculation of risk estimates for
the association with PD. Further studies are required to replicate (for hyposmia,
erectile dysfunction and EDS) or delineate (for RBD) the magnitude of risk
each of these conveys and an appropriate method of measurement for each. The
association of a preceding tremor, imbalance and stiffness with later PD (reported
in single studies), may point to early motor manifestations of the disease before a
diagnosis can be made.92
Co-morbidities and medications
Hypertension was associated with reduced risk of PD, but the role of selective
mortality in these individuals had not been studied. The combined analysis of
studies of CCBs suggested a mild but significant overall reduction of PD risk.
Beta-blockers, on the other hand, were associated with increased PD risk. This
could potentially be explained by trials of beta-blockers in those with isolated
tremor that later go on to be diagnosed with PD. A history of diabetes mellitus
did not significantly alter risk; however further studies may be necessary given
that the case-control studies showed a statistically significant decrease in risk
while the cohort studies, which are less prone to bias, showed a statistically
significant increase in risk. Statins showed a trend for reduction in risk of PD
in the meta-analysis, which may be due to a protective role through reduction
of oxidative stress. Hypercholesterolaemia, obesity and physical activity could
not be included due to differences in assessment, and the systematic review found
conflicting results.
NSAIDs were associated with risk reduction by approximately 17%. There
is increasing evidence that inflammation may play a role in the pathogenesis of PD,
which may underlie this finding.16,17,139,140 Aspirin and acetaminophen/paracetamol
were not associated with significant alteration of risk. A number of studies sug-
gested that raised plasma urate might protect against PD and this may also be
related to inflammatory mechanisms since serum urate is a free radical scavenger
and therefore protects against oxidative stress, which may be contributing to
dopaminergic neuronal loss.141
There was no association of subsequent PD with the oral contraceptive pill,
surgical menopause or hormone replacement therapy, although further studies
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for the latter are needed, given that case-control studies showed a statistically
significant decrease in risk, while cohort studies showed a statistically significant
increase in risk. There was no significant association of PD and preceding cancer.
Whilst melanoma was not included as a specific search term, a recent meta-
analysis suggested a positive association of established PD with melanoma, but
no association when melanoma precedes a diagnosis of PD.142
Helicobacter pylori infection has been suggested as a risk factor for PD but
there were no studies that specifically measured an effect size estimate between H.
pylori and subsequent risk PD. A surrogate for this could be gastric ulceration, but
in the meta-analysis there was no association with gastric ulcer and subsequent
PD diagnosis.
Factors not included in analysis
Age and gender were not included in this review as they have mainly been reported
in uncontrolled prevalence studies. Thus, whilst some of the studies included in
the analysis reported risk associated with these variables, a combined risk estimate
is unlikely to be representative of the full published literature on these factors.
Nevertheless, the increased prevalence rate with increasing age and the higher
prevalence in men is accepted and reporting is therefore usually stratified by age
and gender.143,144
Limitations
The search was restricted to articles written in English and reports written in
other languages were not included. Due to the large number of studies used and
the heterogeneity of methods and reported findings, variables were selected on
the grounds that they could be screened for on a population basis. Risk factors
and early symptoms not easily screened for would not have been included. Not
all studies reported estimates of risk that were adjusted for confounders. Where
adjustments had been made, these data were included in the analysis.
Risk factors were dichotomised, which ignored potential dose effects. However,
an essential feature of the analysis was to define factors that could be defined
in binary terms, to allow them to be employed in combination for large-scale
screening.
Statistically significant heterogeneity was found in the majority (24 out of 30)
of meta-analyses performed. In 16 of these there was moderate heterogeneity (I2 50-
75%) and in 4 there was high heterogeneity (I2>75%). This was expected because
of differences in case ascertainment, study population characteristics, exposure
measurement, and whether crude or adjusted risk estimates were reported. For
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this reason, the pooled estimates should be interpreted cautiously, in particular
for those estimates with high heterogeneity (hypertension, statin use, previous
gastric ulceration and rural living).
2.2 Selection and measurement of factors for a PD
risk algorithm
This was the first comprehensive systematic review and meta-analysis to take
account of all risk factors for PD that might be suitable for screening in the
community, and it provided the strength of evidence and magnitude of effect for
each. Despite the fact that some factors may not operate independently of one
another, the potential to develop a community-level, combined screening algorithm
for PD was apparent. However, in selecting components for an algorithm that
could screen for early non-motor features and risk factors, the following factors
were considered to be important:
1. Was there an appropriate and available screening test or question(naire) for
the exposure/factor/feature of interest?
2. Had the identified test or question(naire) been validated in PD?
3. Could it be administered in a self-report fashion?
4. If not, was there a surrogate?
These four questions were applied to each of the identified factors above to
determine how they could be ascertained and the magnitude of risk/protective
effect that would be appropriate to model in the algorithm.
• Age - Age-specific risk of PD was determined in a prospective study of
approximately 22,000 subjects.143 The 10-year risks were 0.11 (95% CI 0.04
to 0.17) at age 45 years, 0.51 (95% CI 0.41 to 0.63) at age 55 years, 1.51
(95% CI 1.30 to 1.71) at age 65 years, 2.63 (95% CI 2.24 to 3.01) at age 75
years, and 3.91 (95% CI 2.96 to 4.86) at age 85 years. Self-report of age was
felt sufficiently likely to be reliable.
• Family history - Having a first, second and third-degree relative with PD
conveyed different magnitudes of risk. The results of the meta-analysis were
used to estimate odds of PD. Given the self-report nature of the questionnaire
and potential for reporting error, only having a first-degree relative (father,
mother, sister, brother, son, daughter) was included in the algorithm.
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• Gender - Male gender was associated with increased risk of PD in two studies
from the UK that were based in Cambridge (population size = 700 000,
ratio male:female 1.36 (95% CI 1.11 to 1.65)) and Aberdeen (population
size = 148 600, ratio male:female 2.30 (95% CI 1.55 to 3.28)).145 Self-report
of gender was felt sufficiently likely to be reliable.
• Smoking - The results of the meta-analysis were used to estimate odds of
PD according to smoking status (‘ever’ (current and past smokers) versus
‘never’). Self-report of smoking status was felt to be moderately reliable and
additional questions were included to verify information, such as number of
years smoked and number of cigarettes smoked per day.
• Coffee and alcohol - The results of the meta-analysis were used to estimate
odds of PD according to coffee and alcohol drinking status (‘ever’ versus
‘never’ for each). Self reporting of coffee and alcohol consumption was felt
to be moderately reliable and an additional question related to quantity.
• Bowel opening - From the systematic review, there was only one prospective
cohort study (HHP) that provided data on bowel habit and laxative use.85
A criticism of this study is that it did not use a validated questionnaire for
constipation. Questionnaires do exist, and have been highly correlated with
clinical observations and investigations.146 Another criticism is that Abbott
and colleagues demonstrated that individuals who open their bowels less
than once a day are more likely to develop PD compared with those that do
so once a day or more.85 This finding does not fully support constipation as
a predictor, since the definition of constipation requires a combination of
features, one of which is fewer than three defecations per week.147 Validated
questionnaires exist and of those available, the Bowel Disease Questionnaire
from the Mayo Clinic, closely aligned with the information gathered from the
HHP.148 Questions were selected from this questionnaire (under the guidance
of CK) to ascertain presence or absence of constipation including frequency
of bowel opening, laxative use, stool hardness and effort to defecate.
• Anxiety and depression - Numerous studies have assessed risk of PD given
a past history of anxiety or depression and pooled estimates were calculated
in the meta-analysis. The questionnaires used to identify anxiety and
depression are often inadequate because the answers to many questions
overlap between mood disorders and PD. Of the questionnaires that are
validated in PD, the 14-point Hospital Anxiety Depression Score (HADS)
to identify mood disorders was thought most appropriate for use in the
algorithm.149 It has been shown to have moderate suitability for screening
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for depression, provides details on anxiety, and can be self-completed in
about 5 minutes.150 The HADS has been suggested as a screening test for
anxiety in PD since it has satisfactory internal consistency and test-retest
reliability.151 Permission was sought and granted to use the HADS in the
risk algorithm.
• Erectile dysfunction (ED) - ED was shown to antedate PD in a large cohort
study (HPFS).90 Self-report of ED was felt to be moderately reliable and
the question used in the HPFS was selected. Subjects were asked to rate
their ability in the previous 3 months, to have and maintain an erection
adequate for intercourse. In the original study, responses were categorised
as very good, good/fair, poor/very poor.
• Excessive Daytime Somnolence (EDS) - EDS was reported to be associated
with future PD in a large cohort study (HAAS). However, it was ascertained
via a questionnaire administered by a technician. Screening questionnaires
used for EDS were felt to be unreliable as self-report tools (personal com-
munication with Paul Reading, Neurologist and Sleep Expert) and so EDS
was not selected.
• RBD - The evidence for RBD as an early feature of PD was convincing and
derived from a variety of sources and study designs. RBD is diagnosed in
the clinical setting using polysomnography (PSG) and electromyography.
In recognition that RBD can predate diagnosis of PD, a group designed
and validated a five-minute RBD screening questionnaire (the RBDSQ) to
screen for RBD.152 A cut-off score of 5 discriminated RBD subjects from
controls with a sensitivity of 96% and a specificity of 56% compared with
gold-standard PSG. Permission was sought and granted to use the RBDSQ
in the screening algorithm.
• Olfactory loss - The HAAS demonstrated the ability of the 12-item B-SIT to
detect olfactory dysfunction preceding diagnosis of PD. The B-SIT is not as
well validated as the full-length 40-item UPSIT in testing smell identification,
and subjective reporting of smell is inaccurate. It was decided that subjects
could receive the US version of the UPSIT via the post, self-complete the
booklets and return them by post. The US version was selected over the
UK version in light of previous extensive validation, including its use with
UK research participants.
• Head injury - Self-report of head injury was felt to be moderately reliable
but there was concern over what subjects might interpret as being sufficient
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to warrant reporting. Therefore the selected question attempted to capture
significant head injuries only with the following wording - ‘Have you ever
hit your head so strongly that you nearly fainted or lost consciousness, or
sustained significant trauma to the face or nose?’. This question was not
previously validated.
• Hypertension - Self-report of hypertension was thought to be unreliable
given that some participants would not know whether their blood pressure
was elevated and others might interpret treated hypertension as being
normotensive. To improve reliability, self-reported medication lists were also
referred to in order to ascertain presence of hypertension.
• NSAIDs, CCBs and beta blockers - These classes of drug were shown to
have associations with PD in the meta-analysis and information regarding
their use was collected using a free text medication box. Manual checking
and categorisation of medication was required prior to analysis.
• Pesticides - Self report of pesticides was thought to be unreliable in terms of
amount and duration of exposure, and the agents exposed to. It was decided
that even if some subjects were able to report this information accurately,
the numbers that did so would be small and there would be no means of
confirming reports. Rural living, farming, and well water consumption were
assumed to be proxies for pesticide exposure in the systematic review, and
only information on farming was gathered via self-report of occupation.
• Other factors - Determinants that did not reach significance in the systematic
review and meta-analysis but could be ascertained through survey included
height and weight (for calculation of BMI). Various hormonal factors (HRT,
OCP), diabetes, cancer, hypercholesterolaemia, peptic ulcer disease and
statin use could be ascertained through medication and co-morbidity lists.
Education and occupation could be determined through specific questions.
Diet and physical activity are very difficult factors on which to collect
information and were not felt to be appropriate or in keeping with the
necessary brevity of the tests. Serum urate could not be collected and
factors identified in single studies (apart from those listed above) were not
sought.
In addition to selecting the factors that would comprise the risk algorithm,
the method of delivery was a key consideration. Cost-effectiveness and the ability
to ‘scale up’ the approach were important considerations, and it was decided that
the algorithm should test subjects via the internet using a customised portal.
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Screenshots of the screening questionnaire in the web portal are shown in Appendix
B.
2.3 Design and development of the BRAIN-tap
test
The BRadykinesia Akinesia INcoordination (BRAIN) test was developed as a
software tool for detecting signs of neurological disease, including PD and cerebellar
dysfunction.153,154 Sequential finger tapping is part of the routine neurological
examination for the detection of bradykinesia, defined as slowness of initiation
of voluntary movement with progressive reduction in speed and amplitude of
repetitive action.
The traditional alternate finger tap test, in which the patient is observed
tapping two mounted counters 15cm apart as fast as possible, has been used for
many years to measure response to symptomatic drug treatment. The BRAIN
test replicated this using a computer screen and keyboard. The user alternately
tapped the S and the ; (semicolon) keys as rapidly and as accurately as possible
over a 60-second time period.
The original version of the BRAIN test was programmed to run in MS-DOS
mode on an IBM-compatible personal computer.153 Here, a modified version was
developed that could run in all standard internet browsers, called the BRAIN-tap
test.
2.3.1 BRAIN-tap test parameters
A software developer (DD) was commissioned to produce a 60-second test that
would record alternate key taps and calculate appropriate parameters to measure
speed and accuracy of tapping. Raw data were generated from key presses as
follows:
• Time and date
• Hand tested (right/left)
• Key pressed (the American Standard Code for Information Interchange
reference of the key)
• Time down (time at which the key was pressed)
• Time up (time at which the key was released)
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Data from key presses were used in calculations that attempted to replicate
the parameters developed and validated in the original version of the BRAIN test:
• Kinesia score (KS) - a measure of rate of movement. The total number of
keystrokes per 60-second time period. In the original version it was the sum
of ‘key pressed’ values.
• Akinesia time (AT) - a measure of dwell time on the keys. In the original
version, it was the cumulative time over the test period that any key
was pressed for longer than 17 millisecond (msec; the repeat rate for the
keyboard). For example, if the fastest time that a key could be pressed
and released (‘Time Up’ minus ‘Time down’) was 46msec, the AT for that
key would be 29msec (46-17 = 29msec). If 120 keys were pressed during a
60-second test, the AT would be 3.6 seconds.
• Dysmetria score (DS) - a measure of coordination. It was a weighted count
of all incorrectly hit keys, with correction for speed. In the original version,
incorrectly hit keys were weighted according to their distance from the
target key. Keys immediately adjacent to the target key were given a score
of 1, those adjacent to these scored 2, and all other keys scored 3. The
sum of incorrectly hit keys was divided by KS to correct for rate-related
inaccuracies.
• Arrhythmia score (AS) - a measure of rhythmicity. It was the variance
of time in between keystrokes (variance of traveling time). In the original
version, it used the time difference values derived from ‘Time up’ to next
‘Time down’.
Once the software produced a calculation for each parameter, a period of
testing started to compare calculations embedded in the software with hand-
calculations using the raw key-press data. This was to ensure that software
calculations were measuring exactly how they were expected to. Ten full tests
were undertaken in each step of analysis using the 60-second version of the test
and a modified 10-second version of the test for brevity in some instances. A
summary of observations from this comparative analysis and changes to software
calculations were as follows:
• KS was inversely related to DS for both software calculations and hand
calculations - this was expected since faster test performance may result in
decreased accuracy.
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• Differences were observed between software-calculated AS and hand-calculated
AS but the two scores were clearly related - it transpired that the software-
calculated scores included a travelling time of 0msec before the first key
press, resulting in high variance compared with hand-calculated AS. The
variance equation was adjusted to calculate sample variance (as opposed to
population variance) by making the denominator n-1. These steps resolved
the differences observed in the software-calculated AS.
• AT was strongly correlated with KS - this was an undesirable association
because it meant that if a subject achieved high KS scores, their cumulative
dwell time could be higher than a subject who achieved very low KS but
substantially longer AT per key-press. Furthermore the 17msec keyboard
repeat rate used in the calculation of AT in the original version of the test
could not be replicated on modern keyboards (and also varied between
keyboard and operating system settings). The previous calculation of
cumulative AT was therefore revised for a calculation of mean AT (total
dwell time divided by number of key presses), without adjustment for
keyboard repeat rate.
• DS was revised so that the target key would generate a score of 1, adjacent
keys scored 2 and all other keys scored 3.
2.3.2 Preliminary validation
The BRAIN-tap test was embedded in a web-portal to enable further testing
and validation with the support of web-developers (AC and CT). An email
communication was sent to staff at the Blizard Institute, Queen Mary University
of London, inviting them to complete the test remotely. The test was undertaken
by 177 subjects and results are shown in Table 2.1.
Kinesia Akinesia Arrhythmia Dysmetria
score (KS) time (AT) score (AS) score (DS)
Mean 137.9 98.8 36365 1.054
(95% CI) 134.1 to 141.7 89.5 to 108.0 21267 to 51464 1.042 to 1.065
Median 137.0 81 12565 1.029
(IQR) 123.5 to 150.5 68.0 to 99.0 7051 to 21873 1.007 to 1.070
SD 25.8 62.4 97006 0.077
Table 2.1: Preliminary tapping data collected from 177 controls remotely.
Legend: CI = confidence interval; IQR = interquartile range; SD = standard
deviation.
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Further investigation was then undertaken in patients with PD, recruited from
the movement disorders clinic at Barts and the London NHS Trust.155 Patients
were diagnosed according to the Queen Square Brain Bank Criteria.3 Both hands
were tested for each patient and KS was correlated against total motor UPDRS
scores. This preliminary work demonstrated significant correlations between KS
and UPDRS, and established that there was no difference in the mean number of
taps in the first 30-seconds and the last 30-seconds of the 60-second test.155 The
test was shortened to 30-seconds prior to full validation which was undertaken as
part of the work contributing to this degree (see chapter 4).
2.4 Design & development of an internet portal
for PD risk screening
A custom-built website was commissioned to deliver the predictive algorithm in a
user-friendly format and store the results securely in line with data protection laws.
The domain names www.predictpd.com and www.predictpd.org were purchased.
Development was undertaken by a commercial organisation (AC and CT at Grass
Roots) who customised proprietary software called People Portal.
Specific considerations in designing the website were that user age, level of
education and experience with computers and the internet may vary greatly.
The aim was to develop a website where simplicity, brevity and data security
were of paramount importance. It had to engage users through a variety of
media and evolve through user feedback, and be largely automated, with minimal
administrator support needed. Users had to be able to access study information,
self-register and consent, and a facility for requesting forgotten passwords was
necessary. The developers designed a logo for PREDICT-PD to capture the
essence of the project (a crystal ball and bold orange text).
On the administration side of the portal, it was necessary to have a survey tool
that could administer a modifiable questionnaire and that would gather responses
in a secure and reliable manner. The ability to view anonymised data and export
these data in standard spreadsheets was also required. The ability to access user
information that might change during the study period was necessary, including
postal address, phone number and email address. This information was important
to enable communication with study participants.
The ‘user-journey’ was considered carefully throughout development. The
study homepage explained the purpose of the study and what was required of
participants (Figure 2.5). The registration process followed standard procedures
used by other secure websites storing personal information. Registration required
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a first name and surname, date of birth, postal address, email address and
telephone number. The email address served as the username for login to the
website. Registration was completed by choosing a password, comprising letters
and numbers, which was used to access the website in the future alongside the
username.
Fig. 2.5: Study login and registration page.
After registering, participants were shown the online consent form and full par-
ticipant information. Questions about the study were directed to the investigators
via email, telephone or post. After completing the check boxes on the consent
form and clicking the ‘submit’ button, participants were taken to the participant
homepage (Figure 2.6). Participants were shown a brief summary of the tests that
would follow. The first test was the screening questionnaire, which covered the
early features and risk factors discussed in section 2.2 and took approximately 20
minutes to complete. The survey had a user-friendly interface (drop-down boxes
and radio buttons) and navigation options away from the survey were removed to
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improve completion rates. In addition, the screening questionnaire covered level of
education, occupation, height and weight (for BMI). Free text input was used to
record co-morbidities and current medication. Participants were then taken to the
BRAIN-tap test page (section 2.3) and completed a test for each hand. There was
then the opportunity to provide feedback on the website or the study itself. After
completing the test elements, a smell test survey option became automatically
available within the website. This questionnaire enabled the answers of the UPSIT
smell test to be completed online after smell tests had been received in the post.
Fig. 2.6: Participant homepage.
The website was secured by a dedicated Secure Sockets Layer (SLL) certificate.
This was renewed on an annual basis and provided 128-bit (up to 256-bit) data
encryption. SLL certification is designed for websites that deal with sensitive
information such as bank account data and medical health records. The software
and databases hosted and stored by the commercial organisation (Grass Roots)
were ISO 27001 accredited, which is the international data handling standard.
Investigators required access to both subject identifiable information (for commu-
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nications and dispatch of additional tests) and test results. Both datasets were
held separately to preserve the integrity of identifiable information.
The web-portal configuration, development of the BRAIN-tap test and selection
of factors for the screening algorithm were completed before the work pertaining
to the research degree began.
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Chapter 3
Project aims and objectives
• To recruit a group of participants from the community via the internet that
would form the basis of a longitudinal cohort to determine those at risk of
PD.
1. To use a web-based platform for subject recruitment and stratification
with a preliminary algorithm for PD risk, comprising questions on
risk factors and early non-motor features, and objective smell and
finger-tapping tests.
2. To validate the computer keyboard finger-tapping test (the BRAIN-tap
test) in PD patients and healthy controls, and integrate this into the
above web-platform.
• To demonstrate that subjects estimated as being higher risk have an excess
of features associated with the PD prodrome when compared to subjects
estimated to be at lower risk, including:
1. Differences in intermediate markers (smell loss, sleep disturbance and
finger tapping speed).
2. Differences in the frequency of gene mutations.
3. Differences in imaging appearances on transcranial sonography and
123I-FP-CIT SPECT.
• To explore whether subjects estimated as being at higher risk have a greater
chance of diagnosis with PD during follow-up.
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Chapter 4
The BRadykinesia Akinesia
INcoordination (BRAIN)-tap test
4.1 Introduction
The Bradykinesia Akinesia Incoordination (BRAIN) test was a software tool for
detecting signs of neurological disease. The original version of the BRAIN test was
programmed to run in MS-DOS mode on an IBM-compatible personal computer.153
A modified version (the BRAIN-tap test) that can run in all standard internet
browsers was developed, in which the patient or research volunteer completed the
test online and the results were uploaded to a secure database for storage and
analysis (see chapter 2.3). Here the validation of this test is described.
4.2 Methods
Participants gave informed consent via the BRAIN-tap test website. The web-
based consent form listed relevant consent statements and each statement was
associated with a check box. Participants checked each box before clicking
the ‘submit’ button on screen. The Queen Square Research Ethics Committee
approved the study (reference 09/H0716/48) and this specific method of obtaining
consent. Patients who fulfilled the Queen Square Brain Bank criteria for the
clinical diagnosis of PD and age-matched non-neurological controls were recruited
from the outpatient department at the Royal London Hospital and the National
Hospital for Neurology and Neurosurgery.3
Participants undertook the test seated at a desktop computer and keyboard.
They followed on-screen test instructions and received no assistance during the test.
Participants were allowed to choose which hand was tested first in acknowledgement
of the fact that use may frequently be unobserved. Each participant undertook
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two tests (one for each hand). Preliminary study established that a 30 second
time period gave adequate information and would lead to greater compliance than
testing for one minute (see chapter 2.3). Demographic data were recorded for all
participants including gender, year of birth, level of education and self-reported
hand dominance. For controls, additional co-morbidity information was recorded.
For patients with PD, current medication, time of last dose of levodopa, number
of years since diagnosis and Hoehn-Yahr stage were recorded. Patients with PD
were examined using the motor section of the Movement Disorders Society Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS). The MDS-UPDRS includes a
question about the clinical state of patients on medication. ‘On’ is the typical
functional state when patients are receiving medication and have a good response
and ‘Off’ is the typical functional state when patients have a poor response in
spite of taking medication. These definitions of ‘On’ and ‘Off’ were recorded for
each patient.
For reliability testing, 17 of the controls were asked to repeat the test multiple
times for each hand. This had the secondary advantage of being able to investigate
the possibility of a learning effect. Due to the tendency of motor features of PD
to change in relation to medication and potentially time of day, PD patients were
not included in tests measuring reliability. However, six patients with PD and
known motor fluctuations were invited to undertake the test on several occasions
during the day, before and after medication in order to evaluate the BRAIN-tap
test in monitoring motor fluctuations.
The BRAIN-tap test calculates four variables from the raw key-press data:
• kinesia score (KS), the number of key taps in 30 seconds.
• akinesia time (AT), the mean dwell time on each key in milliseconds (msec).
• dysmetria score (DS), a weighted index using the number of incorrectly hit
keys scored in a target fashion (1 point for the correct key, 2 points for
immediately adjacent keys and 3 for other keys) then divided by the total
number of key taps (i.e. if all keys are hit correctly, the score should be 1.0).
• incoordination (or arrhythmia) score (IS), the variance of the time interval
in msec between keystrokes.i
Statistical methods
Descriptive statistics were calculated for all four variables. For continuous vari-
ables, means were reported if the data were normally distributed (assessed using
iIS was called AS in chapter 2 but was changed to IS to avoid confusion with AT.
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the Shapiro-Wilks test) and medians were reported if not normally distributed.
Within-group (PD or control) comparisons were performed using the paired t-test
for normal distributed data or Wilcoxon-signed rank test for non-normally dis-
tributed data. Between-group comparisons were made using the unpaired t-test
or Wilcoxon rank sum test. The sensitivity and specificity of test parameters sep-
arately were determined using receiver operated characteristic (ROC) curves. The
combined effect of parameters to identify cases versus controls was assessed using
logistic regression. Associations between UPDRS and BRAIN-tap test parameters
were estimated using Spearman’s rank correlation coefficient for non-normally
distributed data. Coefficients of variation were calculated to determine reliability
of test parameters in control subjects undertaking the test multiple times and
p-values were derived from using multilevel mixed effects linear regression.ii The
pre-determined significance level for all calculations was p=0.05. All analyses
were performed using Stata and GraphPad Prism for Mac.
4.3 Results
There were 58 PD patients and 93 non-neurological controls included in the
main analysis (for group characteristics see Table 4.1). One PD patient and one
control subject were ambidextrous and were excluded from analyses that compared
dominant and non-dominant hands. One PD patient tested in the clinic had
incomplete UPDRS data and was excluded from those specific analyses.
Associations of KS, AT, IS and DS with age, gender, education, occupation
and co-morbidities were undertaken in controls (see Table 4.2). KS, AT and IS
correlated with age of control subjects (r= -0.47, 0.31 & 0.34 respectively; p<0.001,
0.002 & <0.001 respectively). KS decreased by 0.66 points, AT increased by 1.35%
and IS increased by 4.7% per year of age (all p=0.001). No significant correlation
between DS and age was seen (r=0.16; p=0.12). Lower levels of education tended
to give poorer scores for KS and AT, and gave significantly poorer scores for IS and
DS. Analyses considering occupation showed that having a professional occupation
gave significantly better KS scores, but there were no significant differences in
the other parameters for different occupations. The presence of comorbidity did
little to affect test results except for the finding that having any comorbidity
worsened IS compared to those with no comorbidity and KS was non-significantly
lower in those with depression. There was no significant effect of handedness and
parameters were similar between males and females, except that females were
significantly more accurate than males (improved DS).
iiThis specific analysis was done by Jonathan Bestwick. All other analysis was done by
Alastair Noyce.
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PD Controls
Number 58 93
Mean age (SD) 63.0 (10.6) 60.5 (13.1)
Gender
· Male 37 (64%) 32 (34%)
· Female 21 (36%) 61 (66%)
Education
· Primary 2 (4%) 4 (4%)
· Secondary 35 (60%) 46 (50%)
· Higher 7 (12%) 19 (20%)
· Further 14 (24%) 24 (26%)
Occupation
· Professional 10 (17%) 26 (28%)
· Non-professional skilled 23 (40%) 37 (40%)
· Non-professional non-skilled 10 (17%) 22 (24%)
· Retired with no additional information 15 (26%) 8 (8%)
Handedness
· Right 54 (93%) 81 (87%)
· Left 3 (5%) 11 (12%)
· Ambidextrous 1 (2%) 1 (1%)
Mean years since diagnosis (SD) 8.4 (6.6) -
On/Off at time of test∗
· On 38 (66%) -
· Off 20 (34%) -
Levodopa
· Yes 52 (90%) -
· No 6 (10%) -
Mean minutes since levodopa dose (SD) 186 (133) -
Hoehn-Yahr stage
· Stage 1 11 (19%) -
· Stage 2 34 (59%) -
· Stage 3 13 (22%) -
Table 4.1: Demographic information for cases and controls.
Legend: PD = Parkinson’s disease; SD = standard deviation. ∗On/Off in this
table refers to the question in the MDS-UPDRS, which asks whether participants
could feel the effects of medication at the time of testing.
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When PD patients (n=58) and controls (n=93) were compared using averages
of the scores from each hand; KS, AT and IS discriminated between groups, but
DS did not (see Table 4.3 and Figure 4.1). KS showed the best discrimination
between PD and controls with sensitivities of 45%, 50% and 57% for specificities of
90%, 85%, and 80% respectively. Corresponding sensitivities were 31%, 40% and
43% for AT and 24%, 29% and 36% for IS. The addition of AT or IS to KS did not
improve discrimination compared with KS alone (assessed by multivariate logistic
regression). When patients that were ‘On’ were excluded and patients that were
‘Off’ (n=20) were compared to controls, the sensitivities for 90% specificity were
65%, 50% and 55% for KS, AT and IS respectively. Subjects tested whilst ‘On’
had better KS scores than subjects who were tested whilst ‘Off’ (47.8 and 37.3
respectively, p=0.002). IS scores were also significantly better in those that were
‘On’ (11682 and 29568 respectively, p=0.007) and there was trend for improvement
in AT (125.1msec and 172.6msec respectively, p=0.27).
Fig. 4.1: Comparisons between cases and controls are made for: (a) mean KS
with 95% confidence intervals, (b) median AT with interquartile range, and (c)
median IS with interquartile range. Corresponding receiver-operating
characteristic (ROC) curves are also shown for these three parameters (d-f).
Hands were compared in patients and controls (see Table 4.4). In both the
dominant and non-dominant hands tests mean KS was significantly lower in PD
patients than controls, and AT and IS were significantly higher. In patients and
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controls the dominant hand significantly out-performed the non-dominant hand
for KS and AT, but not for IS or DS.
BRAIN-tap test scores in PD patients only were compared to total motor
UPDRS scores and sub-scores (see Figure 4.2) using averages of the scores from
each hand. KS showed a moderate inverse correlation with total motor UPDRS
(Spearman’s r= -0.53, p<0.001). AT and IS showed weak but significant positive
correlations with total motor UPDRS (Spearman’s r=0.27, p=0.03 and r=0.28,
p=0.03 respectively). DS showed no correlation. Further correlations were
undertaken with sub-sections of the UPDRS including upper limb tone, finger
tapping, hand opening and closing, and pronation-supination (see Table 4.5).
In PD patients there was a difference of borderline significance with lower KS
in the more affected hand when compared to the less affected hand (mean KS
42.5 v 44.8, p=0.053). There was no difference in AT, IS and DS between the
two hands (median AT 134 v 128, p=0.350; median IS 12604 v 12048, p=0.421,
median DS 1.034 v 1.051, p=0.569). Duration of PD in years did not correlate
with any of the four parameters (data not shown).
Seventeen of the controls repeated the BRAIN test five times for each hand
to estimate the reliability of KS, AT, IS and DS. The coefficient of variation for
KS was 6.0%, for AT was 7.3%, and for DS was 3.4%. IS had a high coefficient
of variation reflecting the fact that pauses in the test (even in control subjects)
magnify the variance of travelling time significantly, decreasing the reliability of
IS overall. There was a mild learning effect that saw KS increase by 1.2 taps per
attempt (p=0.002) but no learning effect for AT (decrease of 1.0msec per attempt,
p=0.203) or for IS and DS (p values derived from multilevel mixed effects linear
regression).iii
Finally, using KS and AT, the effect of medication was assessed in a small
number of PD patients with predictable motor fluctuations (Figure 4.3) and also
in patients with unpredictable fluctuations (Figure 4.4).
iiiPerformed by Jonathan Bestwick.
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Fig. 4.2: Total motor UPDRS correlated against BRAIN-tap test parameters.
Legend: r = Spearman’s rho.
KS AT IS DS
r p-value r p-value r p-value r p-value
Tone -0.21 0.03 0.17 0.08 0.10 0.31 -0.02 0.80
Finger tapping -0.44 <0.001 0.20 0.03 0.33 <0.001 0.03 0.79
Hand move -0.57 <0.001 0.35 <0.001 0.39 <0.001 0.06 0.55
Pro-supination -0.34 <0.001 0.31 0.001 0.21 0.02 -0.01 0.91
Table 4.5: BRAIN-tap test parameters and UPDRS sub-scores.
Legend: r = Spearman’s rho.
4.4 Discussion
The BRAIN test has previously been shown to differentiate individuals with
PD from healthy controls and also to correlate with PD severity measured by
disease-specific rating scales.153,154 The results of these two studies, in which the
original version of the test was performed on a single laptop computer under
defined conditions, have been replicated here with this new online version of the
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Fig. 4.3: Predictable motor fluctuations in KS and AT.
Arrows indicate times at which a dose of levodopa-containing medication was
taken.
Fig. 4.4: Unpredictable motor fluctuations in KS and AT.
Arrows indicate times at which a dose of levodopa-containing medication was
taken.
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test, allowing it to be administered without direct observation or investigator
input. It can be accessed remotely from wherever there is an internet connection
and a computer (laptop or desktop) keyboard.
In PD patients, KS correlated significantly with total motor UPDRS score,
and limb specific sub-scores, as clinical indicators of motor disease severity. AT
and IS also correlated significantly, albeit less strongly than KS, with the total
motor UPDRS score and some of the limb specific sub-scores.
Data for PD and non-neurological controls showed wide intra-group variability
and yet the differences between KS, AT and IS are highly significant and of
clinically relevant magnitude, enabling cut-offs for sensitivity and specificity to be
determined. Results are presented to optimise specificity, with resulting moderate
to low sensitivity, thereby reducing the false-positive rate in acknowledgment that
the test will often be performed remotely. Of course sensitivity and specificity
operate on a continuum and much higher sensitivity can be achieved if the cut-offs
are altered to accept a higher false positive rate.
Age clearly affected most of BRAIN-tap test parameters and should be taken
into consideration in future studies using the test. Education also influenced
parameters perhaps reflecting an effect of computer literacy. However, this was not
further reflected when examining occupation, with which strong relationships could
not be found. This perhaps reflects widespread uptake of computers regardless of
whether use is work-related or recreational. Patients that were tested whilst ‘On’
performed better than those that were ‘Off’. When PD patients that were ‘Off’
were compared to controls, the discriminative ability of KS, AT and IS improved
significantly. Comparison of most and least affected sides in PD patients only
showed trends for poorer scores on the most affected side, perhaps reflecting
bilateral involvement in 80% of the patient group (Hoehn and Yahr score 2 & 3).
Whilst not seemingly useful for differentiating PD from healthy controls, the
dysmetria score (DS) does provide a useful reference for judging whether tests
have been completed properly, which is particularly valuable for remote testing.
For example, the mean KS in controls is 60.3 and has a standard deviation of 13.1.
Using three standard deviations as a cut-off, it is unlikely that an individual can
exceed 100 alternate taps in 30 seconds without a dramatic loss of accuracy as
reflected by the DS. Occasionally very high scores have been seen in remote tests,
with perfect or near-perfect accuracy (e.g. KS of 200 and DS of 1.0). This suggests
that the subject is using two hands to hit the keys and is not alternating between
keys with a single hand, and such results should be excluded from analyses.
Some highly specialised tools have been developed that can accurately measure
the specific motor deficit that occurs in PD and some have the capacity to
differentiate the sequential tapping abnormalities in PD (true bradykinesia) from
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that seen in progressive supranuclear palsy and atypical tremors.156,157,158 When
compared to such tools, the BRAIN-tap test appears fairly crude, but these
specialist tests, whilst fulfilling a valuable role in research, are not currently
applicable in routine clinical practice. Further study using the BRAIN-tap test
could assess whether a sequence effect can be demonstrated in patients that are
‘Off’ medication following a period of drug withdrawal and also study greater
numbers of patients with motor fluctuations in their ‘On’ and ‘Off’ phases, since
the current study does not address these important aspects fully.
A criticism levelled at the BRAIN test during preliminary testing was that
not all keyboards have identical characters, particularly outside the US and UK.
Furthermore, the position of the S and ; keys on the keyboard can vary between
countries. These keys were originally chosen because they are 15 cm apart on a
US/UK English standard desktop computer keyboard and most laptop computers.
If one considers a standard keyboard divided in two halves by an imaginary line
down the centre, then these keys occupy a central position on their respective
sides. In countries where US/UK English keyboards are not standard, the test
can still be used with the keys that correspond to the position of S and ; and has
been implemented successfully by groups in Italy, Norway and the Netherlands
(personal communications).
During testing no evidence was found that use of different keyboards resulted
in significant differences to results between subjects. However, use on tablet
computers may be limited by the availability of the ; key and the different nature
of touching a screen rather than pressing a key. As such it is not advisable to
use the BRAIN-tap test on tablet computers or smart phones (but again this is a
focus of further work). In addition, use of sterile covers for keyboards in clinical
settings may impair key presses. This might conceivably result in loss of accuracy
(DS30) but is unlikely to affect the other three parameters (KS, AT and IS).
Undoubtedly the greatest value of the BRAIN-tap test in established PD
may come in the longitudinal monitoring of individual patients throughout the
duration of their disease, including response to treatment and monitoring motor
fluctuations. Repeat testing in controls suggests good reliability for three of the
four parameters and only a minimal learning effect. In this analysis, control
subjects repeated the tapping tests back-to-back and the fact that only a minimal
learning effect was noted makes it unlikely that improvements due to learning
would be seen were serial tests separated by days or weeks.
In the Honolulu Asia Ageing Study (HAAS) it was demonstrated that men in
the slowest tertile of a reaction time test were significantly more likely to have
Lewy body pathology at post mortem.159 Postuma and colleagues have followed
up a large cohort of patients with RBD, which is a strong risk factor for PD. They
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demonstrated that motor deterioration could be measured for approximately 4-8
years across a number of motor domains (including alternate finger tapping) prior
to the diagnosis of PD. The premotor period has been estimated to last between
5-15 years prior to the diagnosis of PD.76 The term pre-diagnostic PD is preferred
in this context; given the stringent motor criteria that must be met for a clinical
diagnosis (including demonstration of a sequence effect), it seems likely that subtle
motor dysfunction must be present at an earlier stage.92,93
The online BRAIN-tap test is a simple, validated, objective tool to longitu-
dinally monitor motor function not only in established PD but also in studies
seeking to identify those at higher risk of future PD. The BRAIN-tap test can be
accessed at www.braintaptest.com. Tokens for individual use can be requested by
clinicians and researchers via the website.
82
Chapter 5
Risk of PD in the community:
baseline data from PREDICT-PD
5.1 Introduction
A range of risk factors and early non-motor features of PD have been reported
from observational studies and were reviewed in chapter 1. Chapter 2 described
preliminary work, including a systematic review and meta-analysis to determine the
magnitude of risk associated with each factor, the selection of factors to ascertain
risk in the community using a preliminary algorithm, and the development of an
online portal to recruit and test research participants. In chapter 5, the initiation
and baseline line data analysis of the PREDICT-PD study is described, which
incorporated the work of previous chapters, including the validated BRAIN-tap
test from chapter 4.
At baseline, the performance of the preliminary algorithm was assessed by
comparing the occurrence of a combination of ‘intermediate markers’ for future
PD, including three of the strongest individual markers of increased PD risk (smell
loss, self-reported RBD and finger-tapping speed), in those estimated to be at
higher risk of PD compared with those estimated to be at lower risk. Confirmation
of validity will be tested in longitudinal follow-up of study participants, using
imaging, genetics and incident PD diagnosis as additional outcomes.
5.2 Methods
The study was approved by Queen Square Research Ethics Committee (reference
10/H0716/85). Participants were recruited via the study website following a
limited advertising campaign on local radio and in magazines with an older
readership, and by email to members of the Parkinson’s UK charity. Participants
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submitted an online consent form before passing to the secure test area. Inclusion
criteria were residency in the UK and age 60-80 years. Exclusion criteria were
pre-existing PD, movement disorder, stroke, motor neurone disease, dementia, or
drug usage known to be associated with iatrogenic parkinsonism.
Participants completed a survey with demographic questions and items related
to early non-motor features and risk factors for PD, which incorporated validated
questionnaires, i.e. the Hospital Anxiety Depression Scale (HADS),149 the RBD
Screening Questionnaire (RBDSQ),152 and a number of individual questions that
had been used in good quality observational studies that previously reported risk
factors for PD (see chapter 2). For the RBDSQ, a cut-off score of ≥5 was used,
which has previously been shown to have a sensitivity of 96% and specificity of 56%
for diagnosis of RBD confirmed by polysomnography (PSG).152 The overall survey
length was 56 items and it took approximately 20 minutes to complete, based
on prior testing by members of the research team and 10 independent healthy
volunteers aged 60-80 years, whose data were not included in the results. Screen
shots of the questionnaire embedded in the website can be seen in Appendix B.
Immediately after the survey, participants were invited to undertake a keyboard
tapping task, the BRAIN-tap test, used to assess upper limb motor function (see
chapters 2 and 4). Participants were also sent the US version of the University of
Pennsylvania smell identification test (UPSIT) via post. The UPSIT is a 40-item
scratch and sniff smell test (composed of 4 booklets, each with 10 test pages) that
has been used extensively in the investigation of smell disturbance in neurological
disease. Based on methods used by the Parkinson’s At-Risk Study (PARS), in
which impaired smell was used to identify individuals at risk of future PD, the
lower 15th centile of UPSIT scores was used as a cut-off to denote hyposmia (scores
were not adjusted for age and gender as they were in PARS).160 Answers to the
UPSIT were entered on the study website by most participants. A minority (n=
155) returned results completed in the test booklets only.
Analysis
Based on the results of systematic review (see chapter 2), which provided risk
estimates for each early non-motor feature or risk factor significantly associated
with altered risk of PD, a preliminary algorithm was developed to provide PD
risk estimates for each participant. The algorithm included age, gender, smoking
status, first degree relative with PD, coffee use, alcohol use, hypertension, NSAID
use, calcium channel blocker use, beta blocker use, constipation, previous head
injury, anxiety or depression and erectile dysfunction (in males only). Most factors
were sought in binary terms (i.e. presence or absence) except for bowel movement
frequency (7 possible answers for frequency with a cut off of less than 1 movement
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per day denoting low frequency or laxative use), erectile dysfunction (3 options
with ‘poor’ indicating dysfunction) and mood (a cut off score of 11 or above in
either the anxiety or depression components of the HADS questionnaire denoting
moderate forms of these disorders or antidepressant use). In order to keep the
survey simple, pesticide exposures, proxies for organo-chemical exposure, and more
complicated factors were not included. Any subject that reported a neurological
diagnosis listed in the exclusion criteria was removed from the analysis.
Smell loss and RBD, which are reported to be two of the strongest estimated
risk factors for future PD (along with finger tapping in selected risk groups76),
were not included in the algorithm. These were instead used as ‘intermediate
markers’ or proxies for preliminary validation of the basic algorithm (see below).
For each individual, the age-related risk (expressed as an odds) of developing
PD was determined based on results from the Physicians Health Study.143 The
equation determined from these data was:i
Odds of PD = 1 : 28.53049 + 73.67057e(−0.165308(age−60))
As these data were from an all-male cohort, and prevalence of PD is approx-
imately 1.5 times greater in men, the age-related odds for women was reduced
accordingly.144 An individual’s risk was increased or decreased by each of the
above factors according to the strength of association with PD reported in the
systematic review. For example a male, current smoker with a 1:100 age-related
odds of developing PD was calculated to have an odds of 0.44×1:100=1:227. If
that individual also had a family history of PD their odds was calculated as
4.45×1:227=1:51. The odds for all participants were ranked and the 15% with
the highest risk and 15% with the lowest risk scores were identified.
The preliminary validity of this recruitment and risk estimation method was
tested by comparing three of the potentially strongest individual markers of
increased PD risk (smell loss, RBD and finger-tapping speed) between the 15% of
participants calculated to be at highest and lowest risk. Several lines of evidence
(including pathology and imaging) suggest that loss of smell may be a sensitive
(albeit not specific) predictor of PD.68,69,70,71 RBD is rare in the general population
but its presence carries a high risk of conversion to PD in longitudinal cohort
studies making it relatively specific, albeit not sensitive.72,75,77 Bradykinesia is a
core feature of PD and subtle motor signs can precede the diagnosis of PD by
several years, suggesting that finger tapping may be a sensitive early feature for
those at higher risk of PD.3,76,92,93
iDerived by Jonathan Bestwick.
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The central hypothesis at baseline was that if the preliminary algorithm was
successful, those in the higher risk group would have significantly lower UPSIT
scores, higher rates of RBD and slower tapping speeds (KS) than the lower-risk
group. Confirmatory findings would suggest that the algorithm was enriching a
population for increased risk of PD.
Statistical methods
UPSIT, RBDSQ and BRAIN-tap test scores between the 15% highest and 15%
lowest risk individuals according to the algorithm were compared using t-tests and
described using means and 95% confidence intervals, where data were normally
distributed. Where data did not follow a normal distribution, medians (with
interquartile ranges) and the Wilcoxon Rank Sum test were used. Comparisons
using categorical data were made using the Chi-squared test. The relationships
between UPSIT, BRAIN and RBDSQ scores with estimated risk of PD (trans-
formed to log odds) in the whole dataset were also examined using median, linear
and Poisson regression respectively.ii All analyses were performed using Stata.
5.3 Results
Figure 5.1 shows the flow of participants in the study. Of the 1463 individuals
that registered, consented and completed the survey, 140 of these met exclusion
criteria in light of their past medical history (including existing PD and other
neurological diagnoses), country of residence or age. This left 1323 eligible survey
responders, of whom 1146 undertook the BRAIN-tap test and submitted results
for at least one hand. Upon analysing these data, 67 BRAIN-tap test results
were deemed unsuitable for inclusion leaving 1079 results for the final analysis.
Most excluded BRAIN-tap test results were because of implausibly low (<20) or
implausibly high (>110) KS scores since they indicated that the test instructions
had been misunderstood or, that the test was performed using two hands together
rather than separately. Other cases were excluded if their dysmetria score (DS)
was greater than or equal to 1.5, indicating at least half the keystrokes were to
the wrong key. These cut-offs were assigned based on previous BRAIN-tap test
data (see chapter 4). The funding enabled 1065 participants to be sent smell
tests. Results were received for 908 of these either via the website or as a hard
copy, of which 20 were incomplete and 888 were suitable for inclusion in final
analysis. Thus 81.6% of eligible individuals who successfully undertook the survey
iiThis part of the analysis was performed by Jonathan Bestwick.
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completed a suitable BRAIN-tap test, and 83.4% of people that were sent a smell
test completed it and submitted results that could be used in the analysis.
The prevalence of factors that contributed to individuals’ predicted risk of PD
is presented for the whole group, for the 15% of participants with the highest
and for the 15% of participants with the lowest estimated risks in Table 5.1. The
results for the three proxies (UPSIT, RBDSQ and BRAIN-tap test scores) were
also determined in these three groups (Table 5.2).
Fig. 5.1: Number of participants that were recruited, were eligible and that were
sent and completed acceptable smell tests (UPSIT), REM-sleep behaviour
disorder questionnaires (RBDSQ) and finger tapping (BRAIN-tap) tests.
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All subjects Higher risk Lower risk
n=1,323 n=198 n=198
Female 806 (61%) 42 (21%) 170 (86%)
Median age (IQR) 66.2 (63.5-70.5) 70.2 (67.1-74.7) 63.0 (61.4-64.6)
Smoking status
· Current 51 (4%) 3 (2%) 28 (14%)
· Former 541 (41%) 87 (44%) 88 (44%)
First degree relative 208 (16%) 74 (37%) 1 (1%)
Drink coffee 1187 (90%) 173 (87%) 194 (98%)
Drink alcohol 1143 (86%) 179 (90%) 177 (89%)
Hypertension 348 (26%) 59 (30%) 75 (38%)
NSAID use 83 (6%) 6 (3%) 19 (10%)
CCB use 155 (12%) 30 (15%) 25 (13%)
Beta blocker use 103 (8%) 30 (15%) 15 (8%)
Constipation 215 (16%) 73 (37%) 1 (1%)
Head injury 327 (25%) 86 (43%) 11 (6%)
Mood 159 (12%) 37 (19%) 9 (5%)
ED (males) 180 (35%) 132 (85%) 0 (0%)
Table 5.1: The prevalence of factors that contributed towards risk estimates
shown for all participants and 15% of participants with highest and lowest risk
estimates.
Legend: IQR = interquartile range; NSAID = non-steroidal anti-inflammatory
drugs; CCB = calcium channel blockers; ED = erectile dysfunction.
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In the 15% of subjects with highest estimated risk, the median UPSIT score
was 31 (IQR 28 to 34) and in the 15% of subjects with the lowest estimated
risk it was 33 (IQR 31-35; p<0.001). Using the lower 15th centile as a cut-off,
corresponded to an UPSIT score of 27 or less.160 Five percent (7/130) of the lower
risk participants had an UPSIT score below or equal to 27 and 22% (30/138) of
the higher risk participants (p<0.001). The median RBDSQ score in the lowest
and highest risk groups was 2 and 2.5 (IQR 0 to 3 and 1 to 4 respectively), and
the sum of the ranks was larger in the higher risk group (p<0.001). Using the
RBDSQ cut-off score of ≥5, more people had RBD in the higher compared to the
lower-risk group (23% versus 12%, p=0.003). For the BRAIN test, the mean KS
scores in the worst hand for each subject in the higher and lower risk groups were
50.9 and 54.6 respectively (p=0.002). There was no significant difference in the
proportion of the higher and lower risk that fell beneath the 15th centile cut-off of
≤44 taps and there was no significant differences in the other three BRAIN test
variables (data not shown).
UPSIT, RBDSQ and KS scores were plotted against estimated risk of PD in
all participants (Figure 5.2). Estimated risk of PD as calculated by the algorithm
doubled with a decrease of UPSIT scores by 0.67 points (95% CI 0.46 to 0.88;
p<0.001), an increase of RBDSQ scores by 9.5% (95% CI 6.2% to 12.7%; p<0.001)
and a decrease of KS scores in the worst hand by 1.0 points (95% CI 0.55 to
1.47; p<0.001). Regression analyses for each outcome were repeated using risk
estimates that excluded age and gender. The association between risk scores and
intermediate markers remained statistically significant (UPSIT p<0.001, RBDSQ
p<0.001, KS p=0.021).
5.4 Discussion
Internet-based recruitment gave rise to a large sample size without high expen-
diture; the participants were recruited relatively easily and completion rates for
individual stages of the study were high. The penetration of the internet has
increased over the last decade, including use in the over 60’s age group. This
means that similar research can be undertaken via the internet as a means of
accessing large populations, with frequent re-testing and relative convenience,
whilst dramatically reducing the cost, when compared to traditional longitudinal
studies. The methods relied on self-recruitment, which introduces potential for
selection bias, and also on self-reporting without confirmation of results (except
smell testing and tapping speed which were objectively measured). This method,
even with future modification, is unlikely, on its own to be a reliable measure
of pre-diagnostic PD. However, one outcome of this type of study would be to
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Fig. 5.2: (a) Smell test (UPSIT), (b) RBD questionnaire (RBDSQ) and (c) finger
tapping scores plotted against estimated risk of PD with regression curves and
p-values.
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provide a mechanism by which a group at increased risk can be identified from the
general community for inclusion in more detailed studies. These could be more
demanding in terms of time, resources and effort by participants and researchers,
including those using imaging and laboratory biomarkers, or potentially in the
future, preventative trials (Figure 5.3).
A significant difference in the average UPSIT score between the higher and
lower risk groups identified through the algorithm was observed, and a significant
difference in proportion in the higher and lower risk group that had a score equal
to or below the lower 15th centile cut-off of 27. Analogous results were reported
from the PARS study where hyposmics were significantly more likely to report
non-motor features, including anxiety and depression, constipation, and rapid eye
movement sleep behaviour disorder symptoms, and to report changes in motor
function.160 RBD, as suggested by an RBDSQ score of ≥5, was significantly
more frequent in the high-risk than the low-risk group, and tapping speed was
significantly lower in the high-risk group (in analyses using continuous data, with a
trend observed in categorical data), indicating that at least some of the individuals
in the higher risk group may be in the very earliest stages of motor impairment.
Subtle changes in movement control have previously been reported in video footage
of the footballer Ray Kennedy several years before onset of diagnosed PD and
in patients with confirmed RBD.76,93 Of note is also that the scores for all three
proxies for PD were significantly worse with increasing predicted risk of PD across
all participants. These analyses remained statistically significant when age and
gender were removed from the risk estimates. Given the role that age (and to a
lesser extent gender) has on risk of PD and since each of the three outcomes could
also be affected by age, it is reassuring to find that the remaining combined risk
factors were still associated with outcomes.
Individually, none of these three outcomes is both specific and sensitive for
early PD. However, evidence from pathological, epidemiological and imaging
studies suggest that each of them is associated with an increased risk of PD, and
all of them were found to be enriched in the higher risk group defined by the
preliminary algorithm.9,161 Taken together, these results all indicate that this
evidence-based algorithm has the potential to be a useful tool to identify groups
at higher risk of future PD.
Limitations
Firstly, many of the participants volunteered following an advertisement by a
Parkinson’s charity. Therefore many had a family history of PD and may have
been fearful about their own risk of the disease. This is a measurable bias in
part and increases the likelihood of finding those at high-risk. Second, in using
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Fig. 5.3: Schematic to indicate how the PREDICT-PD approach might channel
into detailed biomarker and risk-determination studies in groups identified as
being higher risk than the background population. An eventual outcome could be
preventative trials, were suitable drugs to be available.
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proxies for future PD risk it is unknown currently what proportion of those that
are at higher risk will go on to develop PD. The numbers are likely to be small
given the number of participants in the study to-date, and the incidence of PD in
the general population. Nonetheless, the conversion of individuals in the higher
risk group and not the lower risk group to clinically established PD would offer
strong evidence of the predictive nature of the algorithm. Third, for this analysis
it was assumed the predictors were independent, whereas in fact there may be
some association between individual factors. Although many of the effect size
estimates from the systematic review were adjusted for confounders (see chapter
2), fully adjusted estimates were not available for a number of factors. The
simple additive model used may therefore not fully replicate the early stages of
the disease. Currently there are insufficient data in the literature to account for
interactions between exposures, and one aim of the longitudinal study is to modify
the results based on emerging prospective data. Fourth, subjective RBD and
some other clinical features were not confirmed using PSG or other objective tests.
This is likely to reduce the accuracy of these predictive factors; but the purpose
of this methodology is to be easily available and non-invasive, which objective
confirmatory tests often are not. It was notable that the proportion of subjects
exceeding the cut-off for RBD was high (15% of the entire cohort). Fifthly, due
to the design of the study, there is an additional bias in that participants that
are English-speaking and computer literate have been identified. Finally, in order
to test the initial validity of the approach a conservative method was adopted,
excluding the most promising risk factors of smell loss, RBD and tapping speed
from the algorithm, and these used as proxies to evaluate its performance. The
results were statistically significant despite their exclusion and it is likely that
subsequent inclusion of smell loss, RBD and tapping speed would improve the
performance of the algorithm. However to do this will require estimation of the
magnitude of risk conveyed by each since absolute data are currently not available
in the literature. These hypotheses will be tested further when longitudinal results
are available from this study, which will likely result in modifications to the
preliminary algorithm.
Conclusions
This is one of largest cross-sectional studies to-date examining methods to identify
a group of individuals with risk factors for developing PD. The methods are based
on a comprehensive systematic review of the literature on early features and risk
factors of PD that can be identified through history taking, and on calculating
estimates of risk through combination of these factors. Support for the hypothesis
that those deemed to be at higher risk of PD would have poorer smell sense,
94
5.4 Discussion
increased rates of RBD and slower finger tapping speed, when compared to lower
risk, was found. Ultimately, confirmation of the validity of this algorithm requires
recording an increased rate of incident PD in the higher risk group, and this
information will only become available during longitudinal follow-up.
95
Risk of PD in the community: baseline data from PREDICT-PD
96
Chapter 6
GBA and LRRK2 variants in
PREDICT-PD
6.1 Introduction
Variants in the glucocerebrosidase gene (GBA) are the most common genetic risk
factor for PD, found in approximately 9% of unselected UK PD patients and 4%
of healthy controls.32,162 Mutations in the leucine-rich repeat kinase 2 (LRRK2 )
gene are the most common Mendelian cause of PD (1% of sporadic UK cases) but
rare in controls (<0.1%).21
In earlier chapters an evidence-based process of risk stratifying members of
the population for future PD was described. In chapter 5, higher risk subjects
from the PREDICT-PD study were found more likely to have objective smell
impairment and slowed finger-tapping, as well as subjective RBD, compared with
participants estimated to be at lower risk.
Recently, early non-motor features of PD were reported in carriers of GBA
mutations including depression, subjective RBD and objective olfactory distur-
bance, when compared with healthy controls.34 Objective motor impairment was
observed in the same subjects and this was the first report from a longitudinal
study in non-manifesting GBA mutation carriers. Away from asymptomatic GBA
variant carriers, there have been a number of studies reporting on the pheno-
type of parkinsonian GBA carriers, who tend to have a worse cognitive profile
than patients with idiopathic PD and may have an increase in neuropsychiatric
symptoms.32,163,164
There has been limited study in non-manifesting carriers of LRRK2 mutations
to-date, but some observations suggest higher rates of non-motor features of
PD, such as constipation and impairment of colour vision, compared with non-
carriers.165 In parkinsonian LRRK2 carriers, olfactory deficit has been variably
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reported, with some saying it is as frequent and severe as that found in idiopathic
PD, and others suggesting it is milder.26,27 Other observations include potentially
lower frequency of gastrointestinal dysfunction and RBD compared with idiopathic
PD.166 Some of the heterogeneity of LRRK2 -related parkinsonism may depend on
the underlying pathology, with non-motor features such as cognitive impairment
and anxiety occurring more commonly in those subsequently found to have Lewy
bodies.167
Acknowledging the frequency of these mutations (particularly GBA variants),
it was hypothesised that if PREDICT-PD risk stratification were effective, an
excess of GBA variants and perhaps LRRK2 variants would be found in higher
risk subjects compared to lower risk, and this would provide further evidence in
favour of enrichment for PD risk.
6.2 Methods
Detailed information about recruitment and risk stratification are given in chapters
2 and 5. In brief, 1,323 eligible participants were recruited via the study website,
following a limited advertising campaign which included an email to members
of Parkinson’s UK. Inclusion criteria were residency in the UK and age 60-80
years. Exclusion criteria were pre-existing PD, neurological disease or medication
associated with iatrogenic parkinsonism. Participants completed an online consent
form, followed by a survey comprising demographic questions and items related
to early non-motor features and risk factors for PD identified through systematic
review (see chapter 2), and a keyboard tapping task (the BRAIN-tap test; see
chapter 4). Subjects were sent the US version of the University of Pennsylvania
smell identification test (UPSIT), the answers to which were also completed online.
The Queen Square Research Ethics Committee approved the study (reference
10/H0716/85).
A preliminary algorithm was developed to estimate PD risk based on question-
naire answers. Risk scores were ranked to enable comparative analyses between
subjects with the highest 15% and lowest 15% risk scores. Invitations were ex-
tended to these subjects, and additional subjects sampled randomly from the
middle risk group, to participate with in-person clinical (including motor and
brief cognitive assessment) and genetic studies. A greater likelihood of identifying
differences in outcomes was anticipated if extremes of risk were sampled. There-
fore higher, middle and lower risk subjects were approached with a ratio of 2:1:2
(80/40/80 subjects respectively).
During clinical visits, further written consent was obtained and participants
provided saliva samples via specialised collection tubes, which were kept at room
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temperature during transit for 1-4 days, before being cooled to +4oC for longer
term storage. DNA was extracted using standard methods. Sanger sequencing
was used to screen exon 41 of LRRK2 (which contains the commonest c.6055
G>A; p.G2019S mutation) and exons 8-11 of the GBA gene (contains almost
90% of recognised GBA pathogenic variants).32 The sequence reference and
exon numbering were those of RefSeq accession number NM000157.3 (GBA)
and XM058513 (LRRK2 ). The conventional nomenclature for GBA mutated
alleles was used, referring to the processed protein, excluding the 39-residue signal
peptide.i
Statistical methods
The proportion of the higher risk group carrying gene variants and the proportion
of pooled lower and middle risk groups were compared using Fisher’s exact test
and an odds ratio (OR) and 95% confidence interval (CI) were calculated. Cases
of PD identified at the time of examination were excluded from all analyses.
Statistics were performed using Stata and GraphPad Prism for Mac.
6.3 Results
At the time of analysis, 192 saliva samples had been collected from participants.
Sequencing was undertaken in 79/195 higher, 45/927 middle, and 68/198 lower-
risk subjects (Table 6.1). After excluding 7 sequencing failures, GBA variants
were found in 6/75 higher (1 N370S, 2 E326K, 3 T369M), 0/43 middle and 1/67
lower-risk subjects (T369M homozygous). The OR of having a GBA variant in
the higher versus pooled middle and lower-risk group was 9.5 (95% CI 1.10 to 440;
p=0.018). LRRK2 G2019S mutations were not found in any participant.
Comparisons between GBA variant carriers from the higher risk group, with the
remainder of the higher, middle and lower risk groups were undertaken (Table 6.2).
Results in higher risk GBA variant carriers reflected some of the characteristics
upon which risk was calculated (age, gender, family history), as well as a tendency
for lower smell test scores overall. In subjects carrying GBA variants, mild motor
impairment was found in three (mainly soft signs e.g. stooped posture, not
sufficient to diagnose PD), mild cognitive impairment in three and hyposmia in
two, with one subject scoring highly on the REM-sleep behaviour disorder (RBD)
screening questionnaire (Table 6.3).
iExperiments were performed by Alastair Noyce and Niccolo Mencacci.
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Higher risk Middle risk Lower risk p-value
participants participants participants
Subjects per group 195 927 198
Number screened 79 45 68
Sequencing failures 4 2 1
Sequenced (% of group) 75 (38%) 43 (5%) 67 (34%)
GBA variants 6 0 1 0.018∗
LRRK2 G2019S mutations 0 0 0
Table 6.1: Participants, proportions tested and variants across groups.
Legend: ∗p-value from Fisher’s exact test.
Higher risk Higher risk Middle risk Lower risk
GBA carriers non-carriers participants participants
Number 6 189 927 198
Median age in 70 (67-76) 70 (60-81) 66 (60-80) 62 (60-73)
years (range)
Female (%) 1 (17%) 39 (21%) 597 (64%) 168 (85%)
First-degree 4 (67%) 68 (36%) 134 (15%) 1 (1%)
relative (%)
Median UPSIT 30 (23-33) 31 (28-34) 32 (29-34) 33 (31-35)
score (IQR)
KS (95% CI) 56 (48-64) 51 (50-53) 54 (53-55) 55 (53-57)
Table 6.2: Clinical details of higher risk GBA variant carriers and other groups.
Legend: UPSIT = University of Pennsylvania smell identification test; IQR =
interquartile range; CI = confidence interval.
Rank (out of 1,323) Variant UPDRS RBDSQ MoCA UPSIT
1 N370S 3 7 25 32
14 T369M 6 3 25 24
41 E326K 0 2 25 29
100 E326K 3 1 28 21
108 T369M 5 1 30 30
143 T369M 4 0 28 35
1185 T369M∗ 0 1 27 31
Table 6.3: Further details of individual GBA variant carriers (6 carriers from
higher risk group above line and 1 carrier from the lower risk group below line).
Legend: UPDRS = unified Parkinson’s disease rating scale (motor section);
RBDSQ = REM sleep behaviour disorder screening questionnaire; MoCA =
Montreal cognitive assessment; UPSIT = University of Pennsylvania smell
identification test. ∗Homozygous variant.
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6.4 Discussion
PREDICT-PD uses a combination of environmental determinants and early
phenotypic (non-motor) features to develop a prediction algorithm for PD that
estimates risk. GBA variants were found in 8% of higher-risk subjects, a proportion
similar to estimates of frequency in sporadic PD.32 Conversely, less than 1% of
lower-risk subjects were found to have a GBA variant. An overall rate of 3.6%
in the total sample was observed, which is similar to the 4% reported in healthy
controls.162 Age is a powerful determinant of PD risk but has the potential to
confound given its effect on many outcome measures used in predictive studies
(e.g. sense of smell, objective motor function and functional imaging). By using
GBA variants as an outcome for risk stratification, age-independent support for
enrichment by the preliminary algorithm was observed.
Of the variants identified from exons 8-11 of the GBA gene, one subject had
N370S, two subjects had E326K and four subjects had T369M variants. The
N370S variant has a deleterious effect on glucocerebrosidase enzyme activity and
is known to cause Gaucher’s disease (GD) as well as being a clear risk factor for
PD. Although not a cause of GD, the E326K variant is also a known risk factor
for PD, and there is emerging evidence to support the T369M variant similarly.168
The fact that no LRRK2 mutations were found in subjects screened was perhaps
unsurprising given the rarity of the G2019S mutation in healthy controls and
its presence in only 1-2% of patients with PD.21 However, if any subjects had
been identified as LRRK2 mutation positive this would have been a potentially
important observation.
GBA-associated PD can be indistinguishable from sporadic PD, with typical
motor impairment that has a good response to standard treatment, and presence
of non-motor features.32 GBA variants may convey younger age of onset and pre-
ponderance towards cognitive impairment. In kind with studies of non-manifesting
GBA variant carriers, low-normal smell, mild motor signs and mild cognitive
impairment were observed in PREDICT-PD GBA heterozygotes.34 One of the
GBA heterozygotes also scored highly on the RBDSQ, whereas other fell short of
the 5 point threshold score for RBD.152 Here GBA variant carriers were identified
using early phenotypic features for PD, but the motor and non-motor features
listed in Table 6.3 were not included in risk score calculations. This suggests
clustering of early phenotypic non-motor features as has been observed in other
studies.118,160 Of great interest, although perhaps a chance finding, is that the
subject with the highest estimated risk in the whole study at baseline was a carrier
of the N370S mutation. Carriers of other variants were otherwise distributed
evenly throughout the higher-risk group.
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Limitations
There are some limitations to the current study. Firstly, the findings are based on
small numbers, making it difficult to draw robust conclusions. Despite this, the
difference in proportions is clinically meaningful and statistically significant. Fur-
thermore the methods (in-person assessment of a proportion of the online cohort)
favoured sampling from the extremes of risk, resulting in a smaller proportion
being sampled from the middle risk group. This raises the possibility of underes-
timating the frequency GBA variants, but to assess an equivalent proportion of
middle risk participants (35-40%) would have required an additional 350 clinical
visits, which was not feasible. In light of these limitations, self-administered saliva
collection will be used to obtain DNA from all participants to enable further
testing for GBA and LRRK2 in the cohort (see chapter 9 for further work). The
purpose of this is to confirm the observations made in this smaller sample and
also because GBA variants are risk factors in their own right and may eventually
contribute to the risk scoring process.
Of the three variants discovered, there is some controversy over whether T369M
constitutes a true disease-associated variant. Even if subjects carrying T369M
variant were excluded from the analysis (3 from higher-risk and 1 from lower-risk),
the results were still of borderline statistical significance (p=0.06). Nonetheless,
recent reports suggest that although T369M is not sufficient to cause GD, there is
change in glucocerebrosidase activity in heterozgous carriers of the T369M and
E326K variants and it is feasible that these could confer an increase in risk of
PD.168
Conclusions
Taken with earlier observations in chapter 5, these data using GBA variants as
an outcome for PD risk, support the notion that the preliminary PREDICT-PD
algorithm can separate healthy controls into a higher risk group with a mutation
frequency of 8% compared with 0.9% in lower risk subjects. Validation of the
PREDICT-PD risk algorithm will ultimately be achieved through finding an excess
of converters to clinically established PD in the higher risk group with prolonged
follow-up. The higher risk group (and similar numbers of lower risk) will continue
to be studied using a range of clinical and imaging studies, with further genetic
evaluation undertaken across the cohort.
102
Chapter 7
Imaging studies in PREDICT-PD
7.1 Introduction to TCS and SPECT
Ultrasound may play a role in early diagnosis of PD and is attractive due to
its availability, simplicity and cost.105 The technique of transcranial sonography
(TCS) has been most studied in mainland Europe and at the time of beginning this
work there was only believed to be one other centre in the United Kingdom using
TCS for the assessment of movement disorders. Hyperechogenicity describes an
enlarged and contiguous area of increased echogenic signal and when found in the
region of the substantia nigra (SN) is referred to as SN hyperechogenicity (Figure
7.1). This appearance has been observed in 90% of patients with established
PD.169 However, SN hyperechogenicity is not correlated with disease severity or
duration, and does not change over time in patients with PD.169,170 It may also
be observed as a static marker of PD risk, which occurs before the onset of motor
symptoms and does not change with follow-up.171,172
A study in individuals with mild parkinsonian features, found a sensitivity
of 91%, specificity of 82% and positive predictive value (PPV) of 93% for SN
hyperechogenicity and PD diagnosis after follow-up, despite blinding those per-
forming sonography to clinical details at baseline.173 The PRIPS study in Germany
and Austria screened more than 1,800 participants over the age of 50 years with
physical examination and TCS, and 304 had SN hyperechogenicity. At 3 years
follow-up, 11 had developed PD and the relative risk of incident PD was 17.3
(95% CI 3.7 to 81.3) if there was SN hyperechogenicity at baseline.106
The pathological abnormality that is being observed using TCS is uncertain,
but post-mortem studies implicate activated microglial, iron accumulation and
neuromelanin as contributing to the altered signal.174 A further limitation of the
technique is that 10% of people lack the necessary temporal bone window needed
for evaluation.105
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Fig. 7.1: An example of hyperechogenicity in the region of the substantia nigra in
a patient with PD. Picture obtained by Alastair Noyce using GE Logiq 7
ultrasound machine in Innsbruck, Austria.
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123I-FP-CIT SPECT and 123I-β-CIT SPECT are analogous to one another
and are widely used in the work-up of parkinsonian disorders. SPECT may be
helpful in cases where parkinsonism is indeterminate (e.g. isolated rest tremor)
or a degenerative aetiology is uncertain (e.g. if vascular and drug-induced causes
are included in the differential diagnosis).98,99 In a study that recruited patients
with uncertain diagnosis at baseline, 123I-FP-CIT SPECT alone had a low false
positive rate compared with cases diagnosed on clinical grounds alone (3% versus
54%, i.e. high specificity) at acceptable sensitivity (78%).175
The notion that 123I-FP-CIT SPECT might be abnormal prior to PD diagnosis
was prompted by studies showing bilateral changes in patients with clinically
unilateral parkinsonism.176 In keeping with estimates from neuropathological study,
clinical diagnosis of PD tended to be made once there was 40-50% reduction in
tracer binding.4,176 An average 11.2% decline in striatal binding has been observed
each year after diagnosis.177 123I-β-CIT SPECT has been used to assess those with
risk factors for PD including those with RBD and idiopathic anosmia.69,70,73 It is
being used in the PPMI study, which compares de novo PD with healthy controls,
and in the PARS study which operates a two-step screening process for PD, with
objective smell testing at the first stage and 123I-β-CIT SPECT at the second.
The PARS investigators recently reported differences in dopamine transporter
(DaT) binding in hyposmic subjects compared with those that were normosmic.104
TCS and 123I-FP-CIT SPECT were used as outcome measures to determine
whether subjects estimated to be at higher risk of PD using the PREDICT-PD
preliminary algorithm, were more likely to display abnormal imaging features
associated with PD, compared with those estimated to be at lower risk.
7.2 Training to perform TCS
Training was undertaken during a one-month period between February and March
2013 at the Department of Neurosonologie, Ländeskrankenhaus Innsbruck Austria,
and the Department of Neurology, University of Innsbruck. Training in sonogra-
phy was overseen by Dr Martin Sojer (Oberarzt) and Dr Heike Stockner (Post
Doctoral Research Fellow), who have extensive experience in the use of TCS of
the mesencephalon and vascular system.
7.2.1 Methods
Patients that were attending for routine vascular sonography of the extra- and
intra-cranial arteries (undertaken by a trained sonographer) gave further verbal
consent for sonography of midbrain structures so that familiarity with the technique
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could be gained. Additional experience was gained with patients in the emergency
room setting and the intensive care unit. A smaller number of patients with
movement disorders were invited to the Department of Neurosonologie including
those with PD, MSA, essential tremor, and dystonia, as well as some patients
with RBD (with and without parkinsonism).
Scanning was undertaken using a range of ultrasound machines including the
GE Logiq 7, GE Logiq 9 and Acuson Sequoia. Experience was also gained with the
GE Vivid-E, which is a portable machine, and another portable Philips machine.
Most patients were scanned in the semi-recumbent position with the operator
seated on the patient’s right hand side. The right side of the head was examined
first with the patient’s head turned slightly to the left, then the left side of the
head was examined with the head turned to the right. The GE Logiq 7 was most
frequently used and was the machine for which all analyses were undertaken. A
standardised setup was used comprising a 2.5MHz probe, with preset grey-scale
and image gain, and tissue harmonics switched off (i.e. non-harmonic mode).
Focus and depth were set to the centre of the screen, where the midbrain was
expected to be identified.
The mesencephalic scanning plane was identified, in which the midbrain has a
typical butterfly appearance (Figure 7.1). The region of the SN was identified as
a contiguous echogenic area. When best visualised, the image was frozen and the
area of echogenicity was measured using both elliptical and free hand methods,
to give an estimate of the area in centimetres squared (cm2). The same steps
were followed when scanning both sides and a measurement was recorded for each,
along with the side that had the largest area (SN-Max) and the average of both
sides (SN-Mean). The width of the third ventricle was recorded in cm. During
training, further examination was made to identify the anterior horn of the lateral
ventricle, the caudate nucleus, the putamen, the thalamus, the raphe nucleus, the
cerebral aqueduct, the rubral nucleus, the amygdala, the hippocampus and the
pineal gland, which to-date are structures that are incompletely defined using
TCS. If subjects had a temporal bone window that prevented visualisation of the
mesencephalon, note was made that it was inadequate.
Statistical methods
Subjects were included in the analyses if they were scanned using the GE Logiq
7 machine and had at least one adequate temporal bone window. Descriptive
statistics were calculated for controls and patients with parkinsonism. Normally
distributed data were reported as group means with 95% confidence intervals
(CI) and compared using t-tests. Non-normally distributed data were reported
using medians and interquartile ranges (IQR), and groups compared with the
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Mann Whitney U test. Receiver operated characteristic (ROC) curves were
drawn to determine cut-offs that separated cases with parkinsonism from controls
with corresponding sensitivity and specificity. Fisher’s exact test was used for
categorical data to determine differences in the proportion of cases and controls
with hyperechogenicity. Spearman’s correlation was undertaken in controls to
determine the role of age on non-normally distributed continuous measures.
7.2.2 Results
During the four-week time period, 108 patients were scanned (Table 7.1). Gender
and diagnosis was recorded for all subjects (68 males, 40 females) and age was
recorded in 59 of these. Most subjects were attending for routine examination
of the intra- and extra-cranial arteries, and are hereby referred to as vascular
controls (n=70). Other diagnoses included PD (n=8), MSA (n=1), essential
tremor (n=1), dystonia (n=2), ptosis (n=2), intra-cranial haemorrhage (ICH,
n=7), RBD (n=5), acute stroke (n=3), ataxia (n=1), head injury (n=1), abnormal
gait (n=1), dementia (n=1), seizure (n=1), dizziness/syncope (n=2), amaurosis
fugax (n=1) and temporal arteritis (n=1).
Eighty-nine subjects were scanned using the GE Logiq 7 machine. In thirteen
subjects, both bone windows were inadequate for visualisation of the midbrain and
four had vascular ultrasound only without additional parenchymal sonography.
Therefore 72 subjects had at least one bone window that was sufficient for
examination of the midbrain. Analysis was conducted on measurements taken
only after sufficient technical experience had been gained and the area of interest
could be identified confidently and independently of the trainers. Measurement
of at least one area of the SN was made for 51 subjects. Of these, six patients
with parkinsonism (4 PD and 2 RBD plus parkinsonism) were compared to 42
non-degenerative, non-movement disorder control subjects (39 vascular controls, 2
ICH and 1 syncope).i
The median SN-Max in control subjects was 0.15cm2 (IQR 0.09 to 0.20cm2)
and was 0.37cm2 (IQR 0.24 to 0.55cm2) in PD patients (p<0.001; Figure 7.2a).
ROC curves were constructed for SN-MAX and SN-Mean. The ROC curve for
SN-Max had an area under curve (AUC) of 0.94, with a sensitivity of 100% and
specificity of 81% for identifying parkinsonism if a cut-off of 0.23cm2 was used
(Figure 7.2b). The ROC curve for SN-Mean had an AUC of 0.95, with a sensitivity
of 83% and specificity of 93% in identifying PD if a cut-off of 0.23cm2 was used
(not shown). Using an SN-Max cut-off of 0.23cm2 meant that 8/42 (19%) of
iThe remaining three non-parkinsonian cases were excluded (1 with muscular dystrophy, 1
with essential tremor and 1 with isolated RBD).
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controls had SN hyperechogenicity compared with 6/6 (100%) of parkinsonian
patients (p<0.001).
Information regarding year of birth was available for 32/42 controls. There was
no correlation between year of birth and SN-Max (r= -0.097, p=0.60) or SN-Mean
(r= -0.155, p=0.40), and no gender difference in either parameter (p=0.29 and
0.69 respectively).
Subjects (n=108)
Gender (male/female) 68/40
Median age (IQR)∗ 66.0 (57.0 to 72.0)
Diagnosis:
· Vascular controls 70
· Parkinsonism∗∗ 11
· Other neurological 27
Machine used:
· GE Logiq 7 89
· GE Logiq 9 9
· Sequoia 6
· Vivid-e 3
· Portable Philips 1
Table 7.1: Subjects scanned during TCS training.
Legend: IQR = interquartile range.
∗ age available on 59 subjects; ∗∗ group comprised
8 PD, 2 RBD with parkinsonism, 1 MSA.
7.2.3 Discussion
This period of training and investigation provided support for the use of TCS in
the evaluation of parkinsonian subjects and the results suggested that training
was sufficient to practice independently in the UK.ii The results were comparable
to previous studies comparing subjects with PD to healthy controls.105 TCS has
operator- and machine-dependent ranges for the echogenicity of basal ganglia
structures, which must be established for the specific setting in which the method
is to be applied.105 In order that TCS could be used to assess participants from
the PREDICT-PD study, validation of the technique was required in patients
attending the Movement Disorder clinic at the National Hospital for Neurology
and Neurosurgery (NHNN) and a suitable control group.
iiFour weeks training in TCS for use in parkinsonian subjects is considered an unusually
long time with other courses typically lasting 2-7 days.
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Fig. 7.2: Comparison of SN-Max in parkinsonian subjects versus controls: a) bar
graph showing median and 75th centile, b) ROC curve of sensitivity against
1-specificity displayed as percentages. ∗∗∗p<0.001.
7.3 Validation of TCS in UK subjects
7.3.1 Methods
A validation study was undertaken in the Lysholm Department of Neuroradiology
at the NHNN. Patients with PD according to UK Queen Square Brain Bank criteria
were identified from the Movement Disorders clinic and invited to participate,
along with a group of healthy control subjects (partners of patients, spouses,
students and staff).3 Ethical approval for the study was gained from the Queen
Square Research Ethics Committee (reference 13/LO/1457). The Department
of Neuroradiology houses a Philips iU22 (Figure 7.3). Like the GE Logiq 7, the
Philipps iU22 is a high-end sonography machine suitable for transcranial studies.
A 2.5MHz probe was used and the machine was operated in the ‘non-harmonic’
setting, consistent with guidance from trainers in Innsbruck. Greyscale and gain
were preset to identify midbrain structures, and depth and focus were adjusted to
centre the midbrain on the screen.
Participants were scanned in the semi-recumbent position, except for one
parkinsonian subject who was unable to transfer from a wheelchair to the trolley.
A standardised procedure was followed in which the right side of the head was
scanned first and then the left. The probe was applied to the temporal bone
window in the mesencephalic scanning plane and the midbrain identified. The
probe was angled rostrally to identify the third ventricle before returning to the
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Fig. 7.3: Philips iU22 ultrasound machine with 2.5MHz probe in the Lysholm
Department of Neuroradiology at the National Hospital for Neurology and
Neurosurgery.
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mesencephalic scanning plane for detailed examination of the midbrain and the
region of the SN. A contiguous area of echogenicity in the region of the SN was
measured free-hand (rather than elliptically) for each subject with an adequate
bone window. Measurements were taken from both sides (where possible) and
SN-Max and SN-Mean were calculated. Additional imaging and measurement of
other structures was not undertaken (examples listed in section 7.2.1).
Statistical analysis was undertaken using the same methods described above
(section 7.2.1) to determine normal and disease-related operator- and machine-
dependent ranges and cut-off values in the UK. In addition, linear regression
(instead of correlation) was used to explore relationships between continuous
outcomes (SN-Max and SN-Mean) and exposures (age and disease duration).
7.3.2 Results
Fifty patients with parkinsonism were scanned during a 15-month period, as
well as 35 healthy controls (Table 7.2). Patients were older than controls and
the proportion of male patients was higher than male controls. Two patients
were excluded from the analysis because they had indeterminate parkinsonism
rather than PD according to diagnostic criteria.3 Three control subjects were
also excluded from the analysis (one had generalised myoclonus and two carried
recessive genes associated with PD - PARK2 and PINK1 ). At least one adequate
bone window was present in 44/48 PD subjects (91.7%) and 32/32 controls (100%).
The median disease duration in PD subjects was 7.0 years (IQR 4.0 to 10.0 years).
PD (n=48) Controls (n=32) p-value
Mean age in years (SD) 63.2 (10.7) 48.8 (18.1)
Gender (M/F) 40/8 10/22
Adequate bone window 44/48 32/32
Median SN-Max (IQR) 0.24 (0.20 to 0.34) 0.12 (0.08 to 0.14) <0.001
Median SN-Mean (IQR) 0.22 (0.17 to 0.26) 0.09 (0.07 to 0.12) <0.001
SN-Max cut-off Sensitivity Specificity
>0.16cm2 93.2% 90.6%
SN-Mean cut-off Sensitivity Specificity
>0.13cm2 90.9% 84.4%
SN +ve 41/44 3/32 <0.001
PPV 93.2%
Table 7.2: Subjects scanned during TCS validation in the UK.
Legend: SD = standard deviation; IQR = interquartile range;
CI = confidence interval; PPV = positive predictive value.
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The median SN-Max in patients was 0.24cm2 (IQR 0.20 to 0.34cm2) compared
with 0.12cm2 (IQR 0.08 to 0.14cm2) in controls (Figure 7.4a; p<0.001). Median
SN-Mean in patients was 0.22cm2 (IQR 0.17 to 0.26cm2) compared with 0.09cm2
(IQR 0.07 to 0.12cm2) in controls (p<0.001). A ROC curve (Figure 7.4b) for SN-
Max gave a specificity of 90.6% for a sensitivity of 93.2% using a cut-off of 0.16cm2
to diagnose PD. The corresponding ROC curve for SN-Mean gave a specificity of
84.4% for a sensitivity of 90.9% using a cut-off of 0.13cm2 (not shown). Examples
of observations from a case and a control are shown in Figure 7.5. Age was not
associated with SN-Max in either patients (β= 0.0013cm2 per year, p=0.339) or
controls (β= 0.0005cm2 per year, p=0.307). There were no gender differences in
SN-Max for patients (0.25cm2 in males versus 0.24cm2 in females, p=0.720) or
controls (0.12cm2 in males versus 0.11cm2 in females, p=0.528). In patients, disease
duration was not associated with area of echogenicity (Spearman’s rho=0.198
(95% CI -0.114 to 0.475, p=0.197).
Fig. 7.4: Comparison of SN-Max in PD subjects versus controls: a) bar graph
showing median and 75th centile, b) ROC curve of sensitivity against 1-specificity
displayed as percentages.∗∗∗p<0.001.
7.3.3 Discussion
A difference in echogenicity was demonstrated between patients and controls in
line with differences identified during the training period and in the published
literature.105 The difference was both statistically significant and clinically mean-
ingful, enabling machine- and operator-dependent cut-off values to be established
for the next phase of the study. SN-Max offered marginally better screening
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Fig. 7.5: Comparison of SN area of echogenicity in a control subject (a) and a
patient with PD (b), who has SN hyperechogenicity.
performance than SN-Mean and was selected as the parameter by which to as-
sess PREDICT-PD participants. Age and gender did not appear to significantly
affect area of echogencity when patients and controls were analysed separately,
consistent with observations from the training period. Age and gender have been
inconsistently associated with SN hyperechogenicity previously.106,169,178 Ideally
comparisons between cases and controls would have been stratified by age and gen-
der to assess the role of these as confounding factors, particularly given that cases
were older and more likely to be male than controls. However, the low number
of controls with SN hyperechogenicity prevented stratified analysis using either
simple Mantel-Haenszel methods or logistic regression (empty strata due to sparse
data). Further work would aim to clarify better whether SN hyperechogenicity is
independent of age and gender.
Previous studies of TCS and PD have defined hyperechogenicity as being above
the 90th centile of echogenic area in control subjects assessed using that specific
experimental setup (ultrasound machine, transducer and operator).105,106 This is
analogous to creating a cut-off value based on a 10% false-positive rate. From
this validation study, an SN-Max of >0.16cm2 was observed in approximately
10% of controls and this was selected as the cut-off for hyperechogenicity for this
experimental setup and the cut-off for assessment of PREDICT-PD participants.
Previous studies have tended to observe larger areas of echogenicity in the
region of the nigra than were observed in this study, in both PD subjects and
controls.105 This further underlines the need to validate and calculate reference
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ranges for each centre using this method, rather than relying on cut-offs determined
in other centres. Nonetheless data on areas of echogenicity similar to that reported
here have been previously published.179 Similarly, 10% is frequently quoted as the
proportion of subjects with an inadequate bone window, which prevents assessment
with TCS.105 Using the current experimental setup, a smaller proportion of 5%
was observed.
7.4 TCS & SPECT in PREDICT-PD subjects
TCS and 123I-FP-CIT SPECT were then used as outcome measures to test the
hypothesis that subjects estimated to be at higher risk of PD using the preliminary
PREDICT-PD algorithm, would be more likely to display abnormal imaging
features, such as SN hyperechogenicity and DaT deficit, compared with those
estimated to be at lower risk.
7.4.1 Methods
Sample size calculations
A sample size calculation was performed for TCS based on the published literature,
given that results from the validation study were not available at that time. In
other centres, marked hyperechogenicity was represented by SN area of >0.25cm2,
with normal areas <0.20cm2. It was unknown how much higher risk subjects might
differ from lower risk subjects in terms of TCS appearances, so a conservative
calculation was performed. Detection of an average 0.02cm2 difference between
SN-Max for higher versus lower risk controls (90% power, alpha=0.05) required
25 individuals in each group. An SN-Max >0.16cm2 was used to determine SN
positive or negative status (see section 7.3).
For 123I-FP-CIT SPECT, a sample size estimate was calculated after referring
to unpublished data from the Parkinson’s Progression Markers Initiative (PPMI)
study.iii Striatal binding ratios (SBRs) were reported in PPMI data and are
derived from tracer uptake in the striatum compared with uptake in the occiput.
In PPMI, PD patients with mean disease duration of 6.6 months had a mean SBR
of 1.41 and the mean SBR of controls was 2.56. The difference between higher
and lower risk subjects in PREDICT-PD was anticipated to be substantially less
than the difference between cases and controls in PPMI. Performing scans in 29
of the higher-risk group and 22 of the lower risk was expected to demonstrate a
difference in ratios of 0.57 (half of the difference observed in cases and controls
from PPMI; 80% power, alpha=0.05).
iiiData available via formal application to PPMI investigators via www.ppmi-info.org.
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Participant selection
Subjects who had been participating in the PREDICT-PD study since baseline
were invited to undergo imaging investigations between March 2014 and April 2015.
Participants were sampled from the upper extreme of risk, along with a smaller
number of participants that had lower risk estimates (Figure 7.6). Individual
risk status was not revealed. Participants were sent information and returned
signed acceptance via post. Invitations were restricted to those under the age of
80 years because of the potential for long-distance travel in order to participate
in imaging studies. Invitations were sent regardless of participant’s location in
the UK (there was no geographical bias to recruitment). If willing to participate,
subjects were sent iodine tablets, to block uptake of radioactive iodine by the
thyroid gland. These were taken before and after SPECT scanning. Subjects
were apprised of anticipated risks associated with 123I-FP-CIT SPECT including
radiation exposure and the potential of allergic reaction to iodine contained within
the radiotracer. Information relating to potential exclusion criteria (below) and
current medication (some antidepressants and sympathomimetics alter dopamine
transporter binding180) was gathered over the telephone prior to participant travel.
There were no anticipated risks associated with TCS.
Exclusion criteria for 123I-FP-CIT SPECT were:
• Criteria from the main PREDICT-PD study (diagnosed PD, movement
disorder, dementia, motor neurone disease, stroke).
• Previous hypersensitivity to a radioisotope or related product/component.
• Liver disease.
• Epilepsy.
• Pregnant or breast feeding women.
Upon arrival, participants gave written consent to participate in the imaging
studies. TCS was performed at the Lysholm Department of Neuroradiology at
the NHNN and followed the standardised procedures described in sections 7.2
and 7.3. 123I-FP-CIT SPECT was performed at the Institute of Nuclear Medicine,
University College London Hospital using a GE Discovery 670 SPECT/CT machine.
A standardised SPECT protocol was followed with images obtained approximately
3 hours after injection with 185 MBq of 123I-FP-CIT (GE Healthcare). The
imaging parameters used have been described in detail elsewhere.181
For semiquantitative analysis of tracer binding, BRASS software was used
(HERMES Medical Solutions). BRASS software is a 3-dimensional semiautomatic
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Fig. 7.6: Subjects selected for imaging studies within PREDICT-PD: a) Highest
risk 25 subjects in each year (yr). Subjects were either: invited and scanned
(green), declined to have scan or lost to follow-up (red), over 80 years old
therefore not invited (orange), had a significant change in risk away from highest
risk after one year (yellow), or were not contacted for scanning (white). Selection
was based on year 2 or earlier risk estimates because year 3 scores were not
finalised at time of scanning. b) Frequency distribution of subjects that were
scanned using risk estimates in year 2. Note the preference for highest risk and
sampling of lower risk subjects across a range of scores.
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brain analysis package in which the subject’s brain was first registered to a standard
anatomic atlas, then tracer binding in the whole striatum, caudate nucleus, and
putamen was assessed. Volumes of interest (VOIs) were automatically defined
over the caudate nucleus and putamen to assess specific tracer binding and over a
reference region, the occipital cortex (OCC), to assess non-specific binding. The
count concentrations in these regions were used to calculate striatum specific
binding ratios (SBRs) as [VOIstriatum - OCC]/OCC, where VOIstriatum and OCC
are the count concentrations in the striatum and occipital cortex, respectively.
Binding ratios were also calculated for the caudate and the putamen compared to
the occiput. Separately, a reference group of over 100 healthy European controls
was used to determine mean age-expected striatal uptake (not expressed as a
ratio), along with age-related cut-offs at 80% of the mean and 65% of the mean.181
These approaches were consistent with the methods used in the PARS study.104
An experienced image processor performed all semiquantitative analysis.iv
Statistical methods
Risk scores were calculated using the same algorithm described in chapter 5,
which calculated a combined odds of PD derived from meta-analysis (chapter
2), and these risk scores were used as the exposure variable. Outcomes were
SN-Max for TCS and binding ratios from the side with least uptake of tracer for
123I-FP-CIT SPECT. Linear regression was used to study relationships between
continuous variables, including estimated risk (transformed to log odds) with SN-
Max and with binding ratios. T-tests and Wilcoxon Rank Sum tests were used to
compare continuous outcomes (SN-Max and binding ratios) in categorical exposure
groups (higher versus lower risk) depending on whether data were normally or
non-normally distributed. Categorical outcomes were compared in higher and
lower risk groups using Fisher’s exact test where relevant. Linear or median
regression was used to examine the effect of age and intermediate markers from
year 3 (UPSIT, RBDSQ, KS) on continuous outcomes (SN-Max and binding
ratios). Logistic regression using a binary outcome (SN hyperechogenicity positive
or negative) was used to assess the effects of higher risk status, age (as a linear
term) and gender.
7.4.2 Results
Fifty two subjects participated in PREDICT-PD imaging studies. Of these 49
underwent both TCS and 123I-FP-CIT SPECT, two underwent TCS only and
one underwent 123I-FP-CIT SPECT only. The reason for only undergoing TCS
ivDr John Dickson performed all semi-quantitative analysis described in this paragraph.
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was recent cancer in one subjectv and the other subject had suffered a significant
allergic reaction to iodine in the past. The reason that one subject underwent
123I-FP-CIT SPECT only, was because the ultrasound machine was being used
indefinitely at the time of their appointment. Another subject attended for
imaging but had clinical features of PD (which was diagnosed soon after the
appointment). His results were not included in the analysis.
Eleven subjects were sent information about imaging studies but declined to
participate, despite nine continuing to participate in the wider project. A further
6 subjects who were in the top 25 highest risk subjects were over the age of 80
years and were not invited for imaging studies (Figure 7.6). Two subjects were
taking antidepressants known to have the potential to interfere with DaT binding
and these were withheld after discussion with their health practitioner.
Risk estimates in years 2 and 3 of follow-up (the most recent years of surveying
for scanned participants) were available for 49 of 51 subjects and ranged from
odds of 1 in 2.5 to 1 in 310 (median 1 in 8.9). Higher risk subjects were defined
as those with a risk estimate less than 9 (essentially an odds 1 in 9 or greater) in
either one or both of the last two years of follow-up (years 2 and 3). Lower risk
subjects had scores greater than 9 (an odds of PD less than 1 in 9). Higher risk
subjects were older and were all male.
TCS
Of the 50 subjects that underwent TCS, 49 had at least one sufficient bone window
through which SN-Max could be ascertained and measured. Of these 29 exceeded
the cut-off for hyperechogenicity (SN-Max >0.16cm2). Using linear regression,
SN-Max was associated with risk estimates each year, from baseline to year three
of follow-up (Table 7.3).
Risk score year Slope of line 95% CI p-value
· 3 0.0644 0.0348 to 0.0940 <0.001
· 2 0.0520 0.0234 to 0.0806 0.001
· 1 0.0522 0.0217 to 0.0827 0.001
· 0 0.0544 0.0279 to 0.0807 <0.001
Table 7.3: Associations between annual risk estimates and side of
maximum echogenicity (SN-Max) determined through linear
regression modelling log odds of risk.
Legend: CI = confidence interval.
SN-Max was larger in higher risk subjects and smaller in lower risk subjects
(0.22cm2 versus 0.14cm2; p<0.001; Table 7.4). A greater proportion of higher risk
vNot a specific exclusion criterion, but reluctance to expose them to unnecessary radiation.
118
7.4 TCS & SPECT in PREDICT-PD subjects
subjects had SN hyperechogenicity compared with those at lower risk (78% versus
36%; p=0.004). A more stringent definition of higher risk was then used, in which
subjects had to have highest risk estimates in all four years of follow-up (odds of
PD 1 in 9 or more in every year). Fourteen subjects were in the higher risk group
every year and 85.7% of these had SN hyperechogenicity, compared with 48.6% of
the remaining 35 subjects (p=0.024).
Higher risk Lower risk p-value
n 27 22
Median age in year 3 73.8 68.3
(IQR) (69.6 to 78.2) (66.7 to 71.2)
Gender (male/female) 27/0 14/8
Mean SN-Max cm2 0.22 0.14 <0.001∗
(95% CI) (0.19 to 0.26) (0.12 to 0.17)
SN hyperechogenicity 21 (78%) 8 (36%) 0.004∗∗
Table 7.4: Mean area of maximum echogenicity (SN-Max) and proportion
with SN hyperechogenicity in higher versus lower risk subjects.
Legend: CI = confidence interval; IQR = interquartile range.
∗t-test; ∗∗Fisher’s exact test.
Intermediate markers measured in year 3 (UPSIT, RBDSQ and worst hand
KS) were used to predict SN-Max using linear regression for UPSIT and KS, and
median regression for RBDSQ. There was no association between SN-Max and any
of the intermediate markers. SN-Max was not associated with age (β=0.0035cm2
per year, p=0.150), in keeping with the earlier case-control validation phase.
Logistic regression was used to model odds of having SN hyperechogenicity
if higher risk compared with lower risk (Table 7.5). Age and gender were also
modelled in univariate analyses but neither were significantly associated with SN
hyperechogenicity, and therefore multivariate analysis was not undertaken.
OR 95% CI
Univariate analysis
· Higher risk in year 2 or 3∗ 6.13 1.74 to 21.51
· Age in year 3∗∗ (per additional year) 1.07 0.95 to 1.20
· Male gender 2.89 0.60 to 13.83
Table 7.5: Logistic regression giving odds of SN hyperechogenicity in higher risk
subjects compared to lower risk. No effect of age or gender on hyperechogenicity.
Legend: OR = odds ratio; CI = confidence interval. ∗ORs varied between 3.8 and
6.9 if higher risk any single year (baseline to year 3); ∗∗Age modelled as a linear
term.
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123I-FP-CIT SPECT
Forty-nine subjects underwent 123I-FP-CIT SPECT. SBRs were not significantly
associated with risk estimates in any year (Table 7.6), but the slope of the line
favoured a reduction in binding with increasing risk. Putaminal binding ratios
were also not associated with risk estimates in any year, and caudate binding ratios
showed an association of borderline significance in year 3 and a trend towards an
association at year 1 (Table 7.6). However, scatter plots of log odds of risk against
binding ratios suggested that any borderline associations were dependent on 2-3
outliers (not shown). A sensitivity analysis showed that the p-value increased if
any one of the outliers was removed from the analysis (not shown).
Risk score year Slope of line 95% CI p-value
Striatal BR
· 3 -0.1609 -0.3331 to 0.0114 0.067
· 2 -0.1053 -0.2866 to 0.0760 0.249
· 1 -0.1389 -0.3310 to 0.0531 0.152
· 0 -0.1042 -0.2787 to 0.0702 0.235
Putaminal BR
· 3 -0.1295 -0.2988 to 0.0397 0.130
· 2 -0.0892 -0.2726 to 0.0943 0.333
· 1 -0.1057 -0.3012 to 0.0897 0.282
· 0 -0.0785 -0.2555 to 0.0985 0.377
Caudate BR
· 3 -0.1975 -0.3853 to -0.0097 0.040
· 2 -0.1456 -0.3353 to 0.0441 0.129
· 1 -0.1962 -0.3952 to 0.0028 0.053
· 0 -0.1504 -0.3324 to 0.0136 0.103
Table 7.6: Linear regression to assess associations between annual risk estimates
(modelled as log odds) and binding ratios in the whole striatum, and separately
for the putamen and caudate, on the side with least binding.
Legend: CI = confidence interval; BR = binding ratio.
Higher and lower risk groups were defined in the same way that they were for
TCS analysis above (cut-off using median odds 1 in 9). Comparisons between
higher and lower risk subjects found no significant difference in striatal, putaminal
or caudate binding ratios, although there was perhaps a slight trend towards lower
binding ratios in higher risk subjects (Table 7.7).
Cut-off values for striatal uptake were calculated using 80% and 65% of age-
expected mean from a database of over 100 European controls.181 There was no
significant difference between proportion of higher and lower risk subjects that
fell beneath these cut-offs (Table 7.7 and Figure 7.7). However lower risk subjects
were more likely to have striatal uptake counts greater than the age-expected mean
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compared with lower risk (36.4% versus 7.4%, p=0.029; Figure 7.7). Examples of
scans from those with the lowest striatal uptake are shown in Figure 7.8.
Intermediate markers measured in year 3 (UPSIT, RBDSQ and worst hand
KS) were used to predict SBRs using linear regression for UPSIT and KS, and
median regression for RBDSQ. Significant associations were observed between
binding ratios and UPSIT and KS in year 3, but not RBDSQ (Table 7.8). Similar
observations were noted if putamen and caudate binding ratios were used (data
not shown). Age and gender were also significantly associated with striatal binding
ratio (p=0.036 and 0.003 respectively). However, if gender analysis was restricted
to subjects under 70 years the effect of gender lessened significantly (p=0.066).
Logistic regression analysis was not possible due to insufficient numbers meeting
categorical outcomes (i.e. normal versus abnormal 123I-FP-CIT SPECT scan).
Finally no association was observed between striatal binding ratio and SN-Max
analysed using linear regression (p=0.823).
Higher risk Lower risk p-value
n 27 22
Median age in year 3 73.8 68.3
(IQR) (69.6 to 78.2) (66.7 to 71.2)
Gender (male/female) 27/0 14/8
Median Striatal BR 2.790 2.888 0.213*
(IQR) 2.453 to 2.897 2.474 to 3.197
Median Putaminal BR 2.675 2.826 0.278*
(IQR) 2.361 to 2.878 2.339 to 3.065
Median Caudate BR 2.799 2.973 0.148*
(IQR) 2.458 to 3.076 2.686 to 3.295
DaT binding <80% of 9 (33.3%) 7 (31.8%) 1.00**
age-expected mean
DaT binding <65% of 2 (7.4%) 2 (9.1%) 1.00**
age-expected mean
Table 7.7: Median binding ratios in the whole striatum, and separately for the
putamen and caudate for subjects categorised as higher and lower risk.
Legend: IQR = interquartile range; DaT = dopamine transporter; BR = binding
ratio. *Wilcoxon Rank Sum test; **Fisher’s exact test.
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Year 3 intermediate markers Slope of line 95% CI p-value
UPSIT 0.0327 0.0128 to 0.0527 0.002
RBDSQ -0.0447 -0.1031 to 0.0137 0.130
KS worst hand 0.0153 0.0034 to 0.0272 0.013
Table 7.8: Regression analysis of associations between intermediate markers
measured in year 3 of follow-up and striatal binding ratios, on the side with least
binding.
Legend: CI = confidence interval.
7.4.3 Discussion
TCS and 123I-FP-CIT SPECT are currently used as part of the diagnostic work-
up of parkinsonism. For each modality, a variety of studies have demonstrated
differences between subjects with idiopathic PD compared with controls and
subjects with other causes of parkinsonism. Here TCS and 123I-FP-CIT SPECT
were used as outcomes to assess risk scoring in the PREDICT-PD study.
TCS
Area of echogenicity was strongly associated with risk estimates overall and SN
hyperechogenicity occurred in a significantly greater proportion of higher risk
subjects compared with lower risk. SN hyperechogenicity is recognised as being a
risk marker for PD and finding it in higher risk subjects reinforces the notion that
this group has been enriched for PD by the algorithm.95 However, there were no
statistically significant associations observed between SN hyperechogenicity and
age, gender, or intermediate markers measured in year 3.
The PRIPS study was the largest study using TCS to determine PD risk in
subjects over the age of 50 years. In the German arm of the study, healthy subjects
with SN hyperechogenicity (n=193) were more likely to have abnormal smell test
scores (using Sniffin sticks rather than UPSIT) and also to have mild parkinsonian
signs, measured with the UPDRS.182 When the same analysis was undertaken
in the full PRIPS cohort (approximately 1,600 subjects), similar results were
observed.183 Intermediate markers (smell and finger tapping) in PREDICT-PD
subjects were not associated with SN hyperechogenicity, but this may be due to
the small proportion of participants scanned from the project overall or, for motor
testing, because quantitative finger tapping does not pick up the wide range of
mild parkinsonian signs that the UPDRS does.
The PRIPS study reported a non-significant trend in favour of male gender in
those with SN hyperechogenicity but no association with age.182,183 The results for
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the lack of effect of age on SN hyperechogenicity are consistent between PRIPS
and PREDICT-PD, and the trend in favour of male subjects was also observed
in PREDICT-PD. However, male gender is a risk factor in the algorithm which
may have biased results, since higher risk subjects were recruited for imaging
preferentially in this study. No effect of age or gender was observed at the
validation stage, but again female participants were under-represented.
In another study, TCS was performed in small numbers of subjects with
idiopathic anosmia and SN hyperechogenicity was reported in 11 out of 26 (42%).70
The combination of SN hyperechogenicity and hyposmia (with and without motor
features) has been used for distinguishing PD from other types of parkinsonism or
movement disorder.184,185 Data from Innsbruck (Bruneck cohort) have suggested
that the combination of SN hyperechogenicity and hyposmia increases the odds of
having mild parkinsonian signs on clinical examination.186
Subjects diagnosed with RBD using overnight sleep study and polysomnography
(PSG) have been observed to have SN hyperechogenicity more frequently than
control subjects.187,188 That a similar association was not observed between SN
hyperechogenicity and scoring above the threshold of the RBDSQ in PREDICT-
PD, may be due to the small number of subjects included in the imaging studies.
However, poor performance of the RBDSQ in diagnosing RBD in certain settings
has emerged recently, particularly if used without prior sleep history and PSG.189
It is noteworthy that approximately 15% of PREDICT-PD participants have
RBDSQ scores which exceed the cut-off (see chapter 5), suggesting a significant
rate of over-diagnosis. Similar over-diagnosis of RBD with the RBDSQ has been
observed elsewhere, with 15% of healthy controls exceeding the cut-off on the
RBDSQ compared with 2% meeting PSG criteria in the DeNoPa study.179
The rate of SN hyperechogenicity in PREDICT-PD subjects exceeds that
observed in published controls and in control subjects enrolled in the validation
stages (59% versus 10%). Even in the lower risk group, the proportion with SN
hyperechogenicity was 36%. This may be in part due to enrichment of PD risk
factors and early features in the PREDICT-PD cohort compared to community
controls (i.e. selection bias), but is perhaps more likely to result from observer bias
due to unblinded ultrasonographic assessment. Blinded assessment is preferable
when performing TCS due to inherent subjectivity of measurement, but was not
feasible in this study. In addition the cut-offs identified from the validation stage
tended to be lower than previously published cut-offs using other equipment.105
This may in turn have resulted in an excess of PREDICT-PD subjects exceeding
the cut-off for SN hyperechogenicity. Although the proportion of subjects with
SN hyperechogenicity was relatively high, the median scores for higher and lower
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risk were similar in magnitude to the differences observed between cases of PD
and healthy controls at the validation stage.
As far as is known, this is the first time SN hyperechogenicity has been used
as an outcome of risk stratification. Rather like olfaction, RBD and other early
non-motor features, it is more usual that it be used as the exposure variable that
defines risk status. However, similar to finding that there are differences in the
smell, sleep and finger tapping in higher risk subjects from PREDICT-PD, the
excess of subjects with SN hyperechogenicity is reassuring. In line with the other
intermediate markers, SN hyperechogenicity is thought to occur some time before
diagnosis (perhaps five or more years before), although unlike smell and motor
features, it appears to be static and not to vary over time.170,171,172
Further work could examine the expanded use of TCS in PREDICT-PD, not
simply as an outcome, but along with other intermediate markers to determine
those higher risk subjects that are most likely to develop incident PD. TCS is
insufficient as a risk marker in isolation because its PPV alone is very low.106
However, in combination with objective smell and motor tests, it may predict
those most likely to convert to PD, particularly if used in a group that had already
undergone preliminary screening.
123I-FP-CIT SPECT
In contrast with TCS, binding ratios measured using 123I-FP-CIT SPECT tended
not to be associated with estimated risk scores in the PREDICT-PD participants
that underwent scanning. Nor were higher risk subjects more likely to have striatal
uptake below cut-offs defined a priori (below 65% and 80% of age-expected mean
DaT binding in a large group of control subjects). As far as is known this is the
first time 123I-FP-CIT SPECT has been used to assess a composite risk score for
PD. Examples wherein functional imaging has been used, include the assessment
of subjects with individual risk factors for PD such as idiopathic anosmia, RBD
and single gene carriers.25,69,103,104
Binding ratios were negatively associated with age, showing a decline over time,
which is consistent with previous studies.190 Female gender was also associated
with significantly higher binding ratios than those seen in males, again broadly
consistent with what has been observed previously.190 However, as with TCS,
gender analyses should be viewed with caution given the high proportion of males
compared to females. The females that were included tended to be younger than
the males, and when analysis was restricted to participants under 70 years of age,
the association between gender and DaT binding attenuated significantly.
SBRs were associated with UPSIT and KS measured in year 3 of follow-up.
There was no significant association between binding ratios and RBDSQ scores, but
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this may be due to poor specificity of the RBDSQ (discussed above). Nonetheless,
these observations are encouraging because in the longer term, intermediate
markers could be incorporated into the preliminary risk algorithm to augment
its performance in identifying those at higher risk of PD. Currently there exist
insufficient observational study data to model effect size estimates for hyposmia
and possible RBD (were it possible to measure RBD accurately without PSG)
and update the algorithm accordingly. The observed association between binding
ratios and UPSIT scores is consistent with recently reported results from the
PARS study, showing greater deficits in DaT binding in subjects with hyposmia
compared to those without.104 Here PARS methods were replicated using the
same cut-offs, but using risk score as the exposure rather than hyposmia, however
similar results were not achieved.
It has been previously observed that SN hyperechogenicity and DaT binding
tend not to correlate with one another, suggesting that they identify different
pathophysiological processes (e.g. microglial activation versus pre-synaptic dener-
vation).191,192 Similar to what has been reported previously, no association between
SN hyperechogenicity and DaT binding deficit was observed in PREDICT-PD
subjects.
Although trends were observed in the expected direction, that risk scores
generated by the preliminary algorithm were not significantly associated with
binding ratios is perhaps unsurprising. The number of participants scanned was
relatively few and whereas observed TCS differences are marked between higher
and lower risk subjects, differences were far smaller for 123I-FP-CIT SPECT. The
modest sample size may have meant the study was underpowered to detect a
difference. A greater effect may have been observed if lower risk subjects had
been sampled from the extreme low risk, rather than across moderate and low
risk estimates (Figure 7.6).
Although not statistically significant, the directionality of effect in analyses
considering continuous data suggested that a larger sample size may have had a
greater chance of demonstrating significant results. One important consideration
is that the degree of binding deficit is likely to change over time whereas in
comparison, SN hyperechogenicity is unlikely to change.171,177,193 It may be that if
there are differences to be observed between higher and lower risk subjects using
123I-FP-CIT SPECT, the curves are not yet far enough apart for a difference to
be detected (Figure 7.9). Moreover, if Braak staging of PD is accepted as broadly
accurate, then binding deficit may occur relatively close to the point at which a
diagnosis is typically made.9 Differences between higher and lower risk subjects
may be enhanced by repeating 123I-FP-CIT SPECT in subjects that have already
been scanned at two further years of follow-up to assess differences in rate of
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change between higher versus lower risk subjects. However, this assumes that the
repeated measurement of binding ratios in subjects is accurate which it may not
be, and as far is known there are no published data on this topic. An alternative
option would be re-draft sample size calculations based on the observed differences
here, and scan greater numbers of higher and lower risk subjects, with preferential
sampling from the extreme low risk.
Fig. 7.9: A schematic showing how appearances of TCS and 123I-FP-CIT SPECT
may change during the pre-diagnostic stage of PD. TCS is thought to be a static
marker for the PD prodrome meaning that differences ought to be observed
throughout the period (comparisons at point (a) and point (b)). The time point
within the prodromal phase that SN hyperechogenicity appears is not know and
is depicted by fading of the line. In comparison to TCS, 123I-FP-CIT SPECT
tends to become progressively abnormal during the clinical phase of the disease
and likely before diagnosis as well. Sufficient differences in DaT binding may not
be demonstrable until late in the prodromal phase at point (d), meaning that
there may be no clear difference if observed at point (c).
Another possibility is that the preliminary algorithm in its current format
does not adequately identify those at risk of PD. There are currently multiple
examples that support the notion of enrichment, including the results of TCS
above. Furthermore, it was observed that lower risk subjects were significantly
more likely to have striatal uptake above age-expected mean, which suggests that
risk stratification is playing at least a minor role. The two lower risk subjects that
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had striatal uptake below 65% age-expected mean had odds of 1 in 128 and 1 in
90 at the time when they were last measured. Both would therefore be ranked
in the middle risk group from the wider study, rather than the extreme low risk.
In contrast, the two higher risk subjects that had low striatal uptake, have been
ranked in the top 15 highest risk subjects since the study began. Reviewing these
images (Figure 7.8) one can see either marked abnormalities or clear asymmetry
in all four subjects. Further work will also include blinded clinical rating of
the existing scans from higher and lower risk subjects to determine if there are
differences exist that were not picked up by quantitative measures.
Limitations
The major limitation of use of TCS in PREDICT-PD subjects was the unblinded
nature of assessment, which could have resulted in observer bias. The options
to avoid this were limited due to the fact that TCS assessments were performed
by the investigator, who had prior knowledge of the risk status of individuals.
To avoid observer bias, a second investigator would have needed to have been
trained to perform blinded TCS assessments. Another possibility was to have
the static TCS images independently rated, but there was no way to standardise
measurement after images had been exported from the ultrasound machine.
The 123I-FP-CIT SPECT arm of the study was underpowered and could not
demonstrate statistically significant differences between binding ratios in higher
and lower risk subjects. The expected difference in binding ratios between higher
and lower risk subjects that was used in power calculations was an overestimate,
and the observed difference was substantially less. However, there were some
reassuring findings, including observing expected associations with age and smell
test scores, and reassuring associations with finger tapping speed. Analyses using
categorical data were also likely to be underpowered given sampling across a range
of lower risk subjects (rather than just the extreme low risk) and due to sampling
fewer lower risk that higher risk. This method left the analysis vulnerable to type
2 error in which a single abnormal result in the lower risk group would lead to
acceptance of the null hypothesis. An abnormal result in the low risk group was
quite possible given that, whilst the current algorithm includes a variety of risk
factors for PD, it excludes some of the strongest ones (e.g. genetic risk factors,
smell loss and RBD).
Conclusions
The current algorithm is preliminary and will benefit from refinement of effect
size estimates and inclusion of additional predictors. The validity of the algorithm
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will be tested ultimately if sufficient cases of incident PD are diagnosed during
follow-up and the majority of these had been stratified into the higher risk group
at an early stage. Over time statistical power may be improved by combining
incident PD diagnosis and DaT deficit in those as yet undiagnosed as a composite
outcome. This composite outcome could be used in turn to refine the selection of
predictive factors used in the algorithm.
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Chapter 8
Risk of PD in the community:
follow-up from PREDICT-PD
8.1 Introduction
The PREDICT-PD study has been running for the three years of this thesis and
gathering data from participants annually. Here follow-up data are presented to
determine whether the preliminary algorithm continued to identify a higher risk
group enriched for intermediate markers of PD beyond baseline, and crucially,
whether the higher risk group had an elevated incidence of PD. Further objectives
included determining whether participants who were re-scored each year, moved
between risk groups over time and whether, if baseline groups were preserved,
intermediate markers remained different during follow-up.
8.2 Methods
Data collection
Full methods relating to the baseline year of data collection are detailed in chapter
5. Each year participants were prompted via email to return to the website to
complete an annual submission of the risk factor questionnaire and the BRAIN-tap
test. The assessment included a question on whether subjects have been given
any new diagnoses and listed ‘Parkinson’s disease’ and/or ‘Movement Disorder’
specifically. Positive responses to either of these were followed-up in person or by
telephone interview. Smell testing was repeated in year 3 (having been previously
tested at baseline) using the same US-version of the University of Pennsylvania
smell identification test (UPSIT). Participants that were ‘lost to follow-up’ were
defined as subjects that did not complete a submission for any year after baseline.
No additional participants were recruited after the baseline year.
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Construction of risk groups
The same preliminary algorithm was used each year to provide PD risk estimates
(expressed as odds of PD) for each participant. Exposures were ascertained in a
binary fashion, except for age which was included as a continuous variable. Where
data existed on multiple levels (i.e. bowel movement frequency, erectile function,
anxiety and depression), cut-offs were used in the same way that they were at
baseline. Laxative use and antidepressants were used as surrogate markers to
suggest constipation and depression respectively. Information on use of drugs
such as sildenafil (Viagra) was only collected in year three, but was considered
sufficient to suggest erectile dysfunction (ED).
Steps to eliminate inconsistencies in the reporting of risk factors and early
non-motor features were employed, such as checking that those reported ED were
male. A standardised method for handling inconsistencies was used, in which
newly reported factors such as head injury or family history were accepted as
plausible, as well as being a smoker one year and ex-smoker the following year.
However, where a factor had been reported previously and in a subsequent year
not reported, data from all years were reviewed to determine whether the factor
should be included or excluded. For example, in a subject that reported a past
head injury at baseline and at year 1 and 3, but not at year 2, the year 2 data
were re-coded so that the subject would be recorded as having a past head injury
for all years of follow-up. Where the presence of a factor had been reported in
50% or more years of follow-up, it was re-coded as being present for all years. If
reported in less than 50% it was re-coded as having been absent. These methods
were applied to head injury, and smoking, coffee and alcohol consumption, and
family history, where further information was not available.
Hyposmia (measured with the UPSIT), RBD (measured with the RBDSQ)
and finger tapping speed (measured with KS, the most discriminate BRAIN-test
parameter) were not included and were used as ‘intermediate’ markers of PD
risk. KS scores were reported as worst hand KS (the result for the hand with
the lower KS). Annual risk estimates in all subjects were ranked from highest
to lowest. Centile-based cut-offs for higher and lower-risk were used so that the
groups reduced in proportion to the reduction in size of the overall cohort during
follow-up. Data using 15th and 85th centiles to denote higher and lower risk are
reported here. As was the case at baseline, it was hypothesised that the higher risk
group would have significantly lower UPSIT scores, higher rates of RBD and slower
finger tapping speeds than the lower risk group, and that intermediate markers
would correlate with estimated PD risk in the whole cohort. Further hypotheses
were that the higher risk group defined at baseline was expected to maintain
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differences in intermediate markers during follow-up, and that individuals defined
as higher risk would be more likely to be diagnosed with PD.
Statistical methods
The longitudinal performance of the algorithm was assessed in two ways. First,
risk scores were calculated for each individual separately, based on their survey
answers in that year. Subjects in the higher and lower risk groups were compared
in terms of intermediate markers collected that year (except smell which was
tested at baseline and year 3 only) and associations between risk scores in the
whole group and intermediate markers for that year were also examined. Secondly,
the higher and lower-risk groups defined at baseline were compared longitudinally
according to their intermediate marker results. Further analyses considered the
movement between higher, lower and middle risk groups each year, and rates
of PD diagnosis at one, two and three years follow-up in each group were also
recorded.
In group-wise analyses, KS in higher and lower risk subjects was compared
using t-tests and described using means and 95% confidence intervals (CI). UPSIT
and RBDSQ scores did not follow a Gaussian distribution and therefore medians,
interquartile range (IQR) and Wilcoxon Rank Sum tests were used. Comparisons
for categorical data (defined by cut-off values for each intermediate marker) and
for new diagnoses of PD were made using Fisher’s exact test. Cut-off values
for smell loss, RBD and tapping speed corresponding to the 15th centile for
each intermediate marker using UPSIT, RBDSQ and KS were identified (≤27,
≥5 and ≤44 respectively). These were comparable to those in the published
literature.85,152,160 Relationships between estimated risk of PD in the whole dataset
(independent variable) with UPSIT, RBDSQ and KS (dependent variables) were
examined using median, linear and Poisson regression, respectively. Regression
analyses excluding the factors age and gender from the algorithm were also
undertaken as these may be independently associated with the intermediate
markers of PD of smell loss, RBD and tapping speed. Subjects with newly
diagnosed PD were excluded from analyses of data following diagnosis but not
those preceding diagnosis. All analyses were performed using Stata.
8.3 Results
At baseline, 1,323 eligible participants were recruited (see chapter 5). After
contacting participants for follow-up testing, 1,040 responded in year 1, 939 in
year 2 (90% of year 1 and 71% of baseline respondents), and 846 in year 3 (90%
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of year 2 and 64% of baseline). Using 15th centile risk cut-offs, there were 155
subjects each in the higher and lower-risk groups at year 1, 140 subject in each
in year 2, and 125 and 126 in higher and lower risk groups in year 3 respectively.
Figure 8.1 shows the flow of participants in the study and Table 8.1 shows the
demographic and risk factor information for subjects in each group each year.
There were no marked differences between those that continued to participate in
the study and those that were lost to follow-up (Table 8.2).
Fig. 8.1: Flowchart of participants during each year of follow-up, drop-out rates,
risk group sizes and PD diagnoses.
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Followed-up Lost to follow-up
n 1,100 223
Age (IQR) 66.1 (63.5 to 69.9) 67.5 (63.5 to 72.3)
Female 672 (61.1%) 134 (60.1%)
First degree relative 178 (16.2%) 30 (13.5%)
Current smoker 38 (3.5%) 13 (5.8%)
Past smoker 440 (40.0%) 101 (45.3%)
Drink coffee 988 (89.8%) 199 (89.2%)
Alcohol 957 (87.0%) 186 (83.4%)
Hypertension 285 (25.9%) 63 (28.3%)
NSAID use 67 (6.1%) 16 (7.2%)
CCB use 128 (11.6%) 27 (12.1%)
Beta blockers 84 (7.6%) 19 (8.5%)
Constipation 181 (16.5%) 34 (15.3%)
Anxiety/Depression 133 (12.1%) 223 (11.7%)
Head injury 257 (23.4%) 70 (31.4%)
ED (males) 145 (32.7%) 37 (41.6%)
Median UPSIT (IQR) 32 (30 to 34) 32 (28 to 35)
Median RBDSQ (IQR) 2 (1 to 3) 2 (1 to 4)
Mean KS (95% CI) 53.9 (53.2 to 54.5) 52.2 (50.5 to 53.9)
Table 8.2: Prevalence of factors in subjects that were lost to follow-up compared
to those that remained under follow-up.
Legend: IQR = interquartile range; CI = confidence interval; NSAID =
non-steroidal anti-inflammatory drugs; CCB = calcium channel blockers; ED =
erectile dysfunction.
Comparison of ‘intermediate’ markers of PD between higher and lower
risk groups
The differences in median UPSIT, RBDSQ and mean KS were significant between
the higher and lower risk groups in all years of follow-up (Table 8.3). In addition,
a greater proportion of individuals with smell loss, RBD and slowed finger tapping,
according to predefined cut-offs were found in the higher risk compared to lower
risk group each year. Results for categorical outcomes were statistically significant
in all years, except the association between risk group and abnormal smell in year
2 (p=0.094).
The majority of individuals remained in the same risk group (higher, middle,
lower) each year. However, annual changes of risk led to movement of some
subjects between higher, middle and lower risk groups (Figure 8.2). Between
baseline and year 1, approximately 20% of both the higher and lower risk group
moved to the middle risk group, in year 2, 26% and 15% moved groups, and
similar changes were observed in year 3.
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8.3 Results
When analysis was restricted to the higher and lower risk groups defined at
baseline and followed prospectively for three years, the two groups had significantly
different median UPSIT and RBDSQ, and mean KS in all years (Table 8.4). In
addition, a greater proportion of individuals with smell loss, RBD and slowed
finger-tapping according to predefined cut-offs were found in the higher risk group
in every year of follow-up. Results for categorical outcomes were statistically
significant in all years, except for the association between risk group and abnormal
finger tapping in year 2 (p=0.080).
Associations of estimated risk of PD with ‘intermediate’ markers in
the whole cohort
Risk scores were strongly associated with each of the intermediate markers across
the whole group (all p-values <0.001). After exclusion of age and gender from
the algorithm, results comparing smell and RBD scores to risk at each year of
follow-up were similar (all p-values <0.001). Significant associations between risk
excluding age and gender and KS were observed at year 2 and year 3 (p=0.035
and p=0.004 respectively), with a trend observed in year 1 (p=0.079). Figure 8.3
shows regression analyses for association between intermediate markers and risk
estimates excluding age and gender in year 3.
Difference in diagnosis of PD between risk groups during follow-up
At year one of follow-up, three patients had been newly diagnosed with PD, a
further subject was diagnosed by the year two survey, and three more by year
three (seven in total). Of the participants with newly diagnosed with PD at year
1, all 3 were in the higher risk group that year, and 2 were in the higher risk group
at baseline. The subject diagnosed at year 2 was in the higher risk group from
baseline. Of the three subjects diagnosed by year 3, none were in the higher risk
group at baseline and two subjects had missing data for either year 1 or year 2 of
follow-up. However, one of the three was flagged in the higher risk group in a year
prior to diagnosis, and for the other two there were marked changes in their risk
estimates prior to diagnosis. Annual rankings from risk scoring, year of reported
diagnosis and intermediate markers for the seven subjects with incident PD are
shown in Table 8.5.
At baseline, the relative risk of being diagnosed with PD over 3 years in the
higher-risk group (3 subjects out of 198) compared to middle and lower-risk groups
(4 subject out of 1125) was 4.3 (95% CI 0.96 to 19.5) and there was weak evidence
to suggest a difference in proportions (p=0.072). However, if risk scores were used
from one or two years before diagnosis as opposed to at baseline only, then 4 of
139
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265 (1.5%) subjects that had ever been in the higher risk group received diagnosis
of PD, compared with 3 of 1058 subjects that had never been higher risk (0.2%).
The OR for the association was 5.39 (95% CI 1.20 to 24.24; p=0.033). Incidence
of PD in the higher risk group at 3 years was 1.6% per year (6 subjects out of 126
higher risk) and 0.2% across the whole cohort.
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Fig. 8.3: Associations between risk estimates in year 3 excluding age and gender
and (a) smell test (UPSIT) scores, (b) RBD questionnaire (RBDSQ) scores and
(c) finger tapping scores for the worst hand. Note the leftward shift of risk
estimates on the x-axis due to the exclusion of age and gender from the
calculations.
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8.4 Discussion
Further support for PREDICT-PD is provided here by reproducible results at years
1, 2 and 3 of follow-up, which are consistent with the differences in intermediate
markers observed between the higher and lower risk groups at baseline. In all
years, data using continuous measures of olfaction, RBD and finger tapping showed
strong statistically significant differences, with similar trends noted in almost all
years using categorical outcomes defined by cut-offs. For analysis in which risk
estimates were calculated each year, a limited degree of change was observed
between higher, middle and lower risk groups. The maximum percentage change
in group was seen in higher risk subjects between years 1 and 2 (26% moving to
the middle risk group) but in general changes were limited to no greater than
20%. Some change in groups was to be expected given the subjective, unobserved
nature of online surveying and the potential for symptoms to vary over time (e.g.
mood and bowel habit). This method of screening should not be thought of as
a diagnostic test and risk group membership alone is not strongly ‘predictive’
of subsequent PD diagnosis in individual participants, but it is designed as a
method of population enrichment for risk of PD. It suggests that screening may
perhaps need to be repeated on more than one occasion. Moreover these results
demonstrate that recruitment and screening longitudinally using a web-portal
is a cost-effective and efficient means of study, with high annual retention rates
(approximately 90% each year after baseline).
Significant differences in intermediate markers of PD were observed between
higher and lower risk groups, regardless of whether subjects had risk estimates
re-calculated each year or whether groups identified at baseline were compared
longitudinally during follow-up. Given that these results have been replicated over
three additional time points, the likelihood that the observations made at baseline
(see chapter 5) were a chance finding, is significantly reduced. The potential role
of bias and confounding is discussed in the concluding chapter of this thesis.
The effectiveness of the algorithm in identifying a group of individuals with
increased risk of PD is underlined by the fact that all participants with newly
diagnosed PD during follow-up were either in the higher risk group at baseline
(three patients), appeared in the higher risk group before diagnosis (two patients),
or were observed to have substantial changes in risk estimates prior to diagnosis
(two patients). None were ever in the lower risk group. Although numbers are
currently small, new diagnoses in the overall cohort are being made at a rate
comparable to that predicted in the 60-80 years age group from the general
population (1-3 per 1000 per year)143 and the higher risk group appears to be
enriched approximately 5-fold.
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The differences in the presence of intermediate markers in these seven incident
cases further underlines the heterogeneity in prodromes of PD, as only one
subject had all three (RBD, smell loss, abnormal tapping speed). The other
six subjects were only positive for one or two markers. The clustering of early
non-motor features has been studied in the PARS and TREND studies, but the
co-occurrence of features is still in need of further clarification.118,160 However it
is clear that individual prodromal markers are not present in all subjects that are
later diagnosed with PD. Strategies that measure multiple prodromal features and
generate composite exposure information will be more likely to yield the greatest
sensitivity and specificity for future diagnosis. PREDICT-PD may provide such
a composite measure and future challenges and opportunities relating to this
possibility are explored in the next chapter.
Limitations
Specific limitations relating to the intermediate marker analysis are discussed
here, with limitations of the study overall considered in chapter 9, including the
role of selection and information bias, and confounding, and the steps taken to
try to minimise these. Age and gender are likely confounders in the association
between risk scores and intermediate markers. However, once removed from the
algorithm, significant relationships remained between risk scores and intermediate
markers almost every year. Stratification using the preliminary risk algorithm
which includes age and gender, yields a higher risk group which contains more
elderly males. The overall differences in intermediate markers are relatively small,
meaning that a greater sample size would be required to fully test associations
stratified for age and gender.
Intermediate markers were selected on the basis that changes in one or more
of them would be expected prior to a clinical diagnosis of PD. However, there
are some limitations to their use. None of these intermediate markers are 100%
specific and sensitive for PD, with RBD having high specificity and low sensitivity,
and anosmia having comparatively high sensitivity and low specificity. The tool
we used for RBDSQ also has high sensitivity for identifying RBD when compared
against the gold standard, polysomnography (PSG) but low specificity. This may
account for the high proportion of individuals that were observed to exceed the
RBDSQ cut-off for RBD. Smell test data were only collected at baseline and in
year 3 but not in years 1 or 2. Hence comparisons with new risk scores and groups
in the subsequent 2 years were made using these baseline smell results.
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Conclusions
These data support the reproducibility and validity of the PREDICT-PD approach
in identifying individuals with increased risk. However, increased risk must be
distinguished from future diagnosis of PD and a proportion of individuals moved
from a higher to the middle risk group during follow-up. Future work is required to
refine the algorithm to reduce flux between groups, in particular to identify those
with a consistently high risk profile who eventually convert to clinical PD. Longer
follow-up, with in-depth study (including eventual post-mortem examination),
will identify a greater number of participants who have developed PD and allow
further characterisation of the higher and lower risk groups.
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Chapter 9
Overall Discussion
9.1 Main results and approach
This thesis describes an approach to community-level screening for PD risk.
A systematic exploration of risk factors and early disease features formed the
foundation for a longitudinal pilot study investigating intermediate phenotypes,
prodromal markers and incident cases. The PREDICT-PD study is now in its
fourth year and continues to gather data from participants annually. Participants in
the upper 15th centile of risk were found to have more objective prodromal features
of PD (hyposmia and slowed finger-tapping), subjective prodromal symptoms
(RBD), gene variants known to increase PD risk, and some imaging findings
associated with PD, compared with participants at lower risk. Incident PD cases
are being recorded in the 15th centile of risk at a greater rate than incident cases
in subjects at lower risk (the remaining 85%), providing the strongest evidence
that the preliminary algorithm can enrich for future PD.
Previous studies have attempted to identify subjects at risk of PD by studying
individuals with a family history of PD or with idiopathic anosmia or RBD, or
imaging abnormalities associated with increased risk.69,70,71,72,74,75,106 A number
of other ongoing approaches (apart from the TREND study) have focussed on
subjects with RBD, idiopathic anosmia, and non-manifesting carriers of LRRK2
or GBA mutations.34,77,104,118 Such studies are vital to the understanding of pre-
diagnostic PD because they examine relatively homogenous populations and will
provide estimates of ‘time to conversion’, and provide an excellent opportunity to
investigate potential pre-diagnostic biomarkers and targeted disease-modifying
therapies. However they may fail to take account of the heterogeneity of PD
and be unrepresentative of the overall clinical spectrum. They may capture or
alternatively fail to identify those for which the prodromal marker is transient (for
example transient anosmia following sinus disease) but many of these strategies
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do not include repeat testing due to cost and practicality. Such limitations may
have further importance because in preparing proof-of-concept clinical trials,
the markers that change prior to conversion, and their temporal relationship to
conversion, are likely to be key to the study design and perhaps dictate power
calculations.
Studies like PREDICT-PD may provide new knowledge relating to the tem-
porality and natural history of the prodromes of PD, and provide tools for the
further in-depth study of individuals with elevated risk of PD. Whilst the pilot
study described here provides support for this approach, it appears unlikely that
a sample size of approximately 1,000 subjects would achieve the intended goals of
identifying sufficient numbers of higher risk subjects (with sufficient enrichment)
for biomarker studies, and potentially for recruitment to disease-modifying trials.
In order to meet these long-term aims, the sample size would need to be increased
substantially to enable further prospective exploration adequately powered for
outcomes that may not rely on incident diagnosis.
Longitudinal studies provide information and protection from some of the bias
that occurs in cross-sectional studies or retrospective case-control studies. They
can demonstrate the temporality of the effect that factors have on an outcome
such as PD and provide risk estimates based on incidence within a cohort rather
than odds ratios arising from comparison of cases and controls. Longitudinal
studies are also essential to understanding PD and its prodromes, given that
the pathology is likely to be present and undiagnosed for many years before it
manifests with the classic features. Ideally longitudinal studies should be large
enough that they can exclude incident cases diagnosed within the first 2-4 years
of follow-up and avoid the bias created through confounding by prevalent disease.
Longitudinal studies of the PD prodrome including TREND and PARS, are
also in progress.104,118 These studies have great potential to be able to delineate
the features and course of prodromal PD, but widespread screening appears
less achievable since they depend on expensive tests or heavy manpower. PD,
compared to other age-related diseases such as cardiovascular disease and cancer,
is relatively uncommon; the incidence in individuals over the age of 60 years
is 0.1-0.3% per year.143 This means that large numbers of subjects need to be
screened in order to detect small numbers of potential cases. Early-identification
strategies require platforms that can be made widely available and at low-cost.
The approach described in this thesis is scalable and cost-effective, and the web-
platform could test 100 times as many subjects for a negligible increase in price.
It is also now clear, even from the incident PD cases in this study, that hyposmia,
RBD and other individual non-motor features are not always present in the pre-
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diagnostic or immediately post-diagnostic phase, which is another reason why the
PREDICT-PD approach may prove superior.
9.2 Limitations
Algorithm
The preliminary, evidence-based algorithm was developed to estimate the risk
of being diagnosed with PD expressed as an odds. Importantly, some of the
strongest risk factors and early features of PD have been left out of the preliminary
algorithm, first to act as intermediate markers of risk and provide reassurance
that stratification was effective, but secondly because true risk estimates for the
effect of hyposmia and RBD are not available (except for one study for hyposmia
using the B-SIT which provided an estimate with very wide confidence intervals).
Using odds as a measure of disease risk has potential limitations. The equation
that underlies odds is number of events in the exposed / number of events in the
unexposed, which is different to that for risk (number of events in the exposed
/number at risk at the beginning of the study period). However, one can see
that if the event is uncommon (the rare disease assumption) then odds and risk
approximate one another, as do their ratios. In a community cohort such as this,
incident PD is uncommon meaning that estimates of odds and risk will not be
very different.
Calculation of combined odds were derived from multiplying the background
odds (e.g. age-related odds) by the presence of an additional measured factor.
However this approach does not make adjustments in the absence of a measured
factor, which is simply treated as if it were unmeasured. For example, if a 65
year old male had his sense of smell objectively tested and it was found to be
abnormal then he would have a higher risk of PD. If his smell is found to be normal
(particularly at the upper extreme of possible scores) then one would expect him
to have a lower risk of PD than a 65 year old male who had not had their sense of
smell tested at all. To offer an extreme example, a 70 year old female, lifelong
smoker, coffee and alcohol consumer, without any history of constipation, anxiety
or depression would be expected to be at lower risk than a 70 year old female in
whom none of these factors had been ascertained, but with the current algorithm,
their risk scores would be the same. Ranking subjects according to risk estimates
is likely to offer better accuracy than using the risk estimates themselves, and was
the approach used here for analyses. This ranking of odds enabled comparative
analysis to be undertaken between the extremes of risk in the cohort and cut-offs
for higher and lower risk were created at the 15th centile and 85th centile.
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The next phase of the algorithm will incorporate likelihood ratios for individual
risk and protective factors which are due to be released soon by a Movement
Disorders Society (MDS) Task Force.i Likelihood ratios enable the adjustment
of the combined risk estimate upwards or downwards depending on the results
of tests for measured factors. Furthermore the risk estimates for a number of
early non-motor features have been refined since the original systematic review
and meta-analysis (chapter 2) was undertaken, and any changes to these will be
reflected in the upcoming likelihood ratio estimates.
Most of the a priori hypotheses of this study have been met. Higher risk
subjects had an increased presence of intermediate markers for PD during every
year of study, they had an excess of gene variants associated with PD and some
imaging findings associated with PD. Most importantly higher risk subjects appear
more likely to be diagnosed with PD during follow-up. The statistical tests which
underpin the observed associations suggested that these were unlikely to be chance
observations, given the small p-values in general. Repeat testing for intermediate
markers and magnitude of effect for SN hyperechogencity also make chance an
unlikely explanation for the the observed differences between higher and lower risk.
However, before these associations can be accepted as true, one must consider the
roles that bias and confounding could have played in the study overall.
Bias
Selection bias occurs when the sample has different characteristics to the population
from which it was drawn. The participants in the PREDICT-PD pilot study were
recruited through a variety of methods, including some coverage on local radio and
print media with an older readership. However most participants were recruited
following an email to members of Parkinson’s UK, calling on participation by
individuals that did not have PD. This meant that relatives and spouses of patients
with PD were more likely to take part than individuals with no connection with
PD, an observation that is reflected in the relatively high prevalence of family
history and spouse PD in the cohort overall. This in turn may have elevated risk
overall in the cohort, not only via genetic risk factors, but also shared environment
(and environmental risk factors) and cause the incidence of PD to be greater
in this cohort than in a truly unselected population sample. However, this has
not been reflected in the incidence to-date, which appears consistent with prior
estimates.143
Living with or caring for someone with PD may increase the chance of experi-
encing early-non motor features (for example, co-existent depression or anxiety)
iA consensus statement from the MDS Task Force is in the final stages of preparation.
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and in doing so has the potential to falsely elevate risk estimates in these partici-
pants. Separately, having a strong connection with PD may have also improved
recruitment and retention rates, which may have influenced the longitudinal valid-
ity of the study. Overall selection bias can affect the validity and generalisability of
the results and mean that similar outcomes would not be observed if the approach
was applied more widely. Selection bias could have specifically affected imaging
and genetic sub-studies given that participants were preferentially selected from
the upper extreme of risk with less sampling across the remainder of the risk
spectrum. This sampling method may have been vulnerable to false positives in
the control group or conversely underestimate the frequency of an outcome in
that group, leading to type 2 (incorrectly accepting the null hypothesis) or type 1
(incorrectly rejecting the null hypothesis) error respectively.
Information bias or measurement error can arise in a number of ways. Ob-
server bias was unlikely for most methods employed in this study. Regarding
exposures, the algorithm contained all the factors identified in chapter 2 that
could be measured in an appropriate way. No additional factors were added or
removed and therefore the results reflect a priori hypotheses about the preliminary
algorithm, which was not altered by the investigator. For the outcomes, only SN
hyperechogenicity may have been affected by observer bias. SPECT quantification
was undertaken by a researcher that was blinded to participant risk status and was
not unblinded until after the analysis stage, meaning that observer bias could not
have arisen.ii The remaining outcomes (intermediate markers, genotyping) were
measured without observer influence because genotyping results were binary (the
presence or absence of a mutation) and were repeated, and intermediate markers
were measured unobserved in the participant’s own home.
Measurement bias could have arisen through unobserved collection of inter-
mediate markers or indeed exposures recorded through the survey. Outcomes
may have been affected if participants sought help from others when completing
the smell test or used two hands to complete the BRAIN-tap test. Both of these
possibilities were anticipated and steps were taken to minimise them (i.e. clear
instructions, cross-checking smell test booklets with web results, and exclusion of
improbable scores). Identifying inaccuracies in exposure information presented a
greater challenge and the possibility of information bias here cannot be discounted.
For example, with free text medication lists and past medical history, there exists
the possibility that information may have been omitted intentionally or uninten-
tionally. Furthermore individuals may tend to answer questions with a preference
for immediate recall therefore discounting past symptoms and reporting them
as normal, or declaring the presence of the symptom at that given time, which
iiJohn Dickson undertook SPECT quantification.
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subsequently was only transient. Methods of checking data were used to improve
consistency and are described in chapters 5 and 8.
Ascertainment bias occurs when cases (or controls) are not identified reliably.
Those that reported having PD at baseline were excluded from analysis but others
may have had PD at baseline and either not yet have been diagnosed or chose not
to disclose this information. Attempts to verify information were made, including
checking the reason for any dopaminergic medication in medication lists and,
for cases of incident PD, checking the date of first symptoms and details about
the neurologist diagnosis. Incident PD was defined as diagnosis with PD by a
specialist, not onset of symptoms, and therefore some patients may have had
symptoms predating diagnosis. However this is an flaw in most observational
studies that rely on periodic review in-person or medical records, rather than date
of first symptoms. Although the annual retention rate remains high, a further
concern about ascertainment is for those that may have dropped out because they
were diagnosed with PD, and were upset or did not want to continue in a study
aiming to ‘predict’ PD. A table of baseline characteristics of those that completed
at least one follow-up year and those that dropped out after baseline, showed no
major differences but it is conceivable that some of those lost to follow-up may
have included cases of PD.
Bias can only be acknowledged and cannot be accounted for at the analysis
stage of a study (i.e. the results cannot be adjusted in light of perceived bias).
Recognising bias allows one to consider how much the observed results can be
relied upon and how generalisable they might be. Here, reduction in bias could be
achieved at the data collection stage by increasing the number of objective measures
obtained or by triangulating subjectively reported symptoms (e.g. multiple
mood and sleep questionnaires or cross-referencing with primary care records).
Case ascertainment could be strengthened by seeing all participants in-person,
and selection bias reduced by advertising in a random and widespread fashion.
However a degree of selection bias is always likely to be present, because people that
participate in research are more likely to have certain socioeconomic characteristics.
Likewise individuals that have a friend, relative or spouse with a given disease are
more inclined to take part in research pertaining to this. Increasing the number
of tests and in-person assessments for all participants contradicts the successful
approach that has been described here. The best qualities of this project are that
it shows a methodology for large scale, cost effective, low intensity research that
results in high retention rates. Whilst elimination of bias is desirable wherever
possible, it is often the case that practicality and cost are the key influences on
the way that research is conducted.
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Confounding
Away from bias, confounding is another reason that type 1 error can arise (incorrect
rejection of the null hypothesis, a false positive). For most diseases, age is an
important confounding factor and incidence tends to increase in older persons.
Gender is also an important confounding factor with different prevalence occurring
in males and females. Confounders identified a priori can be tested and adjusted
for at the analysis stage of a study, to determine whether they have influenced the
results. For PD, age and gender are important confounding factors, but they are
also two of the most important risk factors for PD and were therefore included in
the algorithm. Adjusting for age and gender at the analysis stage would increase
error substantially due to the potential of multicolinearity (two modelled factors
that are highly correlated i.e. the risk score and age, because age is part of the
risk score). Removing both from the algorithm was another option but could have
resulted in a study that was underpowered to detect differences between higher
and lower risk in comparative analyses. Furthermore, simply removing age and
gender from the algorithm does not account for the effect that they have on the
outcome or indeed on other exposures contained within the algorithm. Limited
analyses did show that when age and gender were dropped from the algorithm,
associations between risk scores and intermediate markers were still observed,
albeit less strongly than when they were included. A major problem with dropping
age is that it is the only continuous variable in the risk score and its removal
meant that lots of subjects ended up with identical scores, given that all other
variables were collected in a binary fashion. The matter of a confounding effect
of age and gender may be better explored in a larger study powered to detect
an effect of the other risk factors in combination. However, in the long-term it
is difficult to see how a combined risk score for PD would not include age and
gender, and the important issue is that they do not explain all of the variance in
risk, and that other factors do also contribute.
9.3 Further work
A few concurrent and possible future approaches are listed below.
Concurrent work
1. From the current group additional data have already been collected that
have not yet been analysed and not included in this thesis. Over 200 of
the current participants have been seen in-person as part of clinical visits
to higher risk subjects and similar numbers of lower risk. These clinical
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visits included a neurological examination, brief cognitive assessment, and a
sample of handwriting. As part of the neurological examination, the motor
section of the MDS-UPDRS was performed and recorded on video. The
purpose of the video is for assessment by two movement disorders specialists
(AJL and AS) who are blind to the risk status of the subjects and who will
look for subtle motor dysfunction. This work may help clarify the nature of
mild parkinsonian signs in subjects estimated to be at higher risk of future
PD and characterise specifically what that motor dysfunction might look
like. In turn this will guide what future remote and objective tests might
be liable to capture this. Other studies have looked at mild parkinsonian
signs in the elderly but have not captured them on video for blinded expert
review.186,194
2. Genotyping of GBA and LRRK2 will be undertaken in the full cohort to
confirm or refute the findings reported in chapter 6. DNA was obtained
from approximately 800 of the participants following the year 3 follow-up
survey in conjunction with repeat smell testing. Many of the samples have
been genotyped (by LR and NM) but final results are not ready. Regardless
of whether GBA variants are more prevalent in the higher risk group, they
do impart increased risk of PD independently and so GBA variant status
can be used to update risk estimates within the cohort and longitudinally.
LRRK2 mutations may be found in 1 or 2 participants in the wider cohort,
but will be valuable because these individuals would be expected to be at
very high risk of PD.
3. Genotyping of variants identified from GWAS studies is being undertaken
using samples from PREDICT-PD participants, to ascertain the role that a
combined clinical-genetic multifactorial risk score may have in predicting
incident PD.
4. Recruitment of positive control groups has begun to assess 50 subjects with
established PD, 30 subjects with idiopathic RBD confirmed using PSG, and
30 subjects with idiopathic anosmia confirmed with objective smell testing,
endoscopy and imaging. Positive control subjects will participate in the
same tests as regular PREDICT-PD subjects and will define reference ranges
against which higher (and lower) risk subjects can be compared.
Future work
1. 123I-FP-CIT SPECT will be carried in those subjects that were already
scanned, 2 years after the first scan. This will examine whether DaT deficit
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is progressing at a faster rate in higher risk participants, since cross-sectional
analysis did not demonstrate statistically significant differences between
higher and lower risk (see chapter 7). To improve statistical power, it is
hoped to also increase the number of higher and lower risk subjects that are
scanned. Power calculations based on the observed differences suggest that
3-4 times as many subjects would need to be scanned (150-200 participants,
power 80%, alpha=0.05). A final decision regarding further imaging will be
made after blind clinical rating of the existing scans has been undertaken.
2. Plans to approach and consent current participants for brain donation or
participation in parallel with wet and/or tissue biomarker initiatives are
underway. The potential to strengthen the algorithm through pathological
confirmation of PD diagnosis is an important consideration, whilst balancing
the interests of the participants within the cohort.
3. In 1-2 years time, it is expected that there may be sufficient ‘converters’ or
DaT positive subjects, that modelling of risk factors for conversion may be
undertaken using data from within the cohort. Logistic regression (predictive
approach rather than aetiological) will enable selection of factors that explain
most of the variation in case load in order that the preliminary algorithm
may be refined, along with inclusion of likelihood ratios reported from the
MDS Task Force. As has been previously noted, the use of longitudinal
data to inform understanding of risk of PD is vital because there is under-
diagnosis in the community and the disease runs an insidious course. The
temporality and lead time of risk factors is vital to the continued study of
pre-diagnostic PD.
Expanding the study
In addition to ongoing work within the current pilot cohort, there exists great
potential benefit in considering the expansion of this programme of work to recruit
a much larger sample of participants. Anticipated benefits include:
1. Greater numbers of clinical converters, sufficient to power clinical trials
with disease-modifying intentions. Expanding the current cohort by 5 or
10-fold would see 50-150 clinical converters over a five year period, which are
sufficient numbers to randomise to RCTs of drugs with an estimate effect
size of 0.5.
2. A generalisable sample reflecting the wider UK population. Furthermore
there is no reason why recruitment should be limited to the UK using this
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platform. Translation of web-based generic components could be used to
‘roll-out’ a study such as this to other countries.
3. Due to the current sample size, it is not possible to rank males and females
separately, due to the risk of under-powering the study. Increasing numbers
of participants would mean that gender could be stratified separately to
ascertain risk for males and risk for females.
4. The implementation of a parallel biomarkers programme (invasive and non-
invasive). To-date objective markers have been limited to clinical (smell and
finger-tapping) and imaging. An expanded programme ought to include a
parallel wet and/or tissue biomarkers programme to develop disease-specific
measures for the prodromal period that can be be applied as outcomes for
clinical trials.
5. A conduit to clinical trials in the long-term, or as a recruitment portal and
a place to register interest in trial participation in the short-term.
6. Linking the cohort to outcome data such as cause of death ascertained
through vital registration.
7. Provision of opportunities to study a wider range of diseases and outcomes
from longitudinal data such as dementia.
Improving the web portal
There are also opportunities to improve and evolve the current web-platform in
terms of the way in which it gathers data.
1. The free-text options for medication and co-morbidity are not ideal, because
they are laborious for participants at the point of data entry and for the
investigator due to a need to clean the data prior to analysis. Options for
this include:
• Incorporating a drug search engine that works by identifying medica-
tions on the first few letters and then presenting list of options.
• Requesting a photograph or copy of the participant’s repeat prescrip-
tion.
• Linking data to primary care records.
• Presenting reported symptoms, medication and co-morbidities back to
participants each year and asking them to update if there are differences
from the year before.
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2. To incorporate brief but valid, computerised tests of cognitive function. It
is known the mild cognitive impairment occurs early in elderly patients
diagnosed with PD, perhaps pre-diagnosis and objective cognitive data are
vital to the long term success of the project.195,196 It would also help ascertain
reliability of other gathered self-report data and support the expansion of
the cohort for the assessment of other disease states.
9.4 Ethical issues
The aim of the PREDICT-PD study is to identify a group of individuals at higher
risk of PD and demonstrate this through a variety of outcomes, including incident
PD. Participants have so far been given no information about their test results or
their estimated risk scores. As such many of the possible ethical issues have been
avoided but as positive results relating to the above aims have started to emerge,
unresolved ethical issues come to the fore.
In the long-term, the purpose of enriching a group for PD risk is to offer
early disease-modifying treatment to slow or prevent PD. The necessary precursor
to this is commencing proof-of-concept clinical trials. It is believed that the
best chance of demonstrating disease-modifying potential will be in the earliest
stages of disease (pre-diagnosis), which makes identification of those at higher risk
of diagnosis a priority.6 The identification of reliable pre-diagnostic imaging or
laboratory markers of PD, so that the outcome of clinical trials is not reliant on
clinical diagnosis, is also an important focus of research.
For a re-purposed drug with previous data on safety and tolerance, the impli-
cations are perhaps less than for novel drugs with unknown safety profiles. Both
types of drug are under investigation already, driven by increasing understanding
about the basic biology of PD. It is unlikely that higher risk subjects identified
through the basic PREDICT-PD approach are sufficiently enriched to be included
directly in clinical trials, but if they were to be or whether they were to require
a further layer of risk stratification (using smell or TCS or genetics), disclosure
of their risk status will be a pre-requisite. Having a biomarker for PD would be
helpful in many ways because it would provide reassurance about the accuracy
of information relating to risk status, but ultimately participants would be likely
to want to know what their risk is, in order to make an informed decision about
drug trial participation.
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9.5 Concluding comments
This thesis describes a pilot study aiming to enrich a sample of the general
population for risk of PD, which could one day underpin efforts to recruit such
subjects to clinical trials of disease-modifying therapy. The higher risk subjects
have been found to have higher rates of intermediate markers, gene mutations
and imaging appearances associated with PD, which adds credence to the notion
that the higher risk group had been enriched for future PD. Follow-up data over
three years have been presented and show the consistency of results over time,
and some evidence that higher risk subjects are more likely to be diagnosed with
incident PD. Modification of the algorithm using incident cases and abnormal
123I-FP-CIT SPECT to determine the most predictive factors in the pilot cohort
will further validate this approach. The next step will focus on how the approach
might be expanded and utilised in further defining risk in the population, support
biomarker initiatives and ultimately lead in to clinical trials with disease-modifying
intentions.
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Appendix A
Details of studies from systematic
review and meta-analysis presented
in chapter 2
Tables providing details of studies included in the systematic review and meta-
analysis are too numerous to be printed here but can be reviewed on the CD/DVD
attached to the inside back cover of this thesis.
The following files are reproduced on the CD/DVD:
• Table 1 - Details of Studies included in the meta-analysis.
• Table 2 - Odds ratios and relative risks of studies included in the meta-
analysis.
• Table 3 - Studies included for systematic review but not suitable for use in
the meta-analysis.
• Extended reference list of studies included in the systematic review and
meta-analysis.
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Details of studies from systematic review and meta-analysis
presented in chapter 2
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Appendix B
Screenshots from the questionnaire
of early non-motor features and risk
factors embedded in the web portal
Fig. B.1: Screenshot - Demographic information
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Screenshots from the questionnaire of early non-motor features and
risk factors embedded in the web portal
Fig. B.2: Screenshot - Risk and Protective Factors
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Fig. B.3: Screenshot - Co-morbidity and Medication
181
Screenshots from the questionnaire of early non-motor features and
risk factors embedded in the web portal
Fig. B.4: Screenshot - Non-motor and motor symptoms
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Fig. B.5: Screenshot - Hospital Anxiety Depression Scale
183
Screenshots from the questionnaire of early non-motor features and
risk factors embedded in the web portal
Fig. B.6: Screenshot - RBD Screening Questionnaire
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